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Introduction  
Children and adolescents diagnosed with autism spectrum disorders (ASD) and 
disruptive behavior disorders (DBD) are often treated with antipsychotics. These 
antipsychotics can correct behavioral disorders, but a large fraction of the pre-
scribed medication influences the hormonal balance of the patient. In particular, 
prolactin levels can be severely affected. 
This thesis focuses on antipsychotic (AP)-induced hyperprolactinemia (the 
presence of abnormally high, above the 97.5th percentile for age and gender, levels 
of the hormone prolactin in the blood) in children and adolescents with ASD and 
DBD. We pay special attention to the prevalence, associated signs and symptoms, 
clinical consequences, and pharmacogenetics of hyperprolactinemia. In the current 
chapter we introduce ASD and DBD, as well as the main functions and pathophysi-
ology of the hormone prolactin, which are the main topics of this thesis. This is 
followed by a description of the state of the art concerning AP-induced hyper-
prolactinemia in children and adolescents. We focus our attention on the preva-
lence, the possible short- and long-term consequences and the genetic risk factors 
of hyperprolactinemia. This chapter ends with an outline of the thesis. 
Autism Spectrum Disorder (ASD) 
ASD is a neurodevelopmental disorder characterized by impaired social interaction 
and communication, and by restricted and repetitive behavior (Wing 1997). Psy-
chiatric disorders are defined and classified by the Diagnostic and Statistical Man-
ual (DSM). The fourth edition (DSM-IV) identifies a set of Pervasive Developmental 
Disorders that are considered “autism spectrum disorders” (ASDs). These disorders 
include Autistic Disorder, Asperger’s Disorder, and Pervasive Developmental Dis-
order Not Otherwise Specified (PDD-NOS). The DSM-IV has been under revision for 
several years and a new edition, the DSM-5, will be released this year. Significant 
changes to the criteria and categories of ASDs are planned for the new edition. One 
of the most significant changes is that the separate diagnostic labels of Autistic Dis-
order, Asperger’s Disorder, and PDD-NOS will be collectively replaced by the term 
“Autism Spectrum Disorder.” Distinctions will now be made according to the level 
of severity of the disorder. The diagnostic criteria require that symptoms become 
apparent before the age of three years. Autism has a strong genetic basis, although 
the genetics of autism are complex and it is unclear to what extent ASD can be ex-
plained by rare genetic variants with potentially major effect size, such as muta-
tions and copy number variations, or by the combined effect of several common 
genetic variants. The prevalence of ASD is about 1–2 individuals per 100 people 
worldwide (Baio 2008). Since the 1980s the number of children and adolescents 
diagnosed with ASD has increased dramatically. This increase can be explained in 
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part by changes in diagnostic practice, a broadening of diagnostic criteria, and 
greater parental age. Whether actual prevalence has increased as a consequence of 
external factors, such as e.g. increased environmental risk factors, is unresolved. 
Recently the relationship between mental health diagnosis and treatment with 
second-generation APs was investigated. The study showed that children and ado-
lescents with an ASD diagnosis were more likely to receive AP treatment to reduce 
maladaptive behaviors, such as irritability, self-injury, stereotypes, and hyperactiv-
ity (Aman 2009, Matone 2012). 
Disruptive Behavior Disorders (DBD) 
The main DBDs are Oppositional Defiant Disorder (ODD) and Conduct Disorder 
(CD). The essential features of ODD are a recurrent pattern of negativistic, defiant, 
disobedient, and hostile behavior toward persons with authority (a defiant head-
strong symptom cluster) and temper tantrums and irritability (a more affective 
symptom cluster). The essential features of CD are a repetitive and persistent pat-
tern of behavioral routines that violate the basic rights of others and major age-
appropriate societal norms or rules. In many cases, CD is preceded by ODD. The 
main four symptom categories of the disorder are: (1) physical aggression or 
threats of harm to people or animals, (2) destruction of property, (3) acts of deceit-
fulness or theft, and (4) serious violations of age-appropriate rules. CD usually oc-
curs in older children and adolescents. The prevalence of DBD is relatively high: 2% 
for CD and 3.2% for ODD (Lahey 1999). Boys seem to be more affected than girls. 
However, the existing classification systems might be intrinsically biased towards 
identifying aggressive and antisocial behavior in boys than in girls (Lahey 1999). 
DBDs result in displayed aggression and severe behavioral problems. These diffi-
culties often result in presentation to psychiatric services. A treatment with medi-
cation such as atypical antipsychotics often occurs. A significant rise in the use of 
atypical antipsychotics to treat DBD-related aggression in child and adolescent 
populations is evident (Loy 2012). Furthermore, there is some limited evidence 
that (primarily) risperidone reduces aggression and conduct problems on the 
short- and the long- term in children aged 5- to- 18 years with DBDs (Chroonen-
berghs 2005, Loy 2012). 
Prolactin 
The anterior pituitary lactotroph cells secrete prolactin, a 198-amino acid polypep-
tide, in a pulsatile manner with 13–14 peaks per day. Prolactin secretion is under 
inhibitory control by the hypothalamus through dopamine. There is a marked cir-
cadian variation with a maximum secretion four hours from sleep onset and a 
I N T R O D U C T I O N  
 13 
minimum secretion six hours after waking (Frantz 1978, Freeman 2000). There can 
be as much as a fourfold variation in prolactin levels depending on the time of day 
or night that sampling is done; there are also transient mild increases related to 
meals, stress, and sexual activity (Bevan 1991). Prolactin levels are higher during 
menstrual midcycle and the second half of the menstrual cycle. During pregnancy, 
levels rise 10–20-fold in the blood, reaching 200 μg/L at term and 300 μg/L during 
nursing (Lenton 1979). The normal upper limit range for adults is 15–25 μg/L 
(Bevan 1991]. Prolactin is known for its ability to induce and maintain lactation and 
cause amenorrhea during lactation. However, prolactin has over 300 separate bio-
logical activities including effects on water and salt balance, growth and develop-
ment, endocrinology and metabolism, brain function and behavior, reproduction, 
and immune system regulation and protection (Bole-Feysot 1998). Indeed, not only 
does prolactin play multiple roles in reproduction in addition to lactation, but it 
also plays multiple homeostatic roles (e.g. immune regulation, angiogenesis, and 
electrolyte transportation) in the body. This diversity in biological activities is im-
portant to bear in mind when prescribing APs with prolactin elevating qualities to 
children and adolescents; an increase in prolactin levels may potentially influence 
multiple homeostatic systems. 
Antipsychotic-induced hyperprolactinemia 
Antipsychotics (e.g. haloperidol, pimozide, risperidone) cause dopamine 2 (D2) 
blockade in the brain. There are four main dopamine pathways: 
1. The nigrostriatal pathway that extends from the substantia nigra to the basal 
ganglia. This pathway is involved in movement and movement disorders. 
2. The mesolimbic pathway that extends from the ventral tegmental area to the 
nucleus accumbens. This pathway is involved in the positive symptoms of 
schizophrenia and plays a role in feelings/ mechanisms of pleasure and reward. 
3. The mesocortical pathway that extends from the ventral tegmental area to the 
cortex. This pathway regulates motivation and emotional response (and is 
thought to cause the negative symptoms of schizophrenia). 
4. The tuberoinfundibular pathway that extends from the hypothalamus to the 
anterior pituitary. Blocking this pathway may cause hyperprolactinemia (Hal-
breich 2003). In this thesis we will focus on this pathway (see table 1 for agents 
with dopamine D2 blocking qualities). 
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Table 1. Agents with dopamine D2 blocking qualities 
Drug class Drug Prolactin Elevation 
Antipsychotics All typical Antipsychotics 
Amisulpiride 
Risperidone 
Olanzapine 
Clozapine 
Quetiapine 
Aripiprazol 
+++ 
+++ 
+++ 
+ 
0 
0 
- 
Antidepressants Amitriptyline 
Clomipramine 
Citalopram 
Fluoxetine 
Paroxetine 
Sertraline 
Mirtazapine 
Venlafaxine 
+ 
+++ 
+/- 
+/- 
+/- 
+/- 
0 
0 
Anti-emetics Domperidone 
Metoclopramide 
+ 
+ 
Estrogens All contraceptives + 
Opiates All + 
Calcium channel blockers Verapamil + 
H2-antagonists Cimetidine + 
Proton pump inhibitors Omeprazole + 
 
Hyperprolactinemia is a common side effect of long-term AP treatment in children 
and adolescents (Calarge 2010, Roke 20121,2). APs are increasingly prescribed to 
children and adolescents with psychiatric disorders and have been used success-
fully to reduce maladaptive behaviors, such as irritability, self-injury, stereotypies 
and hyperactivity in children and adolescents with ASD and irritability and aggres-
sive behavior in children and adolescents with DBD (Aman 2009, Matone 2012). 
While risperidone and aripiprazole have been approved by the United States Food 
and Drug Administration (FDA) for the treatment of children and adolescents with 
irritability associated with ASD (RUPP 2002, Stigler 2006, Wink 2010), these drugs 
have not yet been approved for this indication in Europe. APs are also frequently 
used off-label, to treat severe aggression in children and adolescents with DBD. 
Despite their efficacy (Wink 2010), there are concerns about the widespread use of 
these drugs given their side effect profile, including weight gain, metabolic adverse 
effects (dyslipidemia, hyperglycemia, and diabetes), cardiac side effects (QTc pro-
longation), extrapyramidal side effects, and increased prolactin levels (Molitch 
2005, Correll 20081,2, Vitiello 2009). The side effects of APs are well described in 
adults (Hasan 2012, Singh 2012) but less well studied in children and adolescents. 
One of these side effects is hyperprolactinemia. Hyperprolactinemia may decrease 
gonadotropin levels and thereby decrease estrogen and testosterone levels in the 
blood (Halbreich 2003, Haddad 2004). Estrogen and testosterone levels play im-
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portant roles in puberty, sexual functioning, and bone mineralization (Saranac 
2010); decreased levels may result in delayed puberty and disorders in sexual func-
tioning (Cutler 2003, Knegtering 2003), and may diminish bone mineral density. It 
is not known at what threshold of elevated prolactin level these adverse effects 
develop. In fact, little is known about the consequences of persistently elevated 
prolactin levels in children and adolescents, and in particular about the effects of 
elevated but still subclinical levels of prolactin. This thesis will provide insight into 
the possible short- and long-term effects of hyperprolactinemia and will describe 
monitoring and management strategies. 
Prevalence of AP-induced hyperprolactinemia 
The clinical practice guideline published by the Endocrine Society states that “to 
establish the diagnosis of hyperprolactinemia, we recommend a single measure-
ment of serum prolactin; a level above the upper limit of normal confirms the diag-
nosis as long as the serum sample was obtained without excessive venipuncture 
stress.” (Melmed 2011). In children and adolescent the upper limit of normal can be 
defined as a prolactin level above the 97.5th percentile for age and gender (for ex-
ample the study of Emlinger et al. 2002 describes reference data for children and 
adolescents of Caucasian ethnicity). 
AP-induced hyperprolactinemia is present in about 50% of children and ado-
lescents who are treated long-term (more than two years of treatment) with AP 
with D2 blocking qualities (Roke 20121, Calarge 2010). Short-term studies have 
shown a steep increase in the prolactin level within the first 6 weeks, with levels 
stabilizing in the first 3 months (Aman 2002, Snyder 2002, Findling 2004, Bieder-
man 2005), followed by a slow decline after 1 year (Turgay 2002, Findling 2004, 
Croonenberghs 2005, Stevens 2005, Anderson 2007). Average prolactin levels were 
found to be above the reference value after 2 (Reyes 2006, Staller 2006) and 3 
years of continued risperidone treatment (Calarge 2010, Roke 20121,2), although 
two studies reported that prolactin levels tended to normalize after 12 months 
(Migliardi 2009) and 22 months (Anderson 2007) of AP use. Most studies defined 
hyperprolactinemia using adult reference ranges, primarily 0–18 ng/mL and 0–30 
ng/mL for male and female patients, respectively. Prolactin levels change during 
childhood and adolescence and should be matched for age and gender; otherwise 
there is a risk of underestimating the prevalence of hyperprolactinemia. 
1. Possible prolactin-related side effects 
Gynecomastia 
Gynecomastia is defined as a swelling of the breast tissue in males that is mostly 
caused by an imbalance of the hormones estrogen and testosterone with more ef-
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fect of estrogen. If puberty advances and testosterone levels increase the gyneco-
mastia disappears. Estrogens are primarily produced in adipose tissue. Under the 
influence of the aromatase enzyme adrenal androgens are converted into estrogens 
in the adipose tissue. Gynecomastia is a normal transient phenomenon caused by a 
temporary dysregulation between estrogen and testosterone. There is an associa-
tion between the total percentage body fat and the prevalence of gynecomastia. 
Newborns, pubertal males, and older men have a higher prevalence of gynecomas-
tia. The lifetime prevalence of gynecomastia in males is about 50% (Bembo 2004, 
Hanavadi 2006). Hyperprolactinemia may be an indirect cause of gynecomastia. 
Hyperprolactinemia may cause a decrease in the secretion of luteinizing hormone 
which in turn may lead to decreased testosterone levels in boys. In girls the hypo-
gonadotropic hypogonadism may lead to decreased estrogen levels which may 
delay puberty or cause menstrual disorders. In children and adolescents treated 
with APs, the reported point prevalence of gynecomastia is about 3–7% (Roke 
2009, Sikich 2004, Reyes 2006, Staller 2006). However, the studies primarily re-
ported on pre-pubertal children. The studies relied on spontaneous self-reports, 
rather than physical examination and systematic questionnaires, to establish the 
presence of gynecomastia. This practice has probably led to underestimation of the 
prevalence of gynecomastia. One study did use physical examination and question-
naires to examine the presence of gynecomastia. This study reported a much higher 
point prevalence of 40% for the boys using AP, and a 21% point prevalence of gy-
necomastia in the AP-naïve-boys. These percentages of the AP-naïve group are 
comparable to the prevalence of gynecomastia in healthy pubertal boys. 
Galactorrhea 
Galactorrhea is a milky nipple discharge unrelated to the normal milk production of 
breast-feeding. Although the condition occurs mostly in women, galactorrhea can 
develop in men and even, although rarely, in infants. Excessive breast stimulation, 
medication side effects, or disorders of the pituitary gland may all contribute to 
galactorrhea. Frequently, galactorrhea results from increased levels of prolactin, 
the hormone that stimulates milk production. In female children and adolescents 
treated with APs, the prevalence of galactorrhea varied from 3.6–10%, whereas 
there were no male children or adolescents with galactorrhea (Roke 2009). 
Amenorrhea 
Amenorrhea is the absence of menstruation (one or more missed menstrual peri-
ods). Women who have missed at least three sequential menstrual periods have 
amenorrhea (secondary amenorrhea), as do girls who have not had menarche by 
the age of 16 years (primary amenorrhea). In females treated with prolactin elevat-
ing APs 6–15% report having amenorrhea (Melkersson 2005). However, most stud-
ies investigating the effect of hyperprolactinemia on the menstrual cycle had seri-
ous methodological limitations, such as the small number of patients included in 
most studies and the concomitant use of oral contraceptives, which could have 
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influenced the prolactin level and may have confounded the results (Ouwehand 
2012). Therefore no firm conclusions can be drawn about the relationship between 
the increased frequencies of menstrual disorders in women with AP-induced hy-
perprolactinemia. 
Sexual dysfunctioning 
Sexual dysfunctioning is defined as disorders that interfere with a full sexual re-
sponse cycle (Balon 2007). For men this may be erectile dysfunction, ejaculate dys-
function, lack or loss of sexual desire, and difficulty or inability to have an orgasm. 
For females sexual dysfunctioning involves inadequate lubrication, pain during 
intercourse, lack or loss of sexual desire, and the difficulty or inability to have an 
orgasm. 
Prolactin plays a role in the central control of sexual behavior and activity, 
mainly through modulating the effects of dopaminergic and serotonergic systems 
on sexual function. Circulating prolactin levels increase after having an orgasm, 
implying that prolactin plays a role in the acute regulation of sexual arousal follow-
ing orgasm in both men and women. Prolactin also plays a role in sexual function 
influencing penile erection in men (Galdiero 2012). In adult studies hyperprolacti-
nemia is primarily associated with libido and orgasm dysfunctions (Knegtering 
2008). 
2. Possible long-term consequences of hyperprolactinemia 
Hypogonadotropic hypogonadism 
Gonadotropin-releasing hormone (GnRH), released in a pulsatile manner from the 
hypothalamus, stimulates release of luteinizing hormone (LH) and follicle stimulat-
ing hormone (FSH) from the anterior pituitary. Prolactin inhibits the release of 
GnRH in the hypothalamus. The positive feedback of low estradiol on LH secretion 
in women is also blocked. Consequently, estrogen levels in women and testosterone 
levels in men are suppressed, with marked individual variability in the prolactin 
level causing gonadal hypofunction (Smith 2002, Kishimoto 2008). Hypogonad-
otropic hypogonadism may cause delayed puberty and in adults loss of hair, infer-
tility, orgasm and libido problems, loss of bone mass, high plasma levels of choles-
terol/ lipids, glucose intolerance, and increased abdominal fat (Wu 2009). 
Delayed puberty 
Delayed puberty is defined as a failure to develop secondary sexual characteristics 
by a certain age, usually set as two standard deviations from the mean. In girls, 
delayed puberty is defined as lack of breast development by age 13, lack of men-
arche by age 16, or more than five years between thelarche and menarche. In boys, 
puberty is considered delayed if testicular enlargement does not occur by 14 years 
of age or more than five years are required to complete genital enlargement 
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(McKeever 2000, Rosen 2001). Hyperprolactinemia may cause hypogonadotropic 
hypogonadism, which may lead to a delay in puberty. Just two studies have investi-
gated the possible relationship between hyperprolactinemia and a delay in puberty. 
One retrospective analysis of 222 children (older than 10 years) treated with 
risperidone with a follow-up of one year did not show a delay in progressing Tan-
ner stadia of puberty due to prolactin elevation (Dunbar 2004). Another extension 
study (N=33, children and adolescents 6–15 years of age) also showed no delay in 
puberty after two years of risperidone treatment and prolactin elevation (Reyes 
2006). These studies however have limitations: firstly, an observation period of one 
year is rather short and not enough to conclude whether there truly is a delay in 
pubertal development, and secondly, the two year extension study included just 33 
patients, a small sample size with limited statistical power to draw any final conclu-
sions about hyperprolactinemia and the influence on pubertal development. 
Diminished bone mineral density 
Adolescence is the most important time for attaining peak bone mass (Davies 
2005). Peak bone mass can be defined as the amount of bony tissue present at the 
end of the skeletal maturation. It is an important determinant of future osteo-
porotic fracture risk. During childhood the increase of lean body mass, mainly mus-
cles, is important for optimal bone mass (Taes 2009). Disturbances in this process 
during puberty may increase the risk of osteoporosis later in life. APs may influence 
the attainment of peak bone mass in three ways. Firstly, APs may induce change in 
energy metabolism and insulin signaling, which could lead to a lower bone mineral 
density (BMD) (Houseknecht 2009, Schwetz 2012), which in turn could increase 
the risk of osteoporosis later in life. Secondly, AP-induced hyperprolactinemia 
might directly affect bone turnover, by stimulating bone resorption relative to bone 
formation (Seriwatanachai 2008, Motyl 2012), and thirdly, prolonged hyperprolac-
tinemia may cause hypogonadotropic hypogonadism (Graham 2011), resulting 
from the suppression of gonadotropin-releasing hormone (GnRH) secretion in the 
hypothalamus and the diminished secretion of LH and FSH by the pituitary gland, 
resulting in a diminished secretion of sex hormones and ultimately in changes of 
bone metabolism (Schwetz 2012). Sex hormones increase BMD. 
Only one study has investigated the effect of AP-induced hyperprolactinemia on 
BMD in boys with different diagnoses (n=83; mean age 11.9 years, SD 2.8) (Calarge 
2010). BMD was lower in boys with hyperprolactinemia than in boys without hy-
perprolactinemia, but comparisons with healthy controls were not made. In adoles-
cents with prolactinomas, in which prolactin levels are at least two to four times 
higher than in AP-induced hyperprolactinemia, BMD was decreased and was not 
restored after 2 years of treatment with dopamine agonists (Colao 2000). Several 
studies of adults have shown AP-induced hypogonadism to be associated with a 
decreased BMD (Abraham 20031,2, Meany 2004, ‘O Keane 2005) and two large 
case-control studies (44,500 patients and 16,341 patients) showed AP medication 
I N T R O D U C T I O N  
 19 
to be associated with a two-fold increased risk of hip or femur fractures (Hugen-
tholz 2005, Howard 2007). 
Prolactinomas/ cancer risk 
Treatment with potent D2-receptor antagonists, such as risperidone, may be asso-
ciated with pituitary tumors. A retrospective pharmacovigilance study performed 
as part of the United States FDA’s Adverse Event Reporting System database re-
ported an association between treatment with risperidone and the prevalence of 
pituitary tumors (Sfarzman 2006). A Swedish study (N=969, follow-up 8 years) 
found a small but significant increase in the overall cancer risk in prolactinoma-
induced hyperprolactinemic patients after diagnosis compared to ten individuals 
individually matched to each patient for sex, birth year, and county of residence, 
selected from the general population. This overall increased risk of cancer in hy-
perprolactinemia patients was mainly attributed to an increased risk of upper gas-
tro-intestinal (hazard ratio (HR) 3.69) and hematopoietic cancer (HR 3.51) (Ber-
inder 2011). In prolactinomas the prolactin level is two to four times more elevated 
than in AP-induced hyperprolactinemia. These data are not conclusive and have no 
clinical consequences at this moment. However, the relationship between AP-
induced hyperprolactinemia and (long-term) risk of cancer should be a topic for 
future longitudinal studies. 
3. Hyperprolactinemia and genetic risk factors 
Pharmacogenetic differences in individuals may explain variations in prolactin 
elevation in response to AP medication leading to clinical consequences. As D2 
antagonism plays an important role in the prolactin elevation, the dopamine D2 
receptor gene (DRD2) is an attractive candidate gene to investigate variations in 
AP-induced prolactin elevation response. Post mortem brain studies (Thompson 
1997) revealed a lower dopamine D2 receptor density in the striatum and related 
structures in A1 allele carriers of the DRD2 Taq1A polymorphism (rs1800497) 
compared to that in non-carriers. Similar results, a lower -141C Ins/Del promoter 
polymorphism in the dopamine D2 receptor gene, were found in a Japanese (Ari-
nami 1997) and a Swedish association (Jönsson 1999) studies of patients with 
schizophrenia. Other studies show an association between the presence of the A1 
allele of Taq1A and a higher prolactin level elevation in relation to AP treatment in 
female (Mihara 2001), and male patients with schizophrenia (Young 2004). An-
other study of children and adolescents treated long-term with risperidone showed 
four times more prolactin-related side effects in Taq1A A1 allele carriers (Calarge 
2009). Since prolactin elevation is related to levels of APs in the blood, the gene 
coding for the cytochrome P450 2D6 enzyme (CYP2D6) is another interesting can-
didate gene for explaining variations in prolactin level after treatment with AP 
medication, especially risperidone. The CYP2D6 gene is highly polymorphic result-
ing in different phenotypic metabolism rates of the encoded enzyme. Normal me-
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tabolizers are homozygous for functional CYP2D6 alleles or heterozygous with one 
functional CYP2D6 allele; poor metabolizers (7% of Caucasian, 1% of Asian, and 3% 
of African individuals) have no functional CYP2D6 alleles. Ultra rapid metabolizers 
have a duplication (rapid) or multiplications (ultrarapid) of the intact CYP2D6 gene 
(found in 2% of the Caucasian population and up to 25% of several Ethiopian sub-
populations) (Sachse 1997, Berecz 2004). An earlier study showed the number of 
functional CYP2D6 alleles to be associated with the prolactin level. The more func-
tional the CYP2D6 alleles, the higher the risperidone and 9-OH risperidone levels 
and as a consequence the higher prolactin levels (Troost 2007). However, other 
studies report a higher risk of clinically important side effects among risperidone 
treated patients with impaired CYP2D6 enzyme activity (Berecz 2004, De Leon 
2005). In this thesis we want to investigate whether the A1 allele of the DRD2 
Taq1A polymorphism and the CYP2D6 enzyme activity play a role in developing 
hyperprolactinemia. If these pharmacogenetic differences influence prolactin lev-
els, they may have clinical consequences and provide input to considerations as to 
whether these risk factors should be assessed before prescribing the APs. 
Outline of the thesis 
The overall aim of this thesis was to evaluate the prevalence and (genetic) risk fac-
tors of AP-induced hyperprolactinemia and prolactin-related side effects (e.g., gy-
necomastia, galactorrhea, sexual functioning disorders) in young males with ASD 
and / or DBD treated long-term (>16 months) with AP. Further, this study investi-
gated whether those young males with AP-induced hyperprolactinemia had hypo-
gonadotropic hypogonadism, delayed puberty, or diminished BMD, when compared 
to the males with ASD or DBD without hyperprolactinemia with and without AP 
treatment and to healthy controls. Knowledge about the risk factors and the out-
come parameters could answer the question whether it is better to actively monitor 
prolactin levels before and during treatment in all patients with AP treatment or to 
monitor only when prolactin-related-side effects occur. We also wanted to investi-
gate if pre-treatment assessment of genetic risk factors may help in deciding 
whether to prescribe a prolactin elevating antipsychotic or not. 
 
The study was divided in two parts: 
Part 1, Chapter 2: Literature Review 
This chapter contains a descriptive review of AP-induced hyperprolactinemia in 
children and adolescents. Data on prolactin levels available for haloperidol, pi-
mozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine are re-
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viewed, based on 29 selected studies. Literature searches were done using the Eng-
lish Medline/ Embase/ Psychinfo/ EBM databases (1965– August 2008). 
Part 2a, Chapters 3–5: Prevalence and risk factors 
This part evaluates AP-induced hyperprolactinemia in children/adolescents and 
the risk factors. 
The work is presented in three different chapters (chapter 3-5). 
All participants for this cross-sectional study were recruited from the total pa-
tient population of the outpatient adolescent clinic of the GGz Central Psychiatric 
Center, the Netherlands, during the period from October 2006 to November 2009. 
We included 62 children and adolescents (56 boys and 6 girls aged between 10 and 
20 years) in the AP treated group (treatment with any AP medication lasted con-
tinuously for more than 16 months) and 57 children and adolescents in the medica-
tion-naïve group (47 boys, 10 girls). All participants had an IQ above 85 and were 
excluded if they had a history of thyroid disorders, syndromes or other chronic 
diseases affecting puberty, endocrine disorders, if they used oral corticosteroids or 
anticonvulsants, or if they had a known cause of hyperprolactinemia (Verhelst 
2003, Melmed 2011). 
 
In detail Chapter 3 aims to investigate the long-term treatment effects of risperi-
done on prolactin levels and prolactin-related side effects in pubertal boys with 
ASD and DBD. The prevalence of hyperprolactinemia and prolactin-related symp-
toms such as sexual functioning disorders are described. 
 
Chapter 4 evaluates the effect of AP-induced-hyperprolactinemia on testosterone, 
LH, FSH, Inhibin B, and puberty in boys with ASD and DBD. 
 
Chapter 5 presents a study of the long-term effects of AP treatment and AP-induced 
hyperprolactinemia on BMD and body composition in male adolescents with ASD 
and DBD. 
Part 2b, Chapter 6 
In this study the effect of the Taq1A variant in the Dopamine D2 receptor gene 
(DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene 
(CYP2D6) on prolactin levels in boys with ASD and DBD treated with risperidone is 
investigated. 
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Chapter 7: Summary and discussion 
In this chapter the presented data is summarized and discussed, and recommenda-
tions are given together with suggestions for future research. 
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Abstract 
 Objective: This review reports the incidence of hyperprolactinaemia, its rela-
tion with genotype, and prolactin related side effects in children and adolescents 
treated with antipsychotics.  
 Method: Data on prolactin levels were available for haloperidol, pimozide, 
risperidone, olanzapine, clozapine, ziprasidone and quetiapine. Twenty-nine stud-
ies were selected after a literature search in the English Medline/ Embase/ Psy-
chinfo/ EBM databases (1965- August 2008) 
 Results: All antipsychotics, except clozapine, ziprasidone and quetiapine, in-
crease the mean prolactin level from baseline values of 8.0 ng/ml to 25-28 ng/ml 
after four weeks of treatment (reference range 0-15 ng/ml). Most and best data are 
available for risperidone. Five risperidone studies (n=577) show an increase of 
prolactin level from 7.8 ng/ml to 17.7 ng/ml after one year of treatment and two 
risperidone studies (n=60) show an increase from 7.4 ng/ml to 24.9 ng/ml after 
two years of treatment. Aggregated over all antipsychotics prolactin related side 
effects, such as gynaecomastia, galactorrhea, irregular menses and sexual dysfunc-
tion were reported by 4.8% of the children and adolescents. No data are available 
on bone mineral density in relation to antipsychotic-induced hyperprolactinaemia 
in children and adolescents. Prolactin levels may be influenced by the genetic dif-
ferences that influence prolactin metabolism and D2 receptor density 
 Conclusion: Persistent elevation of prolactin for periods up to two years has 
been documented in the maintenance treatment with risperidone. Very limited 
long-term data of pimozide, olanzapine and quetiapine prohibit drawing conclu-
sions for these antipsychotics. Systematic long-term observational studies including 
specific questionnaires as well as physical examination, are needed to investigate 
prolactin related side effects of antipsychotic treatment in children and adolescents. 
 
 Keywords: Adolescent, Child, Hyperprolactinaemia, Puberty, Bone mineral 
density, Antipsychotic agents, Genetics  
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Introduction 
The number of prescriptions for (a)typical antipsychotics to treat children and 
adolescents with both schizophrenia and other psychotic conditions and with non-
psychotic conditions such as autism spectrum disorders, disruptive behavioural 
disorders, tic disorders and behavioural problems associated with mental retarda-
tion has increased significantly (Schirm 2001) (Zito 2003) (Cooper 2004) (Correll 
2008). This increase can be attributed largely to the introduction of new antipsy-
chotics with fewer extra pyramidal side effects (Correll 2004), greater efficacy for 
broader target symptoms (Buckley 2001) and possibly improved compliance (Dol-
der 2002) (Menzin 2003). 
In particular, low dosages of risperidone and olanzapine appear to be effective 
in the treatment of behavioural problems in autism spectrum disorders (Malone 
2002) (McCracken 2002), conduct disorders (Findling 2000) (Aman 2002) (Snyder 
2002) and acute psychotic symptoms (Arango 2004) (Sikich 2004). However, 
risperidone and olanzapine may have potential long-term side effects. There is 
increasing awareness of the impact of long-term side effects of antipsychotics in 
children and adolescents. Since these children and adolescents are in a continuous 
state of development and maturation they may be more vulnerable to these side 
effects than adults. The understanding of the complex interaction of these drugs 
with neurochemical systems, such as pre- and post synaptic receptor systems and 
binding to transporter sites or to secondary or tertiary messenger systems in the 
brain would explain these potential long term side effects. Many of these interac-
tions have not yet been clarified. Our knowledge about these medication-brain 
interactions has been quite limited.  
One side effect of antipsychotics is hyperprolactinaemia. The secretion of pro-
lactin by the anterior pituitary gland is inhibited by the tubero-infundibular dopa-
mine system. Hyperprolactinaemia is caused by blocking of the D2 dopamine-
receptor at the anterior lobe of the pituitary gland, resulting in high prolactin levels. 
This may cause a decline in gonadotropins and a decrease in oestrogen- and testos-
terone-concentrations (Haddad 2004) (Halbreich 2003). Strong D2 dopamine-
receptor blocking antipsychotics, such as amisulpiride, cause frequent hyper-
prolactinaemia in adults (Paparrigopoulos 2007) but data in children and adoles-
cents are not available. 
The tubero-infundibular D2 dopamine receptors are known to react more sen-
sitively and fast to the D2 blocking effects of antipsychotics than the D2 receptors in 
the mesolimbic and mesocortical dopamine systems (Langer 1977) (Halbreich 
2003). Prolactin is secreted intermittently, which may result in variation between 
single samples. 
Hyperprolactinaemia associated with antipsychotic medication may be more 
prevalent in children and adolescents than in adults, because the density of D2 
dopamine receptors in the central nervous system is higher in children and adoles-
cents than in adults (Seeman 1987).  
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Hyperprolactinaemia may cause gynaecomastia, galactorrhea, irregular menses and 
amenorrhea in women, sexual dysfunction (decreased sexual desire, erectile/ 
ejaculatory dysfunction, orgasmic dysfunction, vaginal dryness), and reduced fertil-
ity (Bobes 2003) (Costa 2007) (Knegtering 2003, 2004, 2006) (Nakonezny 2007). 
The induced hypogonadotropic hypogonadism together with low oestrogen and 
testosterone levels may cause low bone mineral density and osteoporosis (Abra-
ham and Halbreich 2003) (Abraham and Paing 2003) (Meaney 2004) (Hugenholtz 
2005) (O'Keane 2005) (Becker 2006) (Howard 2007). This effect may be even more 
marked in adolescents because puberty is an important period for the attainment of 
peak bone mass (Davies 2005). Serum prolactin levels vary in time and between-
individuals. There is reasonable consensus regarding the upper limit of the normal 
range (hyperprolactinaemia) being 500 mU/L in both men and women at adult age, 
which is approximately 15 ng/ml (Bevan 1991). However, some authors suggest an 
upper limit of 25 ng/ml for adults (Lenton 1979) (Marken 1992). Studies in chil-
dren and adolescents show slightly lower values (Gässler 2000). There is individual 
variation in plasma prolactin level at which symptoms appear. Some symptoms, for 
example galactorrhea, reflect raised prolactin acting on target tissue while other 
symptoms, such as amenorrhoea, are due to secondary hypogonadism. Amenor-
rhoea usually appears at prolactin levels above 60 ng/ml (Haddad 2004).  
A previous review on antipsychotic-induced hyperprolactinaemia in children 
and adolescents was published in 2004 and included 14 studies (Pappagallo 2004). 
Eighteen studies were published thereafter and are include in our review. Pappa-
gallo (2004) reported an overall incidence of 20%. Our review reports an incidence 
of respectively 90%, 80%, 62%, 31% and 12% with haloperidol, pimozide, risperi-
done, olanzapine and quetiapine during treatment. Recent reviews on hyper-
prolactinaemia did not include children and adolescents and were not comparable 
to the incidence numbers of this review (Byerly 2007). The objective of this review 
was to evaluate the incidence and severity of antipsychotic induced hyper-
prolactinaemia, the incidence of prolactin-related side effects, and the role of ge-
netic vulnerability factors among children (≤ 12 years of age) and adolescents (12 
to18 years of age).  
Method 
A search was conducted in the English Medline/ Embase/ Psychinfo/ EBM data-
bases (1965- August 2008) using the terms: “risperidone”, “olanzapine”, “pi-
mozide”, “clozapine”, “quetiapine”, “haloperidol”, “aripiprazole”, “amisulpiride”, 
“ziprasidone”, “(a)typical antipsychotics”, “adverse effects”, “side effects”, ” hyper-
prolactinaemia”, ”bone mineral density”, “children”, “adolescents”, “prolactinoma”, 
“osteoporosis”, “prolactin”, “hypogonadism”, “bone density”, “sex hormone”, “an-
drogen”, “estrogen”, “metabolic”, “endocrine”, “puberty disorders”, “delayed pu-
berty”, “polymorphism”, “genetic” and “puberty”. The terms were used alone or in 
R E V I E W  
 33 
various combinations. Data appearing only in abstracts of scientific meetings or in 
journals written in languages other than English were excluded. The results were 
based upon studies carried out with children and adolescents. All reports (except 
single case reports) with a duration longer than three weeks were included. Data 
about prolactin levels were available for haloperidol, pimozide, risperidone, olan-
zapine, clozapine, ziprasidone and quetiapine. Antipsychotics were converted to 
chloorpromazine equivalent doses (CPZ) (Woods 2003). 
Results  
Data 
Twenty-nine publications with study durations longer than three weeks were 
found: risperidone (n=20), olanzapine (n=7), quetiapine (n=5), haloperidol (n=4), 
pimozide (n=3), clozapine (n=2) and ziprasidone (n=1). These studies varied in 
terms of the duration of treatment which ranged from 3.3 to 106 weeks. Six papers 
were based on the same clinical sample and study (Wudarsky 1999) (Alfaro 2002) 
(Aman 2002) (Findling 2004) (Croonenberghs 2005) (Reyes 2006). The samples 
included children with disruptive disorders, conduct disorder, oppositional defiant 
disorder, autism, schizophrenia, schizoaffective disorder, schizophreniform disor-
der, psychotic disorders NOS, Tourette’s syndrome, bipolar affective disorder with 
psychotic features, depression with psychotic features and children with normal 
and subnormal intelligence. The design of the studies varied. 17 studies had an 
open label design, four studies had an observational design (Frazier 1999) (Masi 
2003) (Stevens 2005) (Staller 2006) and eight studies were double blind (Sallee 
1996) (Wudarsky 1999) (Snyder 2002) (Alfaro 2002) (Aman 2002) (Sikich 2004) 
(Hellings 2005) (Luby 2006). Seven risperidone studies (Turgay 2002) (Findling 
2004) (Croonenberghs 2005) (Stevens 2005) (Reyes 2006) (Staller 2006) (Ander-
son 2007) monitored prolactin for a period of 48 to 106 weeks. For olanzapine, 
quetiapine and pimozide one long-term study has been performed (Suwa 1984) 
(Staller 2006). Clozapine and ziprasidone were studied for six weeks. 
The total number of patients studied for risperidone, olanzapine, quetiapine, 
haloperidol, pimozide, clozapine and ziprasidone were 1382, 170, 72, 56, 46, 30 
and 12 respectively. The weighted average of the percentage of boys included in the 
studies ranged from 63-82.5%. Ten of the 29 studies used a prospective design with 
prolactin as the principal outcome variable (Simeon 1979) (Sallee 1996) (Wudar-
sky 1999) (Masi 2001) (Alfaro 2002) (Masi 2003) (Saito 2004) (Hellings 2005) 
(Anderson 2007) (Troost 2007). Two studies had no medication-free baseline 
measurement (Saito 2004) (Sikich 2004) and six studies had no prolactin baseline 
measurement (Hardan 1996) (Frazier 1999) (McConville 2000) (Fegert 2003) 
(Stevens 2005) (Anderson 2007). Co-medication was permitted in 19 out of 29 
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studies. In five studies (Wudarsky 1999) (Shaw 2001) (Alfaro 2002) (Anderson 
2007) (Dittmann 2008) the use of co-medication was unknown and in six studies 
co-medication was not allowed (Simeon 1979) (Suwa 1984) (Sallee 1996) (Masi 
2001, 2003) (Luby 2006). Eleven studies (Frazier 1999) (McConville 2000) (Shaw 
2001) (Snyder 2002) (Findling 2004) (Saito 2004) (Sikich 2004) (Hellings 2005) 
(Stevens 2005) (Reyes 2006) (Staller 2006) allowed co-medication that can cause 
modest elevations of prolactin levels such as antidepressants (Molitch 2005) and 
melatonin (Blaicher 1999) and five studies allowed other co-medication, such as 
psycho stimulants, benzodiazepines and anticholinergics (Hardan 1996) (Aman 
2002) (Turgay 2002) (Croonenberghs 2005) (Troost 2007) . 
Most studies (17) used 0-18 ng/ml for boys and 0-30 ng/ml for girls, but four 
studies used 0-15 ng/ml for boys and girls (Frazier1999) (Masi 2001, 2003) (Ste-
vens 2005) while eight studies did not give a reference value (Suwa 1984) (Shaw 
2001) (Aman 2002) (Fegert 2003) (Sikich 2004) (Luby 2006) (Anderson 2007). All 
the data are summarized in Tables 1-4; the weighted averages were calculated by 
multiplication of the number of patients and the matching variable of the same 
study. The amounts of the different studies were added and then divided by the 
total number of patients. Medication-free prolactin baseline values were missing in 
two studies and seven studies had no prolactin baseline value measurement; these 
studies were left out of the prolactin baseline weighted average calculation.  
Prolactin level 
All antipsychotics, except clozapine, ziprasidone and quetiapine, increase the pro-
lactin level from baseline values of 8.0 ng/ml to 25-28 ng/ml after four to eight 
weeks of treatment. Eight short-term risperidone studies (n=739) with an average 
duration of 4.6 weeks showed an increase of prolactin from 7.9 ng/ml at baseline to 
27.6 ng/ml at endpoint (Aman 2002) (Snyder 2002) (Masi 2001) (Turgay 2002) 
(Fegert 2003) (Croonenberghs 2005) (Anderson 2007) (Troost 2007). Further 
treatment shows a decrease to 17.7 ng/ml (male 15.8 ng/ml and female 20.8 
ng/ml) after one year of treatment (Croonenberghs 2005) (Findling 2004) (Ander-
son 2007) (Stevens 2005) (Turgay 2002) and to 24.9 ng/ml (male 24.6 ng/ml and 
female 27.6 ng/ml) after two years of treatment (Reyes 2006) (Staller 2006). Long-
term prolactin level is still elevated compared to baseline and compared to refer-
ence value after one year and two year of treatment. A pimozide study (n=13) 
showed an increase after one year of treatment from 12.4 ng/ml to 24.5 ng/ml 
(Suwa 1984), but one olanzapine study (n=7) showed no increase of prolactin level 
after one year of treatment (Staller 2006).  
The possibility to draw conclusions is limited by the small sample size, how-
ever. Thus, persistent elevation of prolactin has been clearly documented in the 
maintenance treatment with risperidone for up to two year. 
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As shown in Tables 1-4, the incidence of hyperprolactinaemia during treatment 
with haloperidol, pimozide, risperidone, olanzapine and quetiapine was respec-
tively 90%, 80%, 62%, 31% and 12%. 
It is not likely that the prolactin elevation is illness-related, since comparative 
populations, namely the one with disruptive disorder, conduct disorder and opposi-
tional defiant disorder (n= 1060) treated with risperidone the one with autism 
treated with risperidone (n=158) showed no difference with respect to the severity 
or incidence of prolactin elevation. It is not possible to draw conclusions about 
illness-related prolactin elevation for the populations with affective, tic and psy-
chotic disorders because of their small sample size. 
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Prolactin related side effects 
Sex hormones 
As far as we know, no attention has yet been given on the prolactin-raising effect on 
sex steroid levels in children or adolescents receiving antipsychotic medication. 
Pubertal development 
Only two studies with duration of one year investigated the association between 
risperidone and the progression of puberty (Dunbar 2004, Reyes 2006). No effect 
was found on the progression of Tanner stages after one year follow-up. 
Neuroendocrine and sexual side effects 
Tables 1-4 show that children and adolescents treated with olanzapine, haloperidol, 
quetiapine and respectively risperidone report 13.8%, 13.5%, 5.7% and 5.1% 
symptoms related to hyperprolactinaemia. Most frequently reported are gynaeco-
mastia (risperidone 3.0%, olanzapine 6.2%, haloperidol 6.7%) and irregular men-
ses (risperidone 6.3%, haloperidol 15.4%, quetiapine 11.8%). In a prospective 
study of hyperprolactinaemia in children and adolescents 25% (10/40) reported a 
decrease in sexual performance, and in another double-blind randomized 8 week 
trial 22% of 50 adolescents treated with prolactin-raising atypical antipsychotics 
reported sexual side effects (Sikich 2004) (Saito 2004). Unfortunately, many stud-
ies did not report on sexual side effects. 
Bone mineral density (BMD) 
So far no studies have examined the effect of prolactin-raising antipsychotic medi-
cation on BMD in adolescents.  
Discussion 
The main conclusion from this review is that all antipsychotics except clozapine, 
ziprasidone and quetiapine, cause a rise in prolactin level to levels higher than two 
times the upper normal limit after four to eight weeks of treatment. Furthermore, 
long-term studies with adequate sample size have only been performed with 
risperidone and limited long-term data are available of pimozide, olanzapine and 
quetiapine which leads to cautiousness in drawing conclusions about these latter 
medications. Anyhow, available data show that risperidone and pimozide induce a 
persistent elevation in prolactin level above the upper limit, while with olanzapine 
the prolactin level normalizes to baseline value. Quetiapine did not increase the 
mean prolactin level (Shaw 2001, Staller 2006). The actual percentage of children 
or adolescents that had hyperprolactinaemia was measured in a few studies (Ta-
bles 1-4). The weighted average incidence of 12 % hyperprolactinaemia in the 
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quetiapine group was reported in the text of three studies. No baseline measure-
ments were available, thus pre-existing hyperprolactinaemia could not be excluded. 
Furthermore, prolactin elevating co-medication was used in two out of three stud-
ies (Saito 2004, Stevens 2005).  
Prolactin levels were averaged across the whole sample studied; including 
those whose prolactin levels were not raised. Therefore, group mean data shown in 
Tables1-4 are lower than the mean data of the subgroup of children and adoles-
cents with prolactin levels above the upper limit. Little is known about the clinical 
consequences of a sustained higher prolactin level over years among children and 
adolescents.  
Only two studies with duration of one year investigated the association be-
tween risperidone and the progression of puberty (Dunbar 2004, Reyes 2006). 
Although no effect was found on the progression of Tanner stages a one year fol-
low-up may be too short to draw conclusions about the effect of pubertal develop-
ment or later developmental processes. It is known that hyperprolactinaemia due 
to prolactinoma is associated with delayed puberty, but in those patients prolactin 
levels were much higher, in the range of 200 ng/ml or above, than in the child and 
adolescent psychiatric samples included in this study (Greenspan 1986) (Howlett 
1989) (Kawano 2000) (Patton 1983) (Sack 1984). It is also known that prolac-
tinoma-induced hyperprolactinaemia induces a decrease in testosterone levels in 
men/pubertal boys but no studies have been performed to examine the effect of 
antipsychotic-induced hyperprolactinaemia on the sex hormone levels. Studies in 
adult males show that the prolactin-raising effect of antipsychotics leads to a sig-
nificant decline in Luteinizing Hormone, Follicle Stimulating Hormone and testos-
terone although the levels remained within the normal range (Carter 1982) (Siris 
1980). Prolactin related side effects, such as gynaecomastia, galactorrhea, irregular 
menses and sexual side effects were reported by 4.8% of the total number of pa-
tients. In several adult studies 30% to 60% of adult patients using prolactin-raising 
antipsychotic medication reported sexual side effects, such as erection and ejacula-
tory and menstrual disturbances compared to about 10% of patients using prolac-
tin-sparing antipsychotic medication (Knegtering 2003). In The Outcomes Research 
Study in schizophrenia (EIRE) (Bobes 2003), the prevalence of sexual dysfunction 
and reproductive side effects was investigated in 365 adult schizophrenic Spanish 
patients using prolactin-raising antipsychotics, risperidone and haloperidol, com-
pared to 43 patients using quetiapine. The prolactin-raising antipsychotic treat-
ment was associated with 40% sexual dysfunction compared to 18% in the quetiap-
ine group. Several studies show a relationship between serum prolactin level and 
sexual functioning, strength of sex drive, penile erection and sexual arousal (Costa 
2007) (Knegtering 2003, 2004, 2006) (Nakonezny 2007). The 4.8% of the total 
number of patients in this review that reported sexual dysfunction is low in relation 
to the percentage of adult patients that report these side effects. This discrepancy 
can be partly explained by comparing the method of the different studies, sponta-
neous self report in adolescents and children versus questionnaires used in adult 
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studies. Besides the method also the age of sexual development and the diagnosis 
play an important role. The adults were mainly adults with psychotic disorders 
whereas the children and adolescents had autistic or behavioural disorders.  
The effect of antipsychotic-induced hyperprolactinaemia on BMD has not been 
studied in children and adolescents. Several adult studies have investigated antip-
sychotic-induced hyperprolactinaemia, and possibly related hypogonadism, and 
related effects on BMD. These studies show a relation between antipsychotic-
induced hypogonadism and a decrease in BMD (Abraham and Halbreich 2003) 
(Abraham and Paing 2003) (Meaney 2003, 2004) (O'Keane 2005) (Becker 2006). 
Furthermore, two large case-control studies (44,500 patients and 16,341 patients) 
showed that prolactin-raising antipsychotic medication was associated with a two-
fold increased risk of hip or femur fractures. The validity of this finding was sup-
ported by a dose increase relationship, i.e. the longer duration of antipsychotic use 
the higher the risk (Howard 2007) (Hugenholtz 2005). 
The relation between hyperprolactinaemia and BMD loss in adolescents was 
studied in patients with prolactinomas. The effect of hyperprolactinaemia on BMD 
was studied by comparing the results for two groups of patients with prolactino-
mas, one group of 20 adolescents and one group of 20 adults. The adolescents had 
more severe bone loss than the adults. After two years of treatment with dopa-
minergic drugs, the bone mass and bone turnover in the adolescent group were still 
not restored to normal values (Colao 2000). Prolactin levels above 60 ng/ml are 
likely to be associated with hypogonadism in adult studies (Haddad 2004). The 
occurrence of osteopenia or osteoporosis correlates with the presence and duration 
of hypogonadism rather than the degree of hyperprolactinaemia (O'Keane 2005) 
(Greenspan 1989) (Misra 2004). Adolescence is an important period for the at-
tainment of peak bone mass (Davies 2005) and disturbances in this process during 
puberty may influence the risk of osteoporosis later in life. The bone cortical thick-
ness was reported to be significant reduced in 75 boys, aged 4 to 8 years, with au-
tism or autism spectrum disorders, indicating that bone development should be 
monitored in these patients (Hediger 2008). Besides the dose and duration of an-
tipsychotic medication, prolactin levels may be influenced by the genetic differ-
ences that influence prolactin metabolism and D2 receptor density. However, the 
genetic studies performed so far; by Anderson et al, (Anderson 2007) and Troost et 
al, (Troost 2007) included small number of patients, respectively 42 and 26. In 
2004 another review on prolactin and antipsychotic agents in children and adoles-
cents was published (Pappagallo 2004) and in 2007 a review on prolactin elevation 
and antipsychotic treatment in adult patients with schizophrenia and bipolar dis-
orders was published (Beyerly 2007). Pharmacovigilance studies indicate that, 
although very rarely, hyperprolactinaemia due to D2 blocking antipsychotics may 
be associated with increased risk for pituitary tumours (Koves 2004, Szarfman 
2006). 
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Prolactin level and mediators 
Post pubertal status (Duval 2007), female gender, higher relative doses of antipsy-
chotic medication and genetic differences are all known risk factors for prolactin 
elevation. Adolescent women of reproductive age have greater prolactin response 
to antipsychotics than prepubertal girls or males. Estrogen stimulates prolactin 
synthesis and enhances prolactin response to neuroleptic medication (Sallee 2000, 
Alfaro 2002, Saito 2004). Age related decrease in dopamine receptors (Seeman 
1987) also gives a more pronounced effect in post pubertal adolescents and chil-
dren compared to adults (Wudarsky 1999). Genetic differences may explain indi-
vidual variation in whether hyperprolactinaemia leads to clinical consequences. 
The Taq1 A1 allele of the D2 dopamine receptor gene (DRD2) is associated with a 
significantly reduced density of D2 receptors. Also the metabolization rate of pro-
lactin-inducing antipsychotics may influence prolactin  
levels.  
Limitations 
The conclusions of this review are limited by the design and limitations of the orig-
inal studies such as the use of concomitant prolactin-elevating medication, the 
short overall study duration of most studies, differences in the diagnosis, age and 
pubertal status and the lack of prolactin baseline values in 7 out of 29 studies (Ste-
vens 2005) (Anderson 2007) (Hardan 1996) (Frazier 1999) (McConville 2000) 
(Fegert 2003), an overlap in populations or the missing of medication-free baseline 
values in 2 out of 29 studies(Sikich 2004) (Saito 2004) they were excluded from the 
analysis. Further, publication bias likely exists in that not all data on prolactin levels 
available in drug companies’ files, have been published. 
Furthermore, since prolactin-related side effects were mainly based on sponta-
neous self-report, the actual percentage of prolactin-related side effects may have 
been underestimated. In addition it may be impossible in some patients to distin-
guish between prolactin-related side effects and common physiological processes 
such as gynaecomastia in early pubertal boys and irregular menstrual cycles in 
females during the first few years after menarche (Bembo 2004) (Hanavadi 2006). 
Higher age, post pubertal status (Duval 2007), female gender and higher rela-
tive doses of antipsychotic medication are all known risk factors for prolactin eleva-
tion. The mean age of the risperidone and respectively pimozide studies was 9.7 
and 10.3 years, of which most patients were pre-pubertal, while the mean age in the 
olanzapine, quetiapine, haloperidol, pimozide, ziprasidone and clozapine studies 
was respectively 14.4, 13.9, 12.7, 14.5 and 14.5 years and the patients were mainly 
post-pubertal. The relative CPZ dose of the antipsychotic used was 80 mg for 
risperidone versus 254 mg, 123 mg, 505 mg, 208 mg, 164 mg and 360 mg for olan-
zapine, pimozide, quetiapine, clozapine, ziprasidone and haloperidol respectively. 
The percentage male vs. female among the different studies was also roughly the 
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same for quetiapine, olanzapine, clozapine and haloperidol, where as for risperi-
done, ziprasidone and pimozide the percentage of males was slightly higher. Lower 
overall age, low relative CPZ dose, higher percentage of males and pre-pubertal 
status may have masked an actual higher elevation of prolactin in the risperidone 
group. 
The CPZ dose varied among the different studies. The overall quetiapine and 
haloperidol dose used were respectively five and four times higher than the risper-
idone dose used. The dose of olanzapine and clozapine were two fold higher and of 
pimozide one and a half times higher than the risperidone dose. This may have 
biased the comparison of these medications in terms of side-effects and elevation of 
prolactin.  
Prolactin reference values differed between the studies and that influenced the 
percentage of hyperprolactinaemia. Most studies (17) used 0-18 ng/ml for boys 
and 0-30 ng/ml for girls, but 4 studies used 0-15 ng/ml for boys and girls (Stevens 
2005) (Masi 2001, 2003) (Frazier1999) while 8 studies did not give a reference 
value (Aman 2002) (Sikich 2004) (Anderson 2007) (Suwa 1984) (Fegert 2003) 
(Shaw 2001) (Luby 2006). Furthermore, only 15 out of 29 studies reported the 
incidence of hyperprolactinaemia (table 1-4).  
Clinical Implications 
The clinical value is related to the consequences of long-term hyperprolactinaemia 
such as a decline in sexual function (Costa 2007) (Knegtering 2003, 2004, 2006) 
(Nakonezny 2007) and decreased bone mineral density (Abraham and Halbreich 
2003) (Abraham and Paing 2003) (Meaney 2003, 2007) (O'Keane 2005) (Becker 
2006). Children and adolescents may be more vulnerable to the adverse effects of 
hyperprolactinaemia.  
Therefore, prolactin-related side effects should be systematically investigated 
e.g. with the help of a side effect checklist for children and adolescents (Saito 2004) 
and with a physical examination.  
This review suggests that prolactin levels should be monitored in children or 
adolescents with sexual dysfunctions, gynaecomastia galactorrhea or hypogonad-
otrophic hypogonadism. The antipsychotic-induced hyperprolactinaemia can be 
treated by lowering the dose or by switching to a prolactin sparing antipsychotic. If 
both strategies fail a dopamine agonist may be added (amantadine, carbergoline) 
(Correll 2008). 
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Abstract 
 Objective: The aim of this study was to investigate the long-term treatment 
effects of risperidone on prolactin levels and prolactin-related side effects in puber-
tal boys with autism spectrum disorders (ASD) and disruptive behavior disorders 
(DBD). 
 Method: Physical healthy 10- to 20-year-old boys with ASD (N=89) and/ or 
DBD (N=10) chronically treated (mean 52 months, range 16-126 months) with 
risperidone (group 1, N=51) or not treated with any antipsychotic (group 2, N=47) 
were recruited to this observational study from the child psychiatry outpatient 
clinic. Morning non-fasting serum prolactin levels were measured and prolactin-
related side effects were assessed by means of questionnaires and physical exami-
nation. Group differences were tested with Student’s t-, Chi-square-, Fisher exact 
tests, Mann-Whitney tests, and logistic regression anal ysis, according to the type 
and distribution of data. 
 Results: Hyperprolactinemia was present in 47% of boys in group 1 but only in 
2% of boys in group 2 (odds ratio 71.9, 95% CI, 7.7; 676.3). 46% of boys in group1 
had asymptomatic hyperprolactinemia. 
Current risperidone dose and 9-OH risperidone plasma level were significant pre-
dictors of hyperprolactinemia (p=0.035 and p=0.03). Gynecomastia and sexual 
dysfunction were present in 43% and 14% of the boys in group1, respectively, 
compared with 21% and 0% of boys in group 2 (p=0.05 and p=0.01). Gynecomastia 
was not significantly associated with hyperprolactinemia. 
 Conclusion: Hyperprolactinemia is a common side effect in boys treated long 
term with risperidone. Boys treated with risperidone are more likely to report di-
minished sexual functioning than are boys not treated with antipsychotics. 
 
 Key words: Prolactin, Hyperprolactinemia, Adolescents, Risperidone, Sexual 
dysfunction  
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1. Introduction 
Second-generation antipsychotics (AP) are increasingly prescribed to children and 
adolescents with psychiatric disorders and have been used successfully to reduce 
maladaptive behaviours, such as irritability, self-injury, stereotypies and hyperac-
tivity in children and adolescents with autism spectrum disorders (ASD) and irrita-
bility and aggressive behaviour in children and adolescents with disruptive behav-
ior disorder (Aman 2009). 
While risperidone and aripiprazole have been approved by the United States 
Food and Drug Administration (FDA) for the treatment of children and adolescents 
with irritability associated with ASD (RUPP 2002, Stigler 2006, Wink 2010), these 
drugs have not yet been approved for this indication in Europe. Antipsychotics are 
also frequently used, off-label, to treat severe aggression in children and adoles-
cents with disruptive behavior disorder. Despite their efficacy (Wink 2010), there 
are concerns about the widespread use of these drugs given their side effect profile, 
such as, weight gain, metabolic adverse effects (dyslipidemia, hyperglycemia and 
diabetes), cardiac side effects (QTc prolongation), extrapyramidal side effects and 
increased prolactin levels (Molitch 2005, Correll 2008, Vitiello 2009). The side ef-
fects of antipsychotics are well described in adults but less well studied in children 
and adolescents. There are indications that children are more sensitive than adults 
to the metabolic adverse effects of antipsychotics (Correll 2006) and tend to gain 
proportionately more weight and do so more rapidly during treatment than do 
adults (Correll 2006).  
This study investigated the prevalence of hyperprolactinemia and prolactin-
related side effects in children and adolescents on long-term risperidone treatment. 
Hyperprolactinemia is caused by dopamine 2 blockade in the tuberoinfundibular 
pathway and may decrease gonadotropin levels and thereby estrogen and testos-
terone concentrations (Halbreich 2003, Haddad 2004). Estrogen and testosterone 
have important roles in sexual functioning, bone mineralization and puberty (Sara-
nac 2010), such that decreased levels may result in disorders of sexual functioning 
disorders (Cutler 2003, Knegtering 2003), and may delay puberty. One study re-
ported antipsychotic-induced hyperprolactinemia not to affect puberty, in prepu-
bertal children (Reyes 2006), whereas another reported diminished bone mineral 
density in boys on long-term prolactin-elevating antipsychotics (Calarge 2010). It is 
not known what the threshold prolactin level is for adverse effects on sexual func-
tioning, puberty, and bone mineralization.  
In fact, little is known about the consequences of persistently elevated prolactin 
levels in children and adolescents, and in particular about the effects of elevated 
but still subclinical levels of prolactin. A systematic review showed that mainte-
nance treatment of children and adolescents with risperidone results in persis-
tently elevated prolactin levels for up to 2 years (Roke 2009).  
 When investigating the effects of antipsychotic-induced hyperprolactinemia, it 
is important to be able to distinguish between the effect of the mental condition for 
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which the antipsychotic is used and the effects of hyperprolactinemia on sexual 
functioning, puberty, and bone mineralization. For this reason, it is important to 
recruit a psychiatric control group that is not treated with antipsychotics to moni-
tor side effects before and during treatment, to use validated instruments, to physi-
cally examine participants, and to use appropriate age and gender-based reference 
data for endocrine variables. Self-report data are less appropriate because children 
and adolescents may feel embarrassed or are not able to express problems of sex-
ual functioning, and they might not notice physical changes, such as gynecomastia 
or galactorrhea.  
In this study, we investigated the consequences of long-term treatment with 
risperidone on prolactin levels and sexual functioning in boys with ASD and DBD. 
We add to the current literature by recruiting a sample of patients using risperi-
done for longer than 16 months, using a validated questionnaire for assessing sex-
ual dysfunction, using appropriate age and gender-based endocrine reference val-
ues, and using a physical examination to assess gynaecomastia. We compared boys 
with ASD and DBD treated with risperidone (group 1) with boys with ASD and DBD 
not treated with antipsychotics (group 2). 
2.1 Methods 
All participants were recruited from the total patient population of the outpatient 
adolescent clinic of the GGz Central Psychiatric Centre, The Netherlands, from Oc-
tober 2006 to November 2009. The GGz Central Psychiatric Centre hardly ever sees 
children and adolescents with psychotic or bipolar disorders, because these indi-
viduals tend to be referred to the nearby university hospital.  
Inclusion criteria for the medication group (group 1) were: (i) an age between 
10 and 20 years, (ii) diagnoses of any psychiatric disorder, (iii) an IQ above 85, and 
(iv) treatment with any antipsychotic medication continuously for more than 16 
months. Inclusion criteria for the comparison group (group 2) were the same ex-
cept for the use of antipsychotic medication, this group had to be AP naïve. Partici-
pants were excluded if they had a history of thyroid disorders, syndromes or other 
chronic diseases affecting puberty, endocrine disorders, if they used oral corticos-
teroids or anticonvulsants, or if they had a known cause of hyperprolactinemia 
(Verhelst 2003, Melmed 2011). 
The first author contacted all children and adolescents that met the inclusion 
criteria by telephone and letter.  
80% of the contacted group 1 patients (56 boys, 6 girls) participated in the 
study compared to 50% of the group 2 patients (47 boys, 10 girls). All participants 
had a diagnosis of ASD or disruptive behaviour disorder (DBD). The main reason 
for not participating was fear of venipuncture.  
Data of female participants (16 in a total study sample of 119), two boys in the 
AP group using concomitant SSRI medication and three boys treated with pimozide 
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instead of risperidone were not analyzed. Thus the risperidone group (group 1) 
consisted of 51 boys with ASD or DBD treated long-term with risperidone and the 
comparison group (group 2) consisted of 47 boys with ASD or DBD but never been 
treated with an AP. 
Use of other concomitant medication, such as, psychostimulants, melatonin, and 
atomoxetine was permitted (Table 1). The Local Medical Ethics Committee ap-
proved this study and written informed consent was obtained from the patient and 
the subject’s parents/ legal guardians after a clear explanation of the study proce-
dures.  
2.2 Procedures 
The clinical diagnosis was obtained from the patients’ chart.  
Pubertal stage was established by showing the boys different Tanner stage pho-
tographs of genitals (G stage) and pubic hair (P stage) and then asking them to se-
lect the photographs that most accurately reflected their appearance (Duke 1980). 
One of the parents/ legal guardians was present during the self-assessment and 
confirmed the stages pointed out. Sexual functioning was investigated using the 
items (change in sex interest, change in orgasm ability, change in erection ability, 
and change in the amount of ejaculate) of the Antipsychotics and Sexual Function-
ing Questionnaire (ASFQ) (Wolters 2003). This instrument has been developed and 
validated to study antipsychotic -related sexual side effects. The first author ex-
plained what change in orgasm, change in erection, change in sex interest, and 
change in amount of ejaculate meant. If the boys did not remember or did not know 
if there was a difference, then relevant items were scored as unknown. 
The first author, who was not aware of the prolactin data, systematically inves-
tigated prolactin-related side effects with the help of a checklist for children and 
adolescents (Saito 2004) and with a physical examination (breast palpitation); after 
first being trained by a pediatric-endocrinologist to detect the presence of gyneco-
mastia and galactorrhea. The first author also measured the participants’ height 
(without shoes to the nearest 0.1 cm using a stadiometer, Seca 206, the Nether-
lands) and weight (participant wearing underwear, to the nearest 0.1 kg using an 
analogue scale, Seca 761, the Netherlands). Age- and gender-specific height, weight 
and body mass index (BMI) Z-scores were calculated using normative data for 
Dutch children (Fredriks 20001, Fredriks 20002). 
A non-fasting morning blood sample was obtained around 9.30 a.m. after a light 
breakfast was eaten at around 7.30. Serum prolactin was measured with an auto-
mated chemiluminescence assay system (Immulite 2000, Siemens Healthcare Diag-
nostics) calibrated on the 3rd IS 84/500. As macroprolactin, a complex of prolactin 
and IgG without biological activity, accounts for 10% of cases of hyperprolactine-
mia (McKenna 2009), seven samples with prolactin concentrations higher than 37 
ng/mL were assessed for the presence of macroprolactin. Polyethylene glycol 6000, 
200 μL, (25% w/w) was added to 200 μL of serum and, after thorough vortex mix-
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ing, the mixture was centrifuged at 2200 g for 30 min at 4 °C. Subsequently, prolac-
tin was measured in the supernatant and the untreated serum. The recovery of 
prolactin after precipitation with polyethylene glycol 6000 was 101.4 ± 9.6 (mean± 
SD), which excluded the presence of macroprolactin. TSH was measured to exclude 
boys with hyperprolactinemia due to thyroid disorders. Plasma levels of risperi-
done and 9-hydroxyrisperidone were measured to evaluate compliance. 
2.3 Data-analysis 
To test for differences between groups 1 and 2, Student’s t-test, Chi-square, Mann-
Whitney tests, Fisher Exact tests, and logistic regression were used according to the 
type and distribution of data. Hyperprolactinemia was defined as a prolactin level 
above the 97.5th percentile based on normative data for age and gender (Emlinger 
2002) (see Table 3). 
Logistic regression analysis was used to investigate whether risperidone was 
associated with hyperprolactinemia. The following covariates were examined 
based on previous literature: age, BMI Z-score and Tanner stage. A subsequent 
logistic regression analysis was performed to evaluate the influence of type of 
medication, duration of antipsychotic use, use of dosage, risperidone levels, and 9-
OH risperidone levels on hyperprolactinemia in the patients using risperidone, 
corrected for age and BMI Z-score. 
Sexual dysfunction was measured with four items of the ASFQ, scored 0-5 as 
follows: unknown (0), strongly diminished (1), diminished (2), unchanged (3), in-
creased (4) and strongly increased (5), The ASFQ item scores were grouped, to 
increase power, as follows: unknown or not applicable, diminished, unchanged and 
increased. 
Sexual dysfunction was present if a patient scored diminished on one or more 
of the four ASFQ items. 
3. Results 
Ninety-eight boys with ASD or DBD took part in the study. There was no difference 
in mean height Z-score, BMI Z-score, pubertal stage, ethnicity, and use of concomi-
tant medication between the boys in groups 1 and 2: however, there were more 
boys with DBD in group 2 than in group 1 (4% versus 15%, p=0.05). Forty-seven 
boys were not using an antipsychotic, but 51 boys were using risperidone (mean ± 
SD daily dose, 1.5 ± 0.9 mg, range 0.25-4 mg) long term (mean ± SD duration, 53 ± 
27.8 months, range 16-126 months), and 36 boys had used risperidone continu-
ously for 3 or more years.  
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At the time of measurement 14 (27%) of all boys in group 1 had undetectable levels 
of risperidone (0 µg/L) and 4 (8%) of these boys had also undetectable 9-OH 
risperidone levels (Table 1).  
Table 2 presents data on prolactin levels and the prevalence of hyperprolacti-
nemia, asymptomatic hyperprolactinemia, and prolactin-related side effects in the 
two groups, as well as the number of boys in each Tanner stage. Hyperprolactine-
mia was significantly more common among the boys treated with risperidone than 
among the boys not treated with antipsychotic (24 versus 1 boy, 47% versus 2%, 
p< 0.0001). In none of the boys was hyperprolactinemia due to macroprolactin or 
thyroid disorders. 
The prolactin levels of the boys with hyperprolactinemia were in 18 out of 24 
patients (75 %) between the 97.5 percentile level and 30 ng/ml, in 2 out of 24 (8%) 
between 30-50 ng/mL and in 4 out of 24 (17%) higher than 50 ng/mL. 
Among the boys treated with risperidone, hyperprolactinemia was present in 5 
of 7 boys in Tanner stage II (71%), in 6 of 15 boys in Tanner stage III (40%), in 8 of 
21 boys in Tanner stage IV (38%), and in 5 of 8 boys in Tanner stage V (63%). 
Hyperprolactinemia was asymptomatic in 11 boys (46%). The odds ratio of 
having hyperprolactinemia with risperidone treatment was 71.9 (95% CI, 7.7; 
676.3). Adjustment for age and BMI Z-score did not influence the results. Gyneco-
mastia was detected in 24 (47%, measured by questionnaire) and 22 (43%, meas-
ured by physical examination) boys in group 1 and in 10 boys (21%) in group 2 
(p=0.05): this difference remained after adjustment for age and BMI Z-score 
(p=0.02). Of the boys with hyperprolactinemia, 8 (36 %) (N=8) had gynecomastia 
on physical examination (OR=2.86, 95% CI 1.16, 7.06, p=0.26).  
 Sexual functioning was diminished in 7 of the boys in group1 (14%), with 2 
(4%), 4 (8%), 5 (10%), and 1 (2%) of the boys reporting diminished sexual interest, 
diminished ability to have an orgasm, diminished ejaculation and, lower ability to 
have an erection, respectively, compared to none of the boys in group 2 (p=0.01). 
Five of the 7 boys scored their sexual functioning as strongly diminished, and 4 of 
these boys were, Tanner stage IV. Fifteen boys in group 1 (29%) reported their 
change in sexual functioning as unknown and 10 (20%) as unchanged compared 
with 19 (40%) unknown and 5 (10%) unchanged in group 2.  
Sexual dysfunction tended to occur more often in boys with hyperprolactinemia 
(N=27) (21% vs. 8%, p= 0.07). Five of the seven boys with sexual dysfunction had 
hyperprolactinemia.  
Table 4 shows predictors of hyperprolactinemia in boys treated with risperi-
done. The current dose of risperidone and the 9-OH risperidone plasma level both 
predicted hyperprolactinemia (OR=2.4 95%, CI 1.1, 5.5, p=0.035 and OR =1.15, CI 
1.02, 1.09, p=0.03, respectively), whereas the mean dose of risperidone over the 
period, the risperidone plasma level and the duration of treatment did not (Table 
4).  
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Table 1. Characteristics of male children and adolescents with autism spectrum disorders or disruptive 
behaviour disorders with long-term risperidone treatment (N=51) and without antipsychotic treatment 
(N=47). 
 Cases 
(N=51) 
 Comparison subjects 
(N=47) 
P value 
 N (%) Mean (SD; range) N (%) Mean (SD; range)  
Age, years  14.7 (2.1; 10,19)  15.1 (1.6; 11,18) 0.27c  
Height z-score   0.40 (1.1; -2.4, 2.1)  0.35 (0.9; -1.5, 2.9) 0.79c  
Weight z-score  0.49 (1.1; -2.5, 3.2)  0.34 (1.2; -2, 3.9) 0.52c  
BMI 
Underweight 
Normal 
Overweight 
Obese 
 
 3 (6) 
41 (80) 
 7 (14) 
 0 
20.3 (3.3; 14.6, 29.5)  
 6 (13) 
32 (68) 
 8 (17) 
 2 (4) 
20.4 (4; 15,32) 0.94c  
BMI z  0.21 (0.87; -1.8, 1.8)  -0.0.9 (1.2; -3.3, 2.3) 0.16c  
Tanner stages 
I 
II 
III 
IIII 
V  
 
 0 
 7 (14) 
15 (29) 
21 (41) 
 8 (16) 
  
 0 
 9 (19) 
13 (28) 
20 (43) 
 6 (13) 
  
Primary diagnosis 
ASD* 
DBD* 
 
49 (96) 
 2 (4) 
  
40 (85) 
 8 (15) 
  
0.11b  
0.05d  
Risperidone (mg/day)  1.5 (0.9; 0.25,4)   - 
RIS* µg/L  2.7 (5; 0,28)   - 
9-OH RIS* µg/L  8.4 (7.5; 0-36)   - 
Duration of use (months)  53 (27.8; 16-126)   - 
Concomitant medication      
Melatonin 
Psychostimulants 
Atomoxetine 
 4 (8) 
10 (20) 
 2 (4) 
  3 (6) 
13 (30) 
 0 
  
Total 13 (25)  13 (30)  0.17d  
Caucasian ethnicity 49 (96)  45 (96)  0.44b  
a Mann Whitney; b Chi square; c Student t-test; d Fisher Exact test; *ASD= autism spectrum disorders; 
*DBD=disruptive behavior disorder; *RIS=plasma levels of risperidone; *9-OH RIS=plasma levels of 9-
OH risperidone 
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Table 2. Prevalence of hyperprolactinemia and prolactin related side effects in male children and ado-
lescents with mainly autism spectrum disorders with risperidone treatment (N=51) compared to male 
patients without antipsychotic treatment (N=47). 
 Cases 
 N=51 
 Comparison subjects 
N=47  
P value 
 N (%) Mean (SD, range) N (%) Mean (SD, range)  
Prolactin ng/ml* 
 
Tanner stage II 
Tanner stage III 
Tanner stage IV 
Tanner stage V 
 19.3 (16.8, 2.4-92.5) 
 
21.2 (10.4, 11.8, 41.0) 
18.9 (21.2, 5.7, 92.4) 
17.9 (16.9, 2.3, 77.8) 
21.7 (13.7, 6.6, 48.6) 
 8.0 (2.8, 3.8-15.1) 
 
7.7 (2.5, 5.7, 10.8) 
7.3 (3.3, 3.8, 15.1) 
8.5 (4.7, 5.2, 13.2) 
8.5 (3.5, 5.2, 15.1) 
<0.0001a  
Hyperprolactinemia 
 
Tanner stage  
II/III/IV/V 
24 (47) 
 
 
5/6/8/5 
 1 (2) 
 
 
0/1/0/0 
 <0.0001b 
Asymptomatic  
hyperprolactinemia 
 
Tanner stage 
II/III/IV/V 
11 out of 
24 (46) 
 
 
3/4/2/2 
 1 out of 1 
(100) 
 
 
0/1/0/0 
 <0.0001b 
Prolactin related side effects      
Gynecomastia 
Questionnaire 
 
Tanner stage 
II/III/IV/V 
24 (47) 
 
 
 
3/5/12/4
 10 (21) 
 
 
 
2/4/4/0 
 0.01b  
Gynecomastia 
physical examination 
  
Tanner stage 
II/III/IV/V 
22 (43) 
 
 
 
1/8/11/2
 10 (21) 
 
 
 
3/4/3/0 
 0.05b  
Galactorrhea 0  0  - 
Diminished sexual functioning 
-sex interest 
-orgasm 
-ejaculate 
-erection 
7 (14) 
2 (4) 
4 (8) 
5 (10) 
1 (2) 
 0 
0 
0 
0 
0 
 0.013c  
*reference value changes with age and gender (Emlinger et al 2002), see Table 3; a Mann Whitney; b Chi 
square; c Fisher Exact test 
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4. Discussion 
Almost half of the boys treated long-term with risperidone but only 2 % of the pa-
tients not treated with an antipsychotic agent had hyperprolactinemia. Although 
prolactin levels were only measured once, it is very likely that hyperprolactinemia 
is a common side effect in children and adolescents treated long-term with risperi-
done. Previous short-term studies have shown a steep increase in the prolactin 
level within the first 6 weeks, with levels stabilizing in the first 3 months (Aman 
2002, Snyder 2002, Findling 2004, Biedereman 2005), followed by a slow decline 
after 1 year (Turgay 2002, Findling 2004, Croonenberghs 2005, Stevens 2005, 
Anderson 2007). Average prolactin levels were found to be above the reference 
value after 2 (Reyes 2006, Staller 2006) and 3 years of continued risperidone 
treatment (Calarge 2010), although two studies reported that prolactin levels 
tended to normalize after 12 months (Migliardi 2009) and 22 months (Anderson 
2007) of antipsychotic use. Our results, obtained for pubertal boys with long-term 
risperidone use, show that half of the patients still have hyperprolactinemia after 
Table 3. 97.5 th percentile of prolactin for age and gender in ng/ml (Emlinger 2002) 
Age, (years) N Female Age (years) N Male 
  97.5th   97.5th 
11 23 44.20 11 22 16.37 
12  18 15.47 12 17 12.93 
13 25 22.78 13 21 18.63 
14 30 31.13 14 32 17.55 
15 48 20.52 15 40 19.81 
16 40 20.71 16 31 15.09 
17 30 17.78 17 22 16.51 
18-19 12 39.53 18-19  8 15.71 
17-19  42 32.78 17-19  30 16.23 
 
Table 4. Predictors of hyperprolactinemia in an children and adolescent population using risperidone.  
 Hyperprolactinemia OR (CI) p-value 
 No, N=27 Yes, N=24 
 Mean (SD) Mean (SD) 
  
Current dose of risperidone (mg/day) 1.25 (0.84) 1.83 (0.95) 2.42 (1.07,5.50) 0.035a 
RIS* µg/L 1.48 (2.14) 4.30 (6.86) 1.19 (0.97, 1.44) 0.090a 
9-OH RIS* µg/L 6.26 (5.32) 11.35 (8.70) 1.15 (1.02, 1.29) 0.030a 
Mean dose of the treatment period (mg/day) 1.41 (0.76) 1.68 (0.53) 1.98 (0.79, 4.97) 0.14a 
Duration of treatment (months) 50.21 (27.24) 55.67 (28.51) 0.99 (0.97, 1.01) 0.40a 
a Logistic regression, corrected for age and BMI-z; OR=odds ratio; CI=95% confidence interval; 
*RIS=plasma levels of risperidone ; *9-OH RIS=plasma levels of 9-OH risperidone 
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53 months. In previous studies hyperprolactinemia was defined using adult refer-
ence ranges, primarily 0-18 ng/mL and 0-30 ng/mL for male and female patients, 
respectively. Our study is the first to use age- and gender-appropriate reference 
ranges (Emlinger 2002, see Table 3) to define hyperprolactinemia. This is impor-
tant because prolactin levels change during childhood and adolescence. 
Gynecomastia was five times more common in our study than in other studies 
(Sikich 2004, Reyes 2006, Staller 2006) (Table 2). Previous studies included mainly 
prepubertal children and used spontaneous self-report, rather than, physical ex-
amination, to establish the presence of gynecomastia, which probably led to under-
estimation of the prevalence of gynecomastia. The prevalence of gynecomastia in 
the antipsychotic-naïve-boys was 21% (10 of 47 boys) comparable to the preva-
lence of gynecomastia in healthy pubertal boys, indicating that it is a normal tran-
sient phenomenon in pubertal boys; the lifetime prevalence of gynecomastia in 
males is about 50% (Bembo 2004, Hanavadi 2006). None of the boys had galactor-
rhea, consistent with earlier findings from a systematic review showing that galac-
torrhea does not occur in pubertal boys whereas it occurs in 0.5% of post-pubertal 
females (Roke 2009). 
Our study is the first to use a validated and standardized instrument to assess 
sexual dysfunction in male adolescents using long-term antipsychotics. We found 
that 1 in 8 boys reported sexual dysfunction in relation to risperidone treatment. 
An earlier study that used a specific questionnaire for sexual adverse events 
showed a similar prevalence of sexual dysfunction among adolescents (Staller 
2006). In studies of adults with schizophrenia or mood disorders, the rate of dimin-
ished sexual functioning due to hyperprolactinemia was about 40% (Bobes 2003, 
Knegtering 2004 and 2006). The boys with ASD included in our study may have 
other sexual behavior than patients with schizophrenia or mood disorders. The 
mean dose of risperidone used in our study population was similar to other studies 
(weighted average 1.6 mg per day) (Roke 2009). However, as our participants were 
older than those of most previous studies (mean age 14.5 in this study versus 
weighted average of 9.7 years in earlier studies) (Roke 2009), the dose corrected 
for age was probably lower in our study. 
4.1 Limitations 
This study had some limitations that should be taken into account when interpret-
ing the results and which should be addressed in future studies. First, our sample 
size was relatively small, but our findings are in agreement with those of larger 
studies (Calarge 2010). In addition prolactin-elevating concomitant medication was 
permitted, such as, atomoxetine and melatonin (Blaicher 1999, Molitch 2005, Coker 
2010), which could have influenced the prolactin levels. However, use of these 
medications was similar in the two groups of boys and appears not to have con-
founded our results. The prolactin-elevating effect of this concomitant medication 
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is considered to be minor compared with that of the antipsychotic used (Coker 
2010). 
Another limitation is the cross-sectional design of the study, so that we cannot 
establish causality and also do not know what baseline prolactin levels were. In-
stead, we compared boys treated with risperidone and boys not treated with antip-
sychotics. Fourteen boys (27%) had undetectable risperidone levels, and 4 of these 
boys (8%) had also undetectable 9-OH risperidone levels. Risperidone has a short 
half-life of three hours compared to the longer half-life of at least 23 hours (de-
pendent on the patients CYP2D6 polymorfism) of 9-OH risperidone, explaining the 
difference in blood level detectability. These data suggest that these fourteen boys 
did not take their risperidone as prescribed. The four boys with undetectable 
risperidone and 9-OH risperidone levels did probably not take their medication at 
all while the ten boys with undetectable risperidone but detectable 9-OH risperi-
done levels probably did not take their AP as prescribed.  
These adherence problems could have led to an underestimation of the actual 
prevalence of hyperprolactinemia and prolactin-related side effects in our study. 
The ASFQ data on sexual functioning may have been biased by recall and time. 
The children and adolescents had to think back to the time when they did not use 
risperidone. Moreover, some of the boys may have started risperidone before pu-
berty and may have become sexually mature since, so that they might have consid-
ered their sexual functioning as unchanged (20% cases and 10% comparison 
group) or unknown (30% cases and 40% comparison group) whereas it was, in 
fact, suppressed. Moreover, boys who were sexually inexperienced or inactive 
could not make a before and after comparison. Another limitation is the self-
assessment of pubertal stage. However, self-assessment has proven to be a valid 
and reliable method in comparison to physical examination especially in non-obese 
adolescent boys in mid to late adolescence (Duke 1980, Wacharasindhu 2002, 
Leone 2007, Chan 2008). We found that the staging of pubic hair development was 
less reliable than staging genital development, and so we used the genital develop-
ment as main measure. Self-assessment of puberty has not been investigated before 
in autistic adolescents, but has proven reliable, in adolescents with other chronic 
diseases such as Crohn’s disease and diabetes mellitus (Schall 2003, Stephen 2008). 
The prevalence of gynecomastia could have been confounded by the presence of 
overweight/ obesity, however the boys’ breasts were palpated to distinguish be-
tween fat and glandular tissue.  
4.2 Clinical implications  
Continuous use of risperidone for 16 months or longer induces hyperprolactinemia 
in about half of the boys and might diminish their sexual functioning. Although 
gynecomastia was two times more common in the risperidone group, hyperprolac-
tinemia was not associated with gynecomastia. However, 46% (11 out of 24) of the 
boys with risperidone-induced hyperprolactinemia did not have prolactin-related 
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side effects. The long-term consequences of asymptomatic hyperprolactinemia are 
unknown, but theoretically, high prolactin levels could result in diminished bone 
mineral density, changes in sexual maturation, or an increased risk of benign 
prolactinomas (Sfarzman 2006) during periods of critical maturation. Long-term 
studies are needed to investigate the relevance of asymptomatic hyperprolactine-
mia. 
Some experts recommend a “wait and see approach” for asymptomatic hyper-
prolactinemia and advise that prolactin levels should be monitored in the event of 
prolactin-related side effects, such as, sexual disorders, menstrual disturbances, 
gynecomastia or galactorrhea (Haddad 2004, Correll 2006 and 2008, Anderson 
2007). Others suggest proactive monitoring of prolactin levels and possible side 
effects before and during treatment with prolactin-elevating antipsychotics (Staller 
2006, Citrome 2008, Ho 2011). This study provides further support for the moni-
toring of prolactin levels in symptomatic patients only. Diminished sexual function-
ing was associated with long-term hyperprolactinemia whereas gynecomastia may 
be a normal phenomenon. Thus sexual function should be addressed before and 
during treatment, using a standardized questionnaire. If symptomatic antipsy-
chotic-induced hyperprolactinemia occurs the antipsychotic should be stopped if 
this is clinically feasible. Prolactin levels should normalize within days dependent 
on the half-life (T 1/2) of the drug (Pollock 1998, Turrone 2002). Alternatively, the 
dosage should be reduced as there is a dose-response relation with prolactin levels 
(Knegtering 2005), or another antipsychotic agent without prolactin-elevating 
qualities should be tried (e.g. quetiapine, aripiprazol, clozapine) (Stevens 2005, 
Greenaway 2009). If the hyperprolactinemia persists despite these steps, further 
investigation of the patient is necessary (Ho 2011). 
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Abstract 
 Aims: This cross-sectional study investigates the effect of antipsychotic (AP) -
induced- hyperprolactinemia on testosterone, luteinizing hormone (LH), follicle 
stimulating hormone (FSH), Inhibin B, and puberty in boys with mainly autism 
spectrum disorders (ASD). 
 Method: One hundred and four physically healthy 10-to 19 year-old-boys with 
ASD or with disruptive behavior disorder (DBD) were recruited between October 
2006 and November 2009. Fifty-six adolescents had been treated with AP for more 
than sixteen months; 48 had never been exposed to AP. Morning non-fasting levels 
of serum prolactin, testosterone, LH, FSH, and Inhibin B level were obtained and 
Tanner pubertal stage was determined. Patients with hyperprolactinemia (N=28) 
were compared to those without hyperprolactinemia (N=76) using non-parametric 
or parametric tests, as appropriate. 
 Results: Patients with AP-induced hyperprolactinemia had significantly lower 
testosterone levels with adjustment for age (p=0.035) compared to patients with-
out hyperprolactinemia and without AP treatment. The difference was not signifi-
cant within the AP treated group, and the level of testosterone was within the ref-
erence range compared to age and gender matched normative data. There was no 
between-group difference for LH, FSH, Inhibin B or Tanner stages. 
 Conclusion: AP-induced hyperprolactinemia is related to significantly lower 
testosterone levels in pubertal boys with ASD and DBD. 
 
 Key words: Hyperprolactinemia, Adolescents, Testosterone, Puberty, Antipsy-
chotics 
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Introduction  
Antipsychotics (AP) are commonly and increasingly prescribed to children and 
adolescents with autism spectrum disorders (ASD) and disruptive behavior disor-
der (DBD) [1]. AP reduce maladaptive behaviors such as irritability, self-injury, 
stereotypes and hyperactivity [2]. Hyperprolactinemia, a side effect caused by do-
pamine 2 blockade in the tuberoinfundibular pathway [3], is a common side effect 
of long-term AP treatment in children and adolescents [4]. Long-term hyperprolac-
tinemia can cause suppression of the hypothalamic-pituitary gonadal axis, so a 
decrease of gonadotrophin-releasing hormone (GnRH) and consequently of lu-
teinizing hormone (LH) and testosterone may be observed in males. This may cause 
sexual dysfunction such as loss of libido, loss of erection, ejaculation disorders, 
gynecomastia and galactorrhea [5]. Hyperprolactinemia may also affect follicle 
stimulating hormone (FSH) and inhibin B levels [6]. Inhibin B is produced by the 
Sertoli cells of the testes and regulates FSH levels through negative feedback on the 
pituitary and is a marker of fertility [7]. Few studies evaluating these hormonal 
effects in adult patients using prolactin-elevating AP have been published. These 
studies report a decrease of testosterone and gonadotropins due to an AP-induced 
hyperprolactinemic effect in men [6]. The same inverse relation between prolactin 
and testosterone in males, as well as arrested pubertal development in adolescence, 
is also seen in prolactinoma-induced hyperprolactinaemia [8]. However, in prolac-
tinomas prolactin levels are two to four times more elevated than in AP-induced-
hyperprolactinemia [9]. The influence of AP-induced hyperprolactinemia on repro-
ductive hormones and gonadotropins during puberty has not yet been investigated 
in pediatric populations. This paper focuses on the effect of long-term AP-induced 
hyperprolactinemia on testosterone, LH, FSH, and Inhibin B, and the influence of 
persistent hyperprolactinemia on pubertal development in adolescents with ASD 
and DBD treated with and without long-term prolactin-elevating AP medication. 
2. Subjects and Methods 
2.1 Subjects 
All participants were recruited from the total patient population of the outpatient 
adolescent clinic of the GGz Central Psychiatric Centre, The Netherlands, from Oc-
tober 2006 to November 2009. Participants were recruited if they were aged be-
tween 10 and 19 years, diagnosed with any psychiatric disorder, had an IQ above 
85, and were male. All participants included had a diagnosis of ASD or DBD, i.e. 
either severe oppositional defiant disorder or conduct disorder. One hundred and 
four patients (66 % of the eligible population) participated. Fifty-six patients of the 
total study population (n=104) were treated with AP for more than 1 year and 48 
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patients had never been exposed to AP. We were primarily interested in the rela-
tionship between hyperprolactinemia and testosterone, LH, FSH, and Inhibin B 
levels. Therefore we divided our study population into a group with hyperprolacti-
nemia and one without.  
The reason for not participating was fear of venapuncture. None of the partici-
pants had a history of diabetes mellitus, thyroid disorders, syndromes or other 
chronic diseases affecting puberty, endocrine disorders, use of oral corticosteroids 
or anticonvulsants, or known causes of hyperprolactinemia [10, 11]. The first au-
thor contacted the parents/ legal guardians and the patients by telephone and let-
ter. The local Medical Ethics Committee approved this study and written informed 
consent was obtained from the patient and the subject’s parents/ legal guardians. 
2.2 Methods 
The clinical diagnosis and IQ was obtained from the patients’ chart. Physical exami-
nation is the clinical standard to investigate stages of puberty, however The Medical 
Ethics Committee unfortunately did not approve this method. Therefore, self-
assessment, the best alternative, was chosen. The boys selected the different Tan-
ner stage photographs of genitals (G stage) and pubic hair (P stage) that most accu-
rately reflected their appearance [12]. One of the parents/ legal guardians was 
present during the self-assessment and confirmed the stages pointed out. The pubic 
hair development self-assessment staging was less reliable than staging of the geni-
tal development. We therefore used the genital development as the main measure.  
The first author measured height and weight, using a standardized procedure. 
Height was measured without shoes to the nearest 0.1 cm using a stadiometer 
while the participant was standing erect (Seca 206, the Netherlands) and weight 
was recorded to the nearest 0.1 kg using an analogue scale (Seca 761, the Nether-
lands) while the participant was dressed in underwear. Age and gender specific 
height, weight and BMI z-scores were calculated using normative data for Dutch 
children [13]. For the Tanner stage data standardized values stratified per age cate-
gory were compared to published normative data of the general population [13]. 
The Tanner stage of our study population was compared to the 50th percentile 
normative data (gender and age matched) of Dutch adolescents: the difference was 
expressed in years. A non-fasting morning blood sample was obtained around 9.30 
a.m. after a light breakfast eaten at around 7.30 a.m. Serum prolactin was measured 
with an automated chemiluminescence assay system (Immulite 2000, Siemens 
Healthcare Diagnostics, Los Angeles, CA, USA) calibrated on the 3rd IS 84/500. As 
macroprolactin, a complex of prolactin and IgG without biological activity, accounts 
for 10% of the cases of hyperprolactinemia [14], seven samples with prolactin con-
centrations higher than 37 ng/mL were assessed for the presence of macroprolac-
tin. Polyethylene glycol 6000, 200 μL, (25% w/w) was added to 200 μL of serum 
and, after thorough vortex mixing, the mixture was centrifuged at 2200 g for 30 min 
at 4 °C. Subsequently, prolactin was measured in the supernatant and the untreated 
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serum. The recovery of prolactin after precipitation with polyethylene glycol 6000 
was 101.4 ± 9.6% (mean ± SD), which excluded the presence of macroprolactin. For 
prolactin a binary value was defined as either above or below the 97.5 th percentile 
corrected for age and gender [15]. LH, FSH were measured in serum by a two-site, 
solid-phase chemiluminescent immunometric assay (Immulite 2000, Siemens 
Healthcare Diagnostics). Total testosterone was measured by a solid-phase 125I 
radioimmunoassay in unextracted serum (Coat-a-count, Siemens Healthcare Diag-
nostics). Inhibin B in serum was measured by a Gen II ELISA assay from Beckman 
Coulter. Inc. (Webster, USA). Testosterone, LH, FSH, and Inhibin B were compared 
to literature reference values for age and gender [15-17]. 
2.3 Statistical analysis  
Chi-square, independent t-tests, Mann-Whitney, linear regression, or binary logistic 
regression were used according to the type and distribution of data. Binary logistic 
regression analysis was conducted to investigate the effect of hyperprolactinemia 
on testosterone, LH, FSH, and Inhibin B in the study population. All regression 
models were corrected for age. Dose equivalence was assumed between pimozide 
(N=3) and risperidone (N=53) [18, 19]. Binary logistic regression analysis was used 
to investigate the difference between our study population and healthy age and 
gender matched normative data described in the literature. These data [13] were 
used to create a new variable showing the difference in years in attaining the 50th 
percentile of P and G stages of puberty. For the difference between our total study 
group and the normative data we have calculated a weighted average in number of 
years late attaining 50th percentile Tanner stage of puberty. We have also calcu-
lated a weighted average for the height-, weight-, and BMI z-scores. We have ap-
plied binary logistic regression analysis to investigate whether ASD or DBD were 
part of the explanation for being years late in attaining stages of puberty. 
3. Results 
Baseline characteristics of the patients included are presented in Table 1. There 
were no statistical differences between the two groups in mean age, weight, height, 
BMI z-scores, and diagnosis. All patients with hyperprolactinemia (N=28) used AP 
except one. The dose of the AP medication used was significantly higher in the 
group with hyperprolactinemia and AP use (N=27) compared to the group without 
hyperprolactinemia with AP use (29 patients out of 76 used AP) (p=0.04, Table 1). 
The duration of AP use (N=27 in the hyperprolactinemia group and N=29 in the 
group without hyperprolactinemia) was the same for both groups with a mean of 
more than four years. The patients with hyperprolactinemia had significantly lower 
testosterone levels compared to the group without hyperprolactinemia, after ad-
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justment for age (9.85 nmol/l compared to 12.41 nmol/l, p=0.035, Table 2). The 
group without hyperprolactinemia and use of AP medication (N=29) had mean 
testosterone levels of 11.31 nmol/L (p=0.14, when compared with AP treated pa-
tients with hyperprolactinemia, Table 2). The group without hyperprolactinemia 
and without AP treatment had mean testosterone levels of 13.12 nmol/L (Table 2). 
There was a significant negative relationship between testosterone and prolactin 
(β=-0.32, p=0.008). In the AP treated group a trend was observed (β=-0.28, p=0.07). 
Testosterone was positively associated with LH (β=0.43, p<0.0001).  
Compared to the normative data for age and gender testosterone levels were in 
the normal range [17]. Results obtained with the Count-a-count (Siemens) assay 
used in this study are comparable with the LC-MS/MS method using Perkin Elmer 
MSMS Steroids kit, which is an in vitro diagnostic HPLC-MS/MS reagent kit. The 
95% limits of agreement of these two methods were -0.87 to 1.13 nmol/L. The re-
sults did not change after adjustment for ASD or DBD.  
LH, FSH, and Inhibin B levels did not differ between the group with and the 
group without hyperprolactinemia. LH, FSH, and Inhibin B were also in the normal 
range when compared to age and gender matched normative data values. The age 
of attainment of Tanner stages was the same for patients with and without hyper-
prolactinemia. Compared to normative data, our total study population was 1.6 
years late in attaining the same Tanner stage. Our study population had normal 
mean z-scores for height (0.40), weight (0.48), and BMI (0.44). When correcting for 
autism (N=92) versus DBD (N=12), autism showed a trend towards significance 
(p=0.067) in being later in attaining the same stage of puberty than healthy con-
trols. 
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Table 1. Characteristics of adolescents with and without hyperprolactinemia in the cross-sectional 
study 
 
 
Patients with hyperprolactinemia 
(N=28) 
Patients without hyperprolactinemia 
(N=76) 
P value 
 N (%) Mean (SD, range) N (%) Mean (SD, range)  
Age, years  15.1 (2.7, 10.3-19.2)  14.9 (1.7, 11.9-18.8) 0.77a 
Height (m)  1.73 (0.1, 1.4-2.0)  1.75 (0.1, 1.4-2.0) 0.66a 
Height z-score $  0.52 (1.1, -1.4-2.1)  0.35 (1.0, -2.4-2.9) 0.47a 
Weight (kg)  65.2 (23.2, 31.5-138)  63.0 (14.9, 33.3-116.0) 0.64a 
Weight z-score $  0.70 (1.3, -1.6-4.5)  0.40 (1.2, -2.5-3.9) 0.28a 
BMI*  21.0 (5.3, 14.6-41.6)  20.2 (3.7, 15.2-32.0) 0.62a 
BMI z-score $  0.23 (1.0, -1.8-2.8)  0.52 (1.1, -3.3-2.3) 0.46a 
Tanner stage 
I/II/III/IV/V 
 3.54 (1.1, 2-5) 
0/6/7/9/6 
 3.55 (0.9,2-5) 
0/11/22/33/10 
0.94a 
Caucasian ethnicity 27 (96)  73 (96)  0.26b 
Primary diagnosis      
ASD* 
DBD* 
26 (93) 
 2 (7) 
 66 (87) 
10 (13) 
 0.83b 
0.39b 
Antipsychotics ^      
Dose (mg/day) # 
Mean dose #  
(mg/day) 
Duration of use #, 
(months) 
 
None 
1.89 (1.0, 0.5-4.0) 
1.75 (0.7, 1-4) 
 
49.4 (26.3, 16-118) 
 
1 (4) 
 1.28 (0.8, 0.3-4.0) 
1.45 (0.8, 0.5-3.5) 
 
53.2 (30.0, 19-126) 
 
 
47 (62) 
 0.04d 
0.03d 
 
0.58d 
 
 
<0.0001c
Concomitant  
medication 
     
Melatonin 
SSRI 
Psychostimulants 
Atomoxetine 
2 (7) 
2 (7) 
4 (14) 
0 
  5 (7) 
 0 
19 (25) 
 2 (3) 
 1.00c 
- 
0.30c 
- 
Total 8 (29)  24 (32)  - 
a=Student’s t-test; b=Chi-square; c=Fisher’s exact test; d=Mann-Whitney; ^=dose-equivalence was as-
sumed for risperidone (N=53 and pimozide N=3); * BMI=body mass index; # only patients with use of AP 
medication; ASD= autism spectrum disorders; DBD=disruptive behavior disorder; - Not-applicable 
because of empty cells; $ Normative data Fredriks et al., 2001 were used to calculate z-scores for height, 
weight and BMI 
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4. Discussion 
Boys with (mainly) ASD and AP-induced-hyperprolactinemia had significant lower 
testosterone levels than male adolescents with ASD and normal prolactin levels.  
The testosterone levels were not significantly different in the group of patients 
with AP treatment with and without hyperprolactinemia. However, the prolactin 
levels of the AP treated patients without hyperprolactinemia were still higher than 
of the patients not treated with AP. Nonetheless, testosterone levels stayed within 
the normal limits suggesting that AP with prolactin elevating properties are save in 
this aspect. We observed a relationship between an increase in prolactin levels and 
a decrease in testosterone levels. The LH levels were not significantly lower in the 
patients with hyperprolactinemia than in the groups without hyperprolactinemia, 
which may be due to lack of power and the range of Tanner stages of the included 
patients. Still, we hypothesise that a high prolactin inhibits the release of LH, which 
results in lower testosterone levels. Hyperprolactinemia in AP use is caused by 
dopamine 2 blockade in the tuberoinfundibular pathway and is a common side 
effect in children and adolescents treated with AP medication. The group of pa-
tients with AP use and hyperprolactinemia had a higher dose of AP than the boys 
with AP use without hyperprolactinemia, so a higher dose seems to be a risk factor 
of hyperprolactinemia. However, pharmacogenetic differences may explain indi-
vidual variation in whether hyperprolactinemia occurs and leads to clinical conse-
quences. For example, the Taq1 A1 allele of the D2 dopamine receptor gene (DRD2) 
is associated with a significantly reduced density of D2 receptors [20]. Also the 
Table 2. Prolactin, gonadotropin, and sex steroid levels of boys with (N=28) and without (N=76) hyper-
prolactinemia  
 
 
Patients with  
hyperprolactinemia 
N=28 
Patients without hyperprolactinemia 
 
N=76 
  Total 
N=76 
With AP  
treatment N=29 
Without AP  
treatment N=47 
P value* P value**
 Mean (SD, range) Mean (SD, range) Mean (SD, range) Mean (SD, range)   
Prolactin ng/ml 27.83 (18, 15.1-92.5) 8.96 (0.07, 2.4-17.0) 10.50 (4.0, 2.4-17.0) 7.83 (2.6, 3.8-15.1) <0.0001 a <0.0001 a
Testosterone 
nmol/L 
9.85 (6.1, 0.2-22.4) 12.41 (6.6, 0.3-29.4) 11.31 (6.4, 0.3-26.4) 13.12 (6.6, 0.3-29.4) 0.035 b 0.14 b 
LH IU/L# 3.25 (2.0, 0.4-8.3) 3.48 (2.0, 0.5-10.2) 3.30 (1.8, 0.5-6.9) 4.00 (2.1, 0.8-10.2) 0.44 b 0.47 b 
FSH IU/L# 4.30 (2.1, 1.9-10.4) 5.50 (4.3, 1.0-27.5) 4.81 (2.6, 1-11.6) 5.95 (5.0, 1.1-27.5) 0.15 b 0.25 b 
Inhibin B ng/L 246 (80, 110-401) 241 (69, 67-383) 245 (82, 110-401) 234 (73, 67-383) 0.79 b 0.69 b 
#LH= luteinising hormone;  #FSH= follicle stimulating hormone; * patients with hyperprolactinemia 
(N=28) compared to the total patients without hyperprolactinemia (N=76); ** patients with hyper-
prolactinemia (N=28) compared to AP treated patients without hyperprolactinemia (N=29); a=Mann-
Whitney; b=logistic regression corrected for age 
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metabolization rate of prolactin-inducing antipsychotics may influence prolactin 
levels [21].  
This is the first study to investigate the difference in testosterone levels in hy-
perprolactinemic pubertal boys with ASD compared to a matched control group 
with ASD with normal prolactin levels. Two previous small studies in ASD patients 
without AP use showed conflicting results; one study showed significantly lower 
testosterone levels in 18 medication naïve autistic adolescents [22] compared to 22 
healthy controls whereas another small study [23] showed no difference in testos-
terone levels between 39 medication naïve autistic children and adolescents com-
pared to 21 healthy controls. In both studies the testosterone levels were within the 
normal range of the normative data [17], like in the present study. LH, FSH and 
Inhibin B did not differ between the two groups and were also normal compared to 
normative data. Because we expected that significantly lower testosterone levels in 
our hyperprolactinemic group could have had a negative influence on puberty, we 
evaluated the pubertal stage of the patients. The group with hyperprolactinemia 
did not differ in pubertal stage from the group without hyperprolactinemia. An 
earlier one- year follow-up study of mainly male (80%) children with DBD (N=222, 
mean age 11.9 years, SD 1.4) starting prolactin-elevating medication showed no 
difference in the progression of stages of puberty [24]. When we compared the data 
of our total study group in attaining the 50th percentile of Tanner stage of puberty 
with the normative data, the adolescents in the present study were 1.6 years late. 
Delay in pubertal development may be related to the presence of an autistic spec-
trum disorder. One study in women with ASD showed a later age of menarche than 
controls [25]. ASD is a neurodevelopment disorder, which may affect the hypotha-
lamic-pituitary-gonadal axis.  
4.1 Limitations  
This study had some limitations that should be taken into account when interpret-
ing the results and should be addressed in future studies.  
A limitation could be that our study attracted in particular patients with par-
ticular concerns regarding development of puberty. However, it is unlikely that this 
biased the results because these concerns could be related to either an early or late 
development of puberty. Another limitation could have been the determination of 
pubertal stage by self–assessment with confirmation of one of the parents. How-
ever, several studies which have investigated this method concluded that compared 
to physical examination, self-assessment is a less reliable but nonetheless valid 
method [12, 26-28]. Self-assessment of puberty has not been investigated before in 
autistic adolescents, but has proven reliable, in adolescents with other chronic dis-
eases such as Crohn’s disease and diabetes mellitus [29, 30]. The present study was 
cross-sectional and longitudinal studies are needed for evaluating the progression 
of puberty.  
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In addition, prolactin-elevating concomitant medication was permitted, such as, 
melatonin and the SSRI’s [9, 31, 32], which could have influenced the prolactin lev-
els. However, use of these medications was similar in the two groups of boys and 
appears not to have confounded our results. The prolactin-elevating effect of this 
concomitant medication is considered to be minor compared with that of the antip-
sychotics used [32]. Furthermore we did not include a group of healthy controls. 
However, we used published normative data of large groups of children and adoles-
cents. Finally, our sample size was relatively small, and its power therefore limited.  
4.2 Conclusions 
AP-induced hyperprolactinemia is related to lower testosterone levels in male ado-
lescents with ASD and DBD, although the testosterone levels were within the nor-
mal range for age and gender. LH, FSH, Inhibin B and pubertal stage were not influ-
enced by hyperprolactinemia. Although hyperprolactinemia may cause sexual side 
effects, gynaecomastia, galactorrhea, and diminished bone mineral density, this is 
the first study to show that AP-induced-hyperprolactinemia has no clinically sig-
nificant effect on sex hormones, gonadotropins, or puberty in adolescent males 
with ASD and DBD. Our data suggest a delay in pubertal development, which may 
be related to the presence of an autism spectrum disorder. Further longitudinal 
research into this area is needed to confirm our results and to examine the mecha-
nisms involved.  
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Abstract 
 Objective: To investigate the long-term effects of antipsychotic (AP) treatment 
and AP-induced hyperprolactinemia on bone mineral density (BMD) and body 
composition in male adolescents with autism spectrum disorders (ASD) and/or 
disruptive behavior disorder (DBD). 
 Design: Physically healthy 10-to 20-year-old boys with ASD and/ or DBD, 
chronically treated (N=56; mean 52 months, range 16-126 months) or not treated 
(N=47) with an AP were recruited to this observational study. Prolactin levels and 
biochemical bone parameters were measured and BMD of the lumbar spine and 
total body, and body composition were assessed by dual energy X-ray absorptiome-
try (DXA), and volumetric BMD of the lumbar spine calculated. Group differences 
were tested with Student’s t-, Chi-square, Fisher exact tests, and logistic regression 
analysis. 
 Results: 49% of the boys treated with an AP had hyperprolactinemia. The 
mean volumetric lumbar spine BMD z-score was lower (p=0.043), the total % body 
fat z-score was higher (p=0.032), and biochemical bone marker carboxyterminal 
cross-linking telopeptide of bone collagen (CTx) was lower in the AP-treated boys 
with hyperprolactinemia than in the AP-treated boys without hyperprolactinemia. 
7-11% of the hyperprolactinemic boys had low BMD. The mean lumbar spine and 
total body BMD z-scores and body composition were similar in the boys who were 
or were not treated with an AP. The total study population had a lower mean lean 
tissue mass (mean z-score -0.37, p=0.004) and a higher % total body fat (mean Z-
score 1.16, p<0.001) than healthy controls (normative data); biochemical bone 
parameters were within normal limits.  
 Conclusion: AP-induced hyperprolactinemia in boys with ASD or DBD may 
have an negative effect on lumbar spine BMD. Longitudinal studies are needed to 
confirm this finding. 
 
 Key words: Hyperprolactinemia, Adolescents, Bone mineral density, Body 
composition, Antipsychotics 
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1. Introduction 
Children and adolescents with autism spectrum disorders (ASD) are often treated 
with antipsychotic (AP) medication, mostly second-generation AP because the inci-
dence of extrapyramidal side effects is lower than with first-generation AP1. AP 
reduce maladaptive behaviors, such as irritability, self-injury, stereotypies, and 
hyperactivity, in children and adolescents with ASD, and reduce irritability and 
aggressive behavior in children and adolescents with disruptive behavior disorder 
(DBD)2 . 
While the Food and Drug Administration (FDA) in the USA has approved risper-
idone and aripiprazole for the treatment of children and adolescents with irritabil-
ity associated with ASD3-5, these drugs have not yet been approved for this indica-
tion in Europe. AP are also frequently used, off-label, to treat severe aggression in 
children and adolescents with DBD. Despite their efficacy5, there are concerns 
about metabolic (such as obesity, hyperglycemia, and dyslipidemia) and endocrine 
(such as hyperprolactinemia) side effects6-8. AP such as olanzapine, clozapine, and 
risperidone can reduce hepatic insulin sensitivity9, possibly by reducing serotonin 
levels in the brain, which causes a reduction in osteocalcin and adiponectin levels 
and ultimately diminished insulin sensitivity10. AP-linked obesity and type 2 diabe-
tes mellitus are more prevalent in children and adolescents than in adults7, possibly 
because of differences in their body composition, e.g. a higher percentage of body 
fat and less lean body mass. Adolescence is the most important time in terms of 
attaining peak bone mass11, and an increase in lean body mass, mainly muscles, is 
important for optimal bone mass12. Disturbances in this process during puberty 
may increase the risk of osteoporosis later in life. The AP-induced change in energy 
metabolism and insulin signaling could lead to a lower bone mineral density 
(BMD)10, which in turn could increase the risk of osteoporosis later in life.  
AP-induced hyperprolactinemia could influence bone metabolism in two ways. 
First, hyperprolactinemia might directly affect bone turnover, by stimulating bone 
resorption relative to bone formation13,14. Secondly, prolonged hyperprolactinemia 
may cause hypogonadotropic hypogonadism15, resulting in suppression of gonad-
otropin-releasing hormone (GnRH) secretion in the hypothalamus and diminished 
secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by 
the pituitary gland, resulting in a diminished secretion of sex hormones and ulti-
mately in changes in bone metabolism. Patients with psychiatric disorders also 
have other risk factors for osteopenia, such as smoking, low calcium intake, vitamin 
D deficiency, and insufficient exercise.  
Only one study has investigated the effect of AP-induced hyperprolactinemia on 
BMD in boys with different diagnoses (n=83; mean age 11.9 years, SD 2.8)16. BMD 
was lower in boys with hyperprolactinemia than in boys without hyperprolactine-
mia, but comparisons with healthy controls were not made. In adolescents with 
prolactinomas, in which prolactin levels are at least two to four times higher than in 
AP-induced hyperprolactinemia, BMD was decreased and was not restored after 2 
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years of treatment with dopamine agonists17. Several studies of adults have shown 
AP-induced hypogonadism to be associated with a decreased BMD18-22 and two 
large case-control studies (44,500 patients and 16,341 patients) showed AP medi-
cation to be associated with a two-fold increased risk of hip or femur fractures23,24. 
In this study, we investigated the consequences of long-term AP treatment and 
AP-induced hyperprolactinemia on BMD, biochemical bone parameters, and body 
composition in boys with ASD and/ or DBD compared with boys with similar disor-
ders never treated with AP. 
2. Subjects and Methods 
2.1 Subjects  
All participants were recruited from the patient population of the adolescent outpa-
tient clinic of the GGZ Centraal Psychiatric Center, The Netherlands, from October 
2006 to November 2009. Eligible participants were aged between 10 and 20 years, 
diagnosed with a psychiatric disorder, treated with potential prolactin-elevating AP 
medication continuously for more than 16 months, and had an IQ above 85. All 
participants (56 boys, 6 girls; 80% of the eligible population) had a diagnosis of 
ASD or DBD and were treated primarily with risperidone (57 out of 62). Compari-
son subjects (47 boys and 10 girls; 50% of the eligible population) met the same 
inclusion criteria except that they had never been treated with AP. The main reason 
for not participating was fear of venipuncture. None of the participants had a his-
tory of chronic diseases affecting puberty, endocrine disorders, thyroid disorders, 
bone diseases, use of oral corticosteroid or anticonvulsants, or known causes of 
hyperprolactinemia25. The data for the girls (15 in a total study sample of 119) 
were not analyzed because of the low number of girls. Thus the AP group consisted 
of 56 boys with ASD or DBD treated with AP and the comparison group consisted of 
47 boys with ASD or DBD who had never been treated with AP. Use of other con-
comitant medication was permitted (Table 1). The first author contacted the par-
ents/ legal guardians and the patients by telephone and letter. The Local Medical 
Ethics Committee approved the study and written informed consent was obtained 
from the patient and his parents/ legal guardians after the study procedures had 
been clearly explained.  
2.2 Methods 
The clinical diagnosis was obtained from the patients’ chart. The first author meas-
ured the participants’ height (without shoes, to the nearest 0.1 cm using a stadi-
ometer, Seca 206, the Netherlands) and weight (participant wearing underwear, to 
the nearest 0.1 kg, using an analogue scale, Seca 761, the Netherlands). Age-specific 
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height, weight, and body mass index (BMI) z-scores were calculated using norma-
tive data for male Dutch children26,27. Pubertal stage was established by showing 
the boys different Tanner stage photographs of the genitals (G stage) and pubic hair 
(P stage) and asking them to select the photographs that most accurately reflected 
their appearance28. One of the parents/ legal guardians was present during the self-
assessment and confirmed the stages pointed out. The severity of disease was 
measured using The Clinical Global Impression - Severity scale (CGI-S)29. It is a 7-
point scale that requires the first author to rate the severity of the patient's illness 
at the time of assessment, relative to the past experience with patients who have 
the same diagnosis. Considering total clinical experience, a patient is assessed on 
severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline 
mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, ex-
tremely ill. 
The average calcium intake (mg/day) was determined using the food frequency 
questionnaire for dairy products30. Physical activity was divided into leisure sports, 
activity at school/work, home activities, and transport (biking or walking)31. Each 
activity was expressed in terms of its ground reaction force (GRF)32,33 and then 
classified into four categories: 0: GRF < 1 x body weight e.g., swimming, cycling, 1: 
GRF between 1 and 2 x body weight, e.g., rowing, dancing, 2: GRF between 2 and 4 x 
body weight, e.g., running, hockey, soccer, 3: GRF > 4 x body weight, e.g., basketball, 
volleyball. The GRF score reported is the sum of the GRF scores. 
A non-fasting morning blood sample was collected at about 9.30 a.m.; a light 
breakfast had been eaten at about 7.30. Serum prolactin was measured with an 
automated chemiluminescence assay system (Immulite 2000, Siemens Healthcare 
Diagnostics) calibrated on the 3rd IS 84/500. As macroprolactin, a complex of 
prolactin and IgG without biological activity, is responsible for 10% of cases of hy-
perprolactinemia34, seven samples with prolactin concentrations higher than 37 
ng/mL were assessed for the presence of macroprolactin. Polyethylene glycol 6000, 
200 μL, (25% w/w) was added to 200 μL of serum and, after thorough vortex mix-
ing, the mixture was centrifuged at 2200 g for 30 min at 4 °C. Subsequently, prolac-
tin was measured in the supernatant and the untreated serum. The recovery of 
prolactin after precipitation with polyethylene glycol 6000 was 101.4 ± 9.6% (SD), 
which excluded the presence of macroprolactin. TSH was measured by means of a 
Vitros Eci system (Ortho Diagnostics) to exclude children or adolescents with hy-
perprolactinemia due to thyroid disorders. Hyperprolactinemia was defined as a 
prolactin level above the 97.5th percentile based on normative data for age and 
sex35.  
Various biochemical bone parameters were measured. Type 1 amino-terminal 
propeptide of procollagen (P1NP) and bone-specific alkaline phosphatase (BAP) 
were measured as markers of bone formation and carboxyterminal cross-linking 
telopeptide of bone collagen (CTx) as marker of bone resorption. Calcium was 
measured with the Modular E170 (Roche Diagnostics, Mannheim, Germany) and 
BAP was measured by an immunoenzymetric assay using the Ostase BAP kit (IDS, 
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Frankfurt am Main, Germany) with an inter-assay coefficient of variation (CV) of 
<7.5%. 25-Hydroxyvitamin D3 was assessed by radioimmunoassay (DiaSorin Inc, 
USA) with intra-assay and inter-assay CVs of <7% and <12%, respectively. P1NP 
was also measured by radioimmunoassay (Orion Diagnostica Oy, Espoo, Finland) 
with intra-assay and inter-assay CVs of 13.7% and <6.4%, respectively. CTx was 
measured in serum by sandwich electrochemiluminescence immunoassay (Roche 
Diagnostics, Mannheim,Germany); the inter-assay CV was 1%. P1NP, BAP and CTx, 
were compared to literature reference values for age and sex37,37. 25-
hydroxyvitamin D3 levels below 30 nmol/L were considered deficient and below 50 
nmol/L as insufficient 38. 
Bone mineral density (BMD, g/cm2) of the lumbar spine and total body was 
measured by dual energy X-ray absorptiometry (DXA, Lunar Prodigy). The reported 
CV is 1.0 % for lumbar spine BMD and 0.73 % for total body BMD39. Quality assur-
ance was performed daily. Ancillary DXA-derived data were used to calculate lum-
bar spine volumetric BMD, to adjust for bone size, bone mineral apparent density 
(BMAD), with the model BMAD=BMD x (4 / (π x width)36, 40,41.  
Body composition was measured as bone mineral content (BMC), lean tissue 
mass (lean, in grams), and fat mass (DXA, Lunar Prodigy), and total % body fat was 
determined. The coefficient of variation for these measurements is reported as 1.29 
% for lean tissue mass, 2.59 % for fat mass, and 0.74 % for BMC39. In the analysis, 
lean body mass and total % body fat were used. The results were compared to age- 
and sex-matched Dutch reference values36,41 and expressed as z-scores. 
Plasma levels of risperidone, 9-hydroxyrisperidone, and pimozide were meas-
ured to evaluate compliance.  
2.3 Data analysis 
One sample t-tests were used to compare the mean z-scores of the boys with age 
matched normative data. To test for differences between the two study groups, 
Student’s t-test, Chi-square, Mann-Whitney tests, or Fisher exact test was applied 
according to the type and distribution of the data. Dose equivalence was assumed 
between pimozide (N=3) and risperidone (N=53)42,43. 
Multiple linear regression was used to investigate whether BMD, body compo-
sition, and biochemical bone parameters were different between the two groups, 
with adjustment for BMI z-score, average daily calcium intake, and serum 25-
hydroxyvitamin D3 level. Low BMD was defined as a z-score ≤ -244. Pearson’s corre-
lation coefficient was calculated to investigate the relationship between prolactin 
levels and the biochemical bone markers. Hyperprolactinemia and inactivity are 
both associated with weight gain, and therefore we also investigated the relation-
ship between prolactin and GRF score and the total % body fat z-score. 
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3. Results 
The baseline characteristics of the participants are presented in Table 1. There was 
no significant difference in mean age, Tanner stage, height z-score, BMI z-score, 
GRF-score, or diagnosis between the boys who were or were not treated with AP. 
The AP treated boys had a higher disease severity score in comparison to the boys 
without AP treatment (respectively 4.7 for the AP treated boys versus 4.0 for the 
boys without AP treatment; p=0.003). Of the boys treated with AP, 53 were treated 
with risperidone at a mean dose of 1.6 mg/day (SD 0.8, range 0.5-4) with mean 
treatment duration of 51.4 months (SD 28, range 16-126), and 3 were treated with 
pimozide at a mean dose of 1.7 mg/day. Two-thirds of the AP-treated boys (37 out 
of 56) had used their AP medication for more than 3 years. The mean prolactin level 
in AP-treated boys was 18.9 ng/mL (SD 16, range 2.4-92.5): it was 28.08 ng/mL (SD 
19.1, range 14.6, 92.5) in the 27 boys with hyperprolactinemia and 10.38 ng/mL 
(SD 4.0, 2.4, 17) in the 29 boys without hyperprolactinemia. Four out of the 27 
(15%) hyperprolactinemic boys had possible prolactin related sexual functioning 
disorders. The mean serum prolactin level was 8.0 ng/mL (SD 2.8, range 3.8-15.1) 
in the boys not treated with AP. The calcium intake was significantly lower in the 
AP-non-treated boys than in the AP-treated boys, but the later had a significantly 
lower 25-hydroxyvitamin D3 level (p=0.017). 25-Hydroxyvitamin D3 levels were 
deficient in 8 (14%) of the AP treated boys and insufficient in 17 (30%). Of the 47 
boys not treated with AP, 5 (11%) and 6 (13%) had deficient and insufficient 25-
hydroxyvitamin D3 levels, respectively. Ten AP-treated boys (18%) reported a his-
tory of a fracture compared with 12 boys not treated with AP (26%). 
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Table 1. Characteristics of adolescents with autism spectrum disorders who were (cases, N=56) or who 
were not (comparison subjects, N=47) treated with antipsychotics  
 Cases  
(N=56) 
Comparison subjects  
(N=47) 
P value 
 Mean (SD; range) Mean (SD; range)  
Age, years 14.8 (2.2; 10, 19) 15.0 (1.6; 12,18) 0.50# 
Height z-score (cm) 0.43 (1.1; -2.4,2.12) 0.36 (0.94; -1.5,2.9) 0.37# 
BMI z-score 0.25 (1; -1.8, 2.8) -0.08 (1.2; -3.3, 2.3) 0.15# 
Tanner stage, N I/II/III/IV/V 0/8/16/22/10 0/9 /13/19 /6  
Caucasian ethnicity, N (%) 55 (98) 46 (96) 0.54^ 
Primary diagnosis, N (%): 
ASD* 
DBD* 
 
52 (93) 
 4 (7) 
 
40 (85) 
 7 (15) 
 
0.17^ 
CGI-S  4.7 (1; 1-7) 4.0 (0.6; 3-6) 0.003# 
Antipsychotic dose (mg/day)  1.6 (0.8; 0.5,4   
Duration of use (months) 51.4 (28; 16-126)   
Concomitant medication, N (%): 
Melatonin 
SSRI 
Psychostimulants 
Atomoxetine 
 
 5 (9) 
 2 (4) 
10 (18) 
 2 (4) 
 
 4 (9) 
 0 
13 (28) 
 0 
 
Calcium intake (mg/day) 1314 (725; 268,4164) 992 (564; 5-2958) 0.008@ 
GRF* 18 (7; 3,40) 19 (6; 10,34) 0.25@ 
History of fracture(s), N (%)* 10 (18) 12 (26) 0.34^ 
25-hydroxyvitamin D (nmol/L) 
Deficient, N (%) 
Insufficient, N (%) 
55.3 (22; 14,107) 
 8 (14) 
24 (43) 
66.4 (23; 14,120) 
 5 (11) 
13 (28) 
0.017# 
0.77 
0.15 
*ASD= autism spectrum disorders; DBD=disruptive behavior disorder; GRF=ground reaction force; 
SSRI=selective serotonin re-uptake inhibitor; CGI-S=The Clinical Global Impression - Severity scale (CGI-
S); History of fracture(s)=number of patients that ever had one or more fractures from birth until now; 
# Independent sample Student’s t-test; ^ Chi square; @ Mann-Whitney 
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Bone mass and body composition 
The mean z-scores of the lumbar spine, total body BMD, and the lumbar spine 
BMAD, (volumetric BMD), for all boys (N=103) were not significantly different from 
zero. The mean height z-score (0.39, p<0.001) and total % body fat z-score (1.16, 
p<0.001) were significantly higher than normal and the mean lean tissue mass z-
score (-0.37, p<0.004) was significantly lower than normal. 
Table 2 shows the differences between AP-treated boys with (N=27) and with-
out (N=29) hyperprolactinemia and the differences between the boys who were or 
were not treated with AP. There were no significant differences in z-scores of the 
lumbar spine and total body BMD, lumbar spine BMAD, lean tissue mass, and total 
% body fat between the boys who were or were not treated with AP. Within the 
group AP-treated boys, the boys with AP-induced hyperprolactinemia had a lower 
BMAD z-score (p=0.043) and a higher total % body fat z-score (p=0.032) than did 
the AP-treated boys without hyperprolactinemia; there were no significant differ-
ences in mean z-scores of lumbar spine and total body BMD and lean tissue mass 
between the two groups of AP-treated boys. The BMD and body composition of the 
hyperprolactinemic boys with prolactin related side effects (4 out of 27) was not 
significantly different from the hyperprolactinemic boys without clinical prolactin 
related signs. 
Table 2. Bone mineral density, body composition, and biochemical parameters of adolescent boys with 
autism spectrum disorders who were treated (N=56) or not treated (N=47) with antipsychotics 
Treated with antipsychotics  
(N=56) 
 
With 
Hyperprolactinemia 
N=27 
Without  
hyperprolactinemia 
N=29 
Not treated with antipsychotics 
(N=47) 
 
 Mean (SD, range) Mean (SD, range) P value1 Mean (SD, range) P value2
Lean tissue mass z-score -0.29 (1.3; -2.24, 2.31) -0.13 (1.1; -1.92, 2.75) 0.69$ -0.57 (1.4; -0.87, 0.15) 0.67$ 
% body fat z-score 1.40 (0.71; -0.26, 2.95) 1.10 (0.83; -0.53, 2.57) 0.032$ 1.06 (0.90; -0.73, 2.74) 0.81$ 
Lumbar spine BMD z-score -0.18 (1.0; -2.36, 1.69) 0.15 (0.78; -1.46, 1.51) 0.15$ -0.026 (1.17; -0.46, 0.35) 0.74$ 
Total body BMD z-score 0.038 (1.16; -2.1, 2.84) 0.083 (0.81; -1.24, 2.24) 0.79$ -0.20 (1.11; -0.67, 0.14) 0.80$ 
Lumbar spine BMAD z-
score 
-0.32 (0.80; -2.49, 0.75) 0.12 (0.77; -1.4, 1.35) 0.043$ -0.12 (0.04; -0.36, 0.30) 0.33$ 
P1NP µg/L 462 (286; 67, 1033) 589 (313; 143, 1111) 0.060$ 546.19 (338.9; 61, 1586) 0.48$ 
BAP µg/L 82.5 (52.1; 10.7, 173) 98.4 (60.3; 16, 257) 0.16$ 78.40 (51.4; 14.3, 241) 0.062$ 
CTx µg/L 0.80 (0.40; 0.23, 1.51) 0.99 (0.39; 0.31, 1.95) 0.042$ 1.11 (0.52; 0.32, 3.22) 0.19$ 
* Students T-test; BMD=bone mineral density; BMAD= bone mineral apparent density; P1NP= type 1 
amino-terminal propeptide of procollagen; CTX= carboxyterminal cross-linking telopeptide of bone 
collagen; BAP= bone-specific alkaline phosphatase; $ Linear regression analysis corrected for BMI Z-
score, 25-hydroxyvitamin D, and average calcium daily intake; P value1 Compares boys treated with 
antipsychotics with and without hyperprolactinemia; P value2 Compares boys treated with antipsychot-
ics with boys not treated with antipsychotics 
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Low lumbar spine BMAD (defined as a z-score of ≤ -2) was present in 2 out of the 
27 (7.4%) hyperprolactinemic AP treated boys and in none of the boys with AP 
treatment without hyperprolactinemia and in none without AP treatment. The two 
boys with hyperprolactinemia and low BMD had no prolactin-related side effects, 
such as erectile dysfuction, gynecomastia, or loss of libido. Low lumbar spine BMD 
was present in 3 out of 27 (11.1%) hyperprolactinemic AP treated boys, of which 
one of these boys had a possible prolactin related side effect; he reported a loss of 
libido and problems in the ability to have an orgasm, and low lumbar spine BMD 
was present in 1 out of 47 (2.1%) boys without AP treatment and in none of the 
boys with AP treatment without hyperprolactinemia.  
Prolactin levels were positively associated with the mean total % body fat z-
score (r=0.188, p=0.06), and the mean total % body fat z-score was negatively asso-
ciated with the GRF score (r=-0.312, p=0.001).  
Biochemical bone parameters 
Table 3 shows that the levels of markers of bone resorption (CTx) and formation 
(BAP, P1NP) were not significantly different between the boys who were or were 
not treated with AP and were also normal compared to normative data36,37. The AP-
treated boys with hyperprolactinemia had significantly lower CTx levels (p=0.042) 
than the AP-treated boys without hyperprolactinemia. P1NP levels showed a trend 
towards being lower in the AP-treated boys compared to those without AP treat-
ment (p=0.06). BAP levels were not different between the two groups (p=0.16). 
Prolactin levels were negatively correlated with CTx (r=-0.20, p=0.048) and showed 
a trend towards negative correlation with P1NP levels (r=-0.17, p=0.095). BAP was 
not associated with prolactin levels (r=-0.05, p=0.60). 
4 Discussion 
4.1 Bone strength and autism spectrum disorders  
There are two previous studies investigating the effect of ASD or infantile autism on 
bone strength. These studies investigated the strength in two different ways; one 
study looked at the outcome measurement of bone strength expressed as fracture 
prevalence, and the other study investigated the bone cortical thickness. The frac-
ture prevalence rate appeared to be lower for the autistic group, 12% for the pa-
tients with infantile autism versus 25% for the comparison group, (follow up for 30 
years, N=118) (Mouridsen 2012). Our study showed a fracture prevalence rate of 
about 20% (19% for the ASD boys with hyperprolactinemia versus 21% for the 
ASD boys without hyperprolactinemia), which was also low, compared to the nor-
mative data fracture rate of 36% (Boot 2010). One explanation could be that boys 
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with ASD have less organized outdoor sports activities, and their preferred leisure 
activities often involve an indoor setting, which would protect them from sustain-
ing fractures49. 
However, when investigating the bone cortical thickness the children with ASD 
(mean age 7 years, N=75) had reduced bone cortical thickness when compared 
with normative data. Our study showed no difference in areal and volumetric BMD 
for the ASD or DBD boys compared to normative data.  
We found, as expected, lean tissue mass to be lower and the percentage of mean 
total body fat to be higher in our total study population than in healthy controls, 
which may be due to disease-specific differences in lifestyle. As mentioned above, 
children or adolescents with ASD do not commonly participate in organized out-
door sports, preferring indoor leisure activities49. The GRF score, a parameter of 
physical activity, was negatively associated with fat percentage. Lean tissue mass, 
which is mainly muscle mass, is highly related to bone mass in children and is im-
portant for the attainment of peak bone mass49. It is reassuring from a clinical per-
spective that the psychiatric condition of ASD or infantile autism does not seem to 
lead to a higher fracture prevalence rate and that at older age the boys did not have 
a lower BMD compared to normative data. 
4.2 Hyperprolactinemia and biochemical bone markers 
Our study is the first to investigate bone markers in boys with hyperprolactinemia. 
The levels of bone resorption marker CTx were significantly lower and levels of 
bone formation marker P1NP tended to be lower in AP-treated boys with hyper-
prolactinemia than in AP-treated boys without hyperprolactinemia. This suggests 
that hyperprolactinemia may inhibit bone turnover, possibly by a direct negative 
effect on osteoblasts, or by a secondary effect through hyperprolactinemia-induced 
hypogonadotropic hypogonadism. We have reported before that the boys with 
hyperprolactinemia had significantly lower testosterone levels47, which may have 
resulted in a decrease in bone turnover. 
Further research in this area is needed since bone turnover markers reflect the 
dynamic aspect of bone metabolism, and longitudinal data are needed to investi-
gate the changes over time.  
4.3. Hyperprolactinemia and body composition 
The AP-treated boys with hyperprolactinemia had higher total % body fat z-scores 
than did the AP-treated boys without hyperprolactinemia, which may be a risk 
factor for future fractures in children and adolescents (Goulding 2005). Prolactin 
levels were positively associated with the total % body fat z-scores. As the AP-
treated boys were earlier found to have low, but still within the normal range, tes-
tosterone levels (Roke et al 2012), the lower testosterone levels could explain in 
part the higher percentage of body fat in relation to the lean tissue mass in these 
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boys because testosterone is an important mediator of gain in muscle mass in ado-
lescence50. Relatively less physical exercise could also be an explanation for the 
higher body fat content of the AP-treated boys. 
4.4 25-hydroxyvitamin D3 
25-hydroxyvitamin D3 is a determinant of peak bone BMD in children and adoles-
cents. Thirteen of the 113 boys (13%) had deficient levels of 25-hydroxyvitamin D3 
and 37 (36%) insufficient levels, these are higher proportions than reported for 
Dutch young adult males without psychiatric disorders (4% and 22%, respec-
tively)51. This difference in 25-hydroxyvitamin D3 levels could be due to the dis-
ease-specific dietary restrictions and/ or food selectivity52, a lack of exposure to 
sunlight, given the preferred indoors activities of our ASD population, or seasonal 
variance49.  
4.5 Hyperprolactinemia and bone mineral density  
In adults with AP-induced hyperprolactinemia the effect on bone mineral density 
and prevalence of fractures has been studied. Patients treated with these AP have a 
two-fold risk in gaining an upper leg or hip fracture (Howard 2007, Hugentholtz 
2007). The patients with schizophrenia treated with AP-inducing hyperprolactine-
mia have significant diminished areal BMD compared to patients without hyper-
prolactinemia (Kishimoto 2008, Misra 2004). However, there are conflicting results 
showing that the negative symptoms and lifestyle differences in schizophrenia may 
be the cause of the diminished BMD in addition to lifestyle differences instead of 
the hyperprolactinemia (e.g. less exercise, nutritional alterations, smoking) (Suga-
wara 2011). In male children and adolescents with various psychiatric conditions 
the effect of AP-induced hyperprolacinemia was investigated in one previous study. 
This study (N=83, mean age 12 years) reported a reduced BMD in the hyperprolac-
tinemic boys, with boys with and without hyperprolactinemia having the same 25-
hydroxyvitamin D3 levels and daily calcium intake; comparisons with healthy con-
trols were not made (Calarge 2010). Our study replicated this finding showing a 
diminished volumetric BMD of the lumbar spine for the group of boys with hyper-
prolactinemia compared to the boys with AP treatment and without hyperprolacti-
nemia. The volumetric BMD of the lumbar spine is a good predictor of future frac-
tures (especially wrist and forearm fractures)45,46, and therefore our findings sug-
gest that AP-induced hyperprolactinemia may have a negative influence on BMD, 
especially of trabecular bone, such as of the lumbar vertebrae. Low BMD was pre-
sent in respectively 7% (volumetric lumbar spine BMD) and 11% (areal lumbar 
spine BMD) of the AP treated hyperprolactinemic boys. Just one of these boys had 
possible clinical prolactin related signs of hypogonadism; thus clinicians should be 
aware that hyperprolactinemia may be associated with low BMD without alarming 
signs. However, both our study as the Calarge study had a cross-sectional design; 
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therefore it is not possible to draw any final conclusions about these results. Well-
designed prospective studies are needed to assess the relative contributions of 
hyperprolactinemia, hypogonadotropic hypogonadism, the psychiatric condition, 
nutritional alterations and other lifestyle changes on BMD and it’s clinical conse-
quences. 
4.6 Limitations 
This study had some limitations that should be taken into account when interpret-
ing the results and which should be addressed in future studies. Since the study was 
observational and cross-sectional, we cannot establish causality and the power of 
the study was limited because of the relatively small sample size. Peak bone mass is 
usually attained between 18 and 23 years49, and as our study participants were 
about 15 years old, bone growth, modeling, and remodeling were all active, which 
makes it difficult to evaluate bone metabolism at one time point. Another potential 
limitation was the choice to measure BMD using DXA, instead of the more sensitive 
peripheral quantitative computed tomography (pQCT). Although DXA is the clinical 
standard, trabecular bone, which is more vulnerable than cortical bone to hormonal 
abnormalities, such as hyperprolactinemia53, cannot be distinguished from cortical 
bone by DXA, and thus early effects of hyperprolactinemia on BMD might have been 
missed54. Even so, we did find significant differences in the lumbar spine BMAD, 
measured by DXA, between the AP-treated boys with or without hyperprolactine-
mia.  
We further measured bone turnover markers, which reflect the dynamic aspect 
of bone metabolism, however, bone markers of bone turnover are difficult to inter-
pret, especially in children and adolescents since they reflect both growth and bone 
modeling and remodeling. Longitudinal data are needed to investigate the changes 
over time and to establish a clinical important difference in these markers due to 
AP-induced hyperprolactinemia.  
The boys with AP were more severely ill than the boys without AP, and we can-
not exclude that severity of the illness had a negative effect on BMD. We could hy-
pothesize that more severely ill patients had specific dietary restrictions and/ or 
food selectivity and less physical exercise and this could have had a negative influ-
ence on their BMD. Another potential limitation is that the boys were allowed to 
use concomitant prolactin-elevating medication, such as melatonin and selective 
serotonin re-uptake inhibitors, which could have influenced the prolactin levels and 
BMD16. However, use of these medications was similar in both groups and proba-
bly did not confound our results. Moreover, the prolactin-elevating effect of this 
concomitant medication is considered to be relatively minor compared with that of 
the AP used55. 
C H A P T E R  5  
 96 
4.7 Conclusion 
This study suggest that AP-induced hyperprolactinemia in boys with ASD may have 
a negative influence on BMD. Further research including longitudinal studies is 
needed to disentangle the effects of psychiatric conditions (ASD or DBD) and the 
effects of AP treatment and hyperprolactinemia. The physician should evaluate the 
history of fractures, calcium intake, sun exposure and exercise in boys with hyper-
prolactinemia due to AP treatment. Assessment of serum 25-hydroxyvitamin D3 
and BMD measurement should be considered. If AP-induced hyperprolactine-
mia occurs, the AP should be reduced if this is clinically feasible. Prolactin levels 
should normalize within days dependent on the half-life (T1/2) of the drug56. If this 
is not effective a switch to an AP without prolactin-elevating qualities may be use-
ful57,58. 
References 
1. McDougle C, Stigler K, Erickson C & Posey D. Atypical antipsychotics in children and adolescents 
with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008 69 15-20.  
2. Aman M, McDougle C, Scahill L, Handen B, Arnold L, Johnson C, Stigler K, Bearss K, Butter E, Swiezy 
N, Sukhodolsky D, Ramadan Y, Pozdol S, Nikolov R, Lecavalier L, Kohn A, Koenig K, Hollway J, Kor-
zekwa P, Gavaletz A, Mulick J, Hall K, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B &Wagner A. Medi-
cation and Parent Training in Children With Pervasive Developmental Disorders and Serious Behav-
ior Problems: Results From a Randomized Clinical Trial. J Am Acad Child Adolesc Psychiatry 2009 
48 1143-54. 
3. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with 
autism and serious behavioral problems. New Eng. J Med 2002 347 314–321.  
4. Blankenship K, Erickson C, Stigler K, Posey DJ & McDougle CJ. Aripiprazole for irritability associated 
with autistic disorder in children and adolescents aged 6-17 years. Ped Health 2010 4 375-381. 
5. Wink L, Erickson C & McDougle C. Pharmacologic treatment of behavioral symptoms associated with 
autism and other pervasive developmental disorders. Curr Treat Opt Neurol 2010 12 529-38.  
6. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive 
literature review. CNS Drug 2005 19:1-93.  
7. Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J & Malhotra A. Cardiometabolic risk of second-
generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009 
21 2302-22. 
8. Roke Y, Van Harten P, Boot A & Buitelaar J. Antipsychotic medication in children and adolescents: A 
descriptive review of the effects on prolactin level and associated side effects.J Child Adolesc Psy-
chopharmacol 2009 19 403-14. 
9. Houseknecht K, Robertson A, Zavadoski W, Gibbs E, Johnson D & Rollema H. Acute effects of atypical 
antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. 
Neuropsychopharmacology 2007 32 289-97. 
10. Schwetz V, Pieber T & Obermayer-Pietsch B. Mechanisms in endocrinology: The endocrine role of 
the skeleton: background and clinical evidence. Eur J Endocrinol 2012 166 959-967 
11. Davies J, Evans B & Gregory J. Bone mass acquisition in healthy children. Arch Dis Child 2005 90 
373-8. 
12. Taes Y, Lapauw B, Vanbillemont G, Bogaert V, De Bacquer D, Zmierczak H & Goemaere S. Fat Mass Is 
Negatively Associated with Cortical Bone Size in Young Healthy Male Siblings. J Clin Endocrinol Me-
tab 2009 94 2325-31. 
B O N E  M I N E R A L  D E N S I T Y  
 97 
13. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpun-
takit J, Suthiphongchai T& Krishnamra N. Prolactin directly enhances bone turnover by raising os-
teoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 
2008 42 535-46.  
14. Motyl K, Dick-de-Paula I, Maloney A, Lotinun S, Bornstein S, de Paula F, Baron R, Houseknecht K & 
Rosen C. Trabecular bone loss after administration of the second-generation antipsychotic risperi-
done is independent of weight gain. Bone 2012 50 490-8. 
15. Graham S, Howgate D, Anderson W, Howes C, Heliotis M, Mantalaris A, Tsiridis E & Tsapakis E. Risk 
of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 
2011 10 575-602. 
16. Calarge C, Zimmerman B, Xie D, Kuperman S & Schlechte J. A cross-sectional evaluation of the effect 
of risperidone and selective serotonine reuptake inhibitors on bone mineral density in boys. J Clin 
Psychiatry 2010 1 338-347. 
17. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M & Pivonello R. Prolactinomas in adolescents: 
persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 2000 52 319-27. 
18. Abraham G, Halbreich U, Friedman R & Josiassen R. Bone mineral density and prolactin associations 
in patients with chronic schizophrenia. Schizophr Res 2003 59 17-8. 
19. Abraham G, Paing W, Kaminski J, Joseph A, Kohegyi E & Josiassen R. Effects of elevated serum prolac-
tin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospec-
tive study. Am J Psychiatry 2003 160 1618-20. 
20. Meaney A, Smith S, Howes O, O'Brien M, Murray R, O'Keane V. Effects of long-term prolactin-raising 
antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 
2004 184 503-8. 
21. O'Keane V & Meaney A. Antipsychotic drugs: a new risk factor for osteoporosis in young women 
with schizophrenia? J Clin Psychopharmacol 2005 25 26-31. 
22. Becker A & Epperson C. Female puberty: clinical implications for the use of prolactin-modulating 
psychotropics. Child Adolesc Psychiatr Clin N Am 2008 15: 207-20. 
23 Hugenholtz G. Antipsychotic in daily clinical practice: patterns, choices and consequences. Univer-
siteit Utrecht. Utrecht, Utrecht 2005. 
24. Howard L, Kirkwood G & Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br 
J Psychiatry 2007 190 129-34. 
25. Verhelst J & Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003 2 
23-32. 
26. Fredriks A1, van Buuren S, Burgmeijer R, Meulmeester J, Beuker R, Brugman E, Roede M, Verloove-
Vanhorick S & Wit J. Continuing positive secular growth change in The Netherlands 1955-1997. Pe-
diatr. Res 2000 47 316-23. 
27. Fredriks A2, van Buuren S, Wit J & Verloove-Vanhorick S. Body index measurements in 1996-7 
compared with 1980. Arch Dis Child 2000 82 107-12. 
28. Duke P, Litt I & Gross R. Adolescents’self-assesment of sexual maturation. Pediatrics 1980 66 918-
20. 
29. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of 
Health, Education, and Welfare; 1976. 
30. Angus R, Sambrook P & Pocock N. A simple method for assessing calcium intake in Caucasian 
women. J Am Diet Assoc 1989 89 209-214. 
31. Greendale G, Huang M, Wang Y, Finkelstein J, Danielson M & Sternfeld B. Sport and home physical 
activity are independently associated with bone density. Med Sci Sports Exerc 2003 35 506-512, 
2003.  
32. Kemper H, Twisk J & van Mechelen W. A fifteen-year longitudinal study in young adults on the rela-
tion of physical activity and fitness with the development of the bone mass: The Amsterdam Growth 
And Health Longitudinal Study. Bone 2000 27 847-853. 
33. Bakker I, Twisk J, van Mechelen W, Roos J & Kemper H. Ten-year longitudinal relationship between 
physical activity and lumbar bone mass in (young) adults. J Bone Miner Res 2003 18 325-332. 
C H A P T E R  5  
 98 
34. Amadori P, Dilberis C, & Marcolla A. All the studies on hyperprolactinemia should not forget to 
consider the possible presence of macroprolactinemia. Eur J Endocrinol 2004 150 93-94. 
35. Emlinger M, Kühnel W & Ranke M. Reference ranges for serum concentrations of Lutotropin (LH), 
Follitropin (FSH), Estradiol (E2), Prolactin, Progesterone, Sex Hormone Binding Globuline (SHBG), 
Dehydroepiandrosterone sulfate (DHEAS), Cortisol and Ferritin in neonates, children and young 
adults. Clin Chem Lab Med 2002 40 1151-1160. 
36. Van der Sluis I, de Ridder M, Boot A, Krenning E & de Muinck Keizer-Schrama S. Reference data for 
bone density and body composition measured with dual energy x ray absorptiometry in white chil-
dren and young adults. Arch Dis Child 2002 87 341-7. 
37. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, 
Finkenstedt G & Högler W. Sex- and age-specific reference curves for serum markers of bone turn-
over in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 2007 92 443-9.  
38. Allgrove J & Shaw N. Calcium and Bone Disorders in Children and Adolescents. Karger Basel 2009. 
39. Margulies L, Horlick M, Thornton J, Wang J, Ioannidou E & Heymsfield S. Reproducibility of pediatric 
whole body bone and body composition measures by dual-energy X-ray absorptiometry using the 
GE Lunar Prodigy. J Clin Densitom 2005 8 298-304.  
40. Kröger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of the spine and femur in children by 
dual-energy x-ray absorptiometry. Bone Miner 1992 17 75-85. 
40. Boot A, Bouquet J, de Ridder M, Krenning E & de Muinck Keizer-Schrama S. Determinants of body 
composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents. Am 
J Clin Nutr 1997 66 232-8. 
42. Atkins M, Burgess A, Bottomley C & Riccio M. Chlorpromazine equivalents: a consensus of opinion 
for both clinical and research applications. Psychiatric Bulletin 1997 21 224-226. 
43. Woods S. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 
2003 64 663-7. 
44. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi M, Kalkwarf HJ, Langman CB, 
Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB & Silverman 
S.International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 
2008 43 1115-1121. 
45. Boot A, de Ridder M, van der Sluis I, van Slobbe I, Krenning E & Keizer-Schrama S. Peak bone mineral 
density, lean body mass and fractures. Bone 2010 46 336-41.  
46. Jones G, Ma D & Cameron F. Bone density interpretation and relevance in Caucasian children aged 9-
17 years of age: insights from a population-based fracture study. J Clin Densitom 2006 9 202-9. 
47. Roke Y, van Harten P, Buitelaar J, Tenback D, de Rijke Y, & Boot A. Antipsychotic-induced hyperpro-
lactinemia and testosterone levels in boys. Horm Res Paediatr 2012 77 235-40. 
48. Hediger ML, England LJ, Molloy CA, Yu KF, Manning-Courtney P& Mills JL. Reduced cortical bone 
thickness in boys with autism or autism spectrum disorders. J Autism Dev Disord 2008 38 848-56. 
49. Macdonald M, Esposito P & Ulrich D. The physical activity patterns of children with autism. BMC Res 
Notes 2011 18 4-422. 
50. Herbst K, Anawalt B, Amory J, Matsumoto A & Bremner W. The male contraceptive regimen of tes-
tosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but 
attenuates a decrease in fat mass induced by testosterone alone. J Clin Endocrinol Metab 2008 88 
1167-73. 
51. Boot A, Krenning E & de Muinck Keizer-Schrama S. The relation between 25-hydroxyvitamin D with 
peak bone mineral density and body composition in healthy young adults. J Pediatr Endocrinol Me-
tab 2011 24 355-60. 
52. Kodak T & Piazza C. Assessment and behavioral treatment of feeding and sleeping disorders in 
children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008 17 887-905. 
53. Schlechte J, Walkner L & Kathol M. A longitudinal analysis of premenopausal bone loss in healthy 
women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992 75 698–703. 
54. Pitukcheewanont P & Chen P. Bone density measurements in children and adolescents. Quantitative 
computed tomography versus dual-energy X-ray absorptiometry. The Endocrinologist 2005 15 232–
239. 
B O N E  M I N E R A L  D E N S I T Y  
 99 
55. Coker F & Taylor D. Antidepressant-induced hyperprolactinaemia. CNS Drug 2010 24 563-574. 
56. Turrone P, Kapur S, Seeman M & Flint A. Elevation of prolactin levels by atypical antipsychotics. Am J 
Psychiatry 2002 159 133-135. 
57. Stevens J, Kymissis P & Baker A. Elevated prolactin levels in male youths treated with risperidone 
and quetiapine. J Child Adolesc Psychopharmacol 2005 15 893-900. 
58. Greenaway M & Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. 
J Can Acad Child Psychiatry 2009 18 250-60. 
 
 
 

  101 
 
 
PART 2b 
Genetic risk factors 
 
 
 
 
 
  
 
 
 
 103 
Chapter 6 
The effect of the Taq1A variant in the 
dopamine D2 receptor gene and common 
CYP2D6 alleles on prolactin levels in 
risperidone treated boys. 
Yvette Roke, Peter N. van Harten, Barbara Franke, Tessel E. Galesloot,  
Annemieke M. Boot, Jan K. Buitelaar 
 
Accepted for publication in Pharmacogenetics and Genomics 
C H A P T E R  6  
 104 
Abstract 
 Objective: To investigate the effect of the Taq1A variant in the Dopamine D2 
receptor gene (DRD2) and common functional genetic variants in the cytochrome 
P450 2D6 gene (CYP2D6) on prolactin levels in risperidone treated boys with au-
tism spectrum disorders (ASD) and disruptive behavior disorders (DBD). 
 Methods: 47 physically healthy 10- to 19-year-old boys with ASD and/ or DBD, 
chronically treated (mean 52 months, range 16-126 months) with an antipsychotic 
were recruited to this observational study. Prolactin levels, hyperprolactinemia, 
risperidone levels and 9-hydroxy-risperidone levels were assessed and the partici-
pants were genotyped for common CYP2D6 polymorphisms and the Taq1A allele of 
the dopamine D2 receptor gene. Group differences were tested with Student’s t-
test, Chi-square, and logistic regression analysis. 
 Results: Prolactin levels were positively and significantly associated with 
risperidone levels (p=0.05), 9-hydroxy risperidone levels (p=<0.0001) and with 
oral risperidone dose in milligram per kilogram (p=<0.0001). Furthermore, multi-
ple regression analysis revealed no correlations between prolactin level and the 
presence of a least one Taq1A A1 allele of the DRD2 gene (p=0.12).  
 Conclusion: While CYP2D6 might have an effect, the presence of a least one 
Taq1A A1 allele of the D2DR gene did not contribute to one’s susceptibility to 
risperidone-induced hyperprolactinemia, and as a result to developing prolactin 
related adverse events such as amenorrhea, galactorrhea, and sexual dysfunction-
ing.  
 
 Keywords: risperidone, prolactin, genetics, adolescents 
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1. Introduction 
Second-generation antipsychotics are increasingly prescribed to children and ado-
lescents with psychiatric disorders and have been used successfully to reduce mal-
adaptive behaviours, such as irritability, self-injury, stereotypies and hyperactivity 
in children and adolescents with autism spectrum disorders (ASD) and irritability 
and aggressive behaviour in children and adolescents with disruptive behavior 
disorder (DBD) [1]. 
While risperidone and aripiprazole have been approved by the United States 
Food and Drug Administration (FDA) for the treatment of children and adolescents 
with irritability associated with ASD [2-4], these drugs have not yet been approved 
for this indication in Europe. Their clinical effectiveness is well established and 
there is a lower risk of neurological adverse effects compared to the first generation 
antipsychotics [4]. However, some concerns exist about the treatment with risperi-
done, as it may induce side effects like weight gain, glucose dysregulation and 
dyslipidemia, and hyperprolactinemia [5-8]. 
Hyperprolactinemia may cause amenorrhea, galactorrhea, impotence, libido 
loss, hypospermatogenesis, hypogonadotropic hypogonadism, and further a long-
term risk of osteoporosis [9, 10]. Fifty percent of the children and adolescents that 
have been long-term treated with antipsychotics still have hyperprolactinemia 
[11,12]. Antipsychotics increase plasma prolactin concentration through anti-
dopamine activity by the blockade of dopamine D2 receptors in the anterior pitui-
tary [13]. Pharmacogenetic differences may explain individual variation in prolac-
tin elevation in response to antipsychotic medication leading to clinical conse-
quences. As dopamine 2 antagonism plays an important role in the prolactin eleva-
tion, the dopamine D2 receptor gene (DRD2) is an attractive candidate gene. Stud-
ies on human post mortem brains [14] revealed a lower dopamine D2 receptor 
density in the striatum and related structures in A1 allele carriers of the DRD2 
Taq1A polymorphism (rs1800497). Similar results were found in vivo [15]. Studies 
showed an association between the presence of the A1 allele of the Taq1A poly-
morphism and a higher prolactin elevation to antipsychotics in adult females [16] 
and in the general population [17, 18]. However, another study showed no correla-
tion between prolactin concentration and dopamine-related polymorphisms in 
male and female patients with schizophrenia [19]. In addition one study with long-
term risperidone treated children and adolescents showed four times more prolac-
tin-related side effects in Taq1A A1 allele carriers [20]. Since prolactin elevation is 
(partly) related to antipsychotic blood levels, the gene coding for the cytochrome 
P450 2D6 enzyme (CYP2D6) is another interesting candidate gene for explaining 
variation in prolactin levels after treatment with antipsychotic medication. This 
enzyme metabolizes many antipsychotics including risperidone. The CYP2D6 gene 
is highly polymorphic resulting in different phenotypic metabolism rates of the 
encoded enzyme. Normal metabolizers are homozygous for functional CYP2D6 
alleles or heterozygous with 1 functional CYP2D6 allele; poor metabolizers have no 
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functional CYP2D6 alleles (7% of the Caucasian, 1% of the Asian and 3% of the 
African individuals). Ultrarapid metabolizers have a duplication (rapid) or multipli-
cations (ultrarapid) of the intact CYP2D6 gene (found in 2% of the Caucasian popu-
lation and up to 25% of several Ethiopian subpopulations) [20, 21].  
The half-life for risperidone depends on its metabolization rate, and ranges be-
tween 2-4 hours in normal metabolizers and 22 hours in poor metabolizers. Risper-
idone is converted into its major active metabolite 9-hydroxy risperidone by the 
enzyme CYP2D6. The half-life of 9-hydroxy risperidone is 21 hours partly depend-
ent of the CYP2D6 metabolism [22, 23]. Usually the ratio of risperidone to 9-
hydroxy risperidone is about 1:3, but this ratio is typically inverted in poor metabo-
lizers [23,26]. A previous study showed the number of functional CYP2D6 alleles to 
be associated with prolactin levels [27]. Prolactin levels were also positively corre-
lated with the oral dose of risperidone and serum 9-hydroxy risperidone levels 
[27]. On the other hand, other studies reported a higher risk of clinically important 
side effects among risperidone-treated patients with impaired CYP2D6 enzyme 
activity [22,28]. 
The primary aim of this study was to determine the association between the 
prevalence of hyperprolactinemia in children and adolescents long-term treated 
with risperidone on the one hand, and the DRD2 Taq1A polymorphism and func-
tional genetic variants of CYP2D6 on the other. 
Additional aims included the exploration of the effects of clinical and pharma-
cogenetic factors on prolactin levels in this sample. 
2. Methods  
2.1 Subjects 
All participants were recruited from the total patient population of the outpatient 
adolescent clinic of the GGz Central Psychiatric Centre, The Netherlands, from Oc-
tober 2006 to November 2009 [12, 29]. All participants had a diagnosis of ASD or 
DBD. The GGz Central Psychiatric Centre hardly ever sees children and adolescents 
with psychotic or bipolar disorders, because these individuals tend to be referred 
to the nearby university hospital.  
Inclusion criteria were: (i) an age between 10- and 20 years old, (ii) diagnoses 
of any psychiatric disorder, (iii) an IQ above 85, and (iv) treatment with any poten-
tial prolactin-elevating antipsychotic medication continuously for more than 16 
months. Participants were excluded if they had a history of thyroid disorders, syn-
dromes or other chronic diseases affecting puberty, endocrine disorders, if they 
used oral corticosteroids or anticonvulsants, or if they had a known cause of hyper-
prolactinemia [30, 31]. 
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The first author contacted all children and adolescents that met the inclusion crite-
ria by telephone and letter. Seventy-seven children and adolescents were con-
tacted. From this group 56 boys and 6 girls (80% of the contacted patients) partici-
pated in the study. The main reason for not participating was fear of venipuncture.  
For the homogeneity of the group data of six female participants, two boys us-
ing concomitant SSRI medication and three boys treated with pimozide instead of 
risperidone were not analysed. The data of another four boys were not analyzed 
since they were not compliant to antipsychotic treatment (defined as having a 9-
hydroxy risperidone serum level of 0 μg/l). Thus the risperidone group consisted of 
47 boys with ASD or DBD treated long-term with risperidone and being compliant 
to this treatment. Use of other concomitant medication, such as, psychostimulants, 
melatonin, and atomoxetine was permitted (Table 1). The Local Medical Ethics 
Committee approved this study and written informed consent was obtained from 
the patient and the subject’s parents/legal guardians after a clear explanation of the 
study procedures.  
2.2 Procedures 
The clinical diagnosis was obtained from the patients’ chart. The first author meas-
ured the participants’ height (without shoes to the nearest 0.1 cm using a stadiome-
ter, Seca 206, The Netherlands) and weight (participant wearing underwear, to the 
nearest 0.1 kg using an analogue scale, Seca 761, The Netherlands). Age- and gen-
der-specific height, weight and body mass index (BMI) z-scores were calculated 
using normative data for Dutch children [32, 33]. 
A non-fasting morning blood sample was obtained around 9.30 a.m. after a light 
breakfast was eaten at around 7.30 a.m. Serum prolactin was measured with an 
automated chemiluminescence assay system (Immulite 2000, Siemens Healthcare 
Diagnostics) calibrated on the 3rd IS 84/500. As macroprolactin, a complex of pro-
lactin and IgG without biological activity, is responsible for 10% of cases of hyper-
prolactinemia [34], seven samples with prolactin concentrations higher than 37 
ng/ml were assessed for the presence of macroprolactin. Polyethylene glycol 6000, 
200 μl, (25% w/w) was added to 200 μl of serum and, after thorough vortex mixing, 
the mixture was centrifuged at 2200 g for 30 min at 4 °C. Subsequently, prolactin 
was measured in the supernatant and the untreated serum. The recovery of prolac-
tin after precipitation with polyethylene glycol 6000 was 101.4 ± 9.6 (mean± SD), 
which excluded the presence of macroprolactin. TSH was measured to exclude boys 
with hyperprolactinemia due to thyroid disorders. Plasma levels of risperidone and 
9-hydroxyrisperidone were measured by HPLC (reverse phase, CN column, Thermo 
Fisher Scientific, Dreieich, Germany) to evaluate compliance. Genetic analyses were 
performed in a CCKL (Central Commission for the promotion of quality of Labora-
tory research)–accredited laboratory at the Department of Human Genetics, Rad-
boud University Nijmegen Medical Centre, the Netherlands. Blood samples were 
obtained by venipuncture, and DNA was isolated using standard protocols. The 
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DRD2 Taq1A (rs1800497) polymorphism and the CYP2D6 single nucleotide poly-
morphisms (SNPs) CYP2D6*3 del A (rs35742686), CYP2D6*4 G>A (rs3892097), 
CYP2D6*6 del T (rs5030655) as well as the CYP2D6 gene deletion (CYP2D6*5) and 
the gene duplication (CYP2D6xn) were genotyped using TaqMan-based analysis. 
Genotyping was performed in a volume of 10 μl containing 10 ng of genomic DNA. 
For DRD2, 5 μl of TaqMan Mastermix (2x; Life Technologies, Nieuwerkerk a/d 
Ijssel, The Netherlands) and 0.125 μl of TaqMan assay (Assay ID: C_7486676_10, 
reporter 1, VIC-A-allele, reverse assay; Life Technologies) were added to 3.875 μl of 
H2O. For the CYP2D6 variants CYP2D6*4 G>A, CYP2D6*3 del A and CYP2D6*6 del 
T, 0.25 μl of TaqMan assay (Assay IDs: C__27102431_B0, reporter 1, VIC-C-allele, 
reverse assay, C__32407232_50 reporter 1, VIC-T-allele, forward assay, 
C__32407243_20, reporter 1, VIC-A-allele, forward assay; Life Technologies) were 
added to the Mastermix and 3.75 μl of H2O. The gene deletion/duplication copy 
number polymorphism was genotyped using 0.25 μl of TaqMan assay (Assay ID: 
Hs00010001_cn, Fam label; Life Technologies) and 0.25 μl of assay for the refer-
ence gene RNASE P (Assay ID: 4316844, Vic label; Life Technologies) in combina-
tion with 5 μl Mastermix and 4.50 μl of H2O. Amplification was performed using the 
7500 Fast Real-Time PCR (Life Technologies). The PCR program for SNP genotyping 
started with 15 minutes at 95°C, followed by 50 cycles of 15 seconds at 95°C and 1 
minute at 60°C. Genotypes were scored using the algorithm and software supplied 
by the manufacturer. The PCR program for the copy number analysis started with 2 
minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 
95°C and 1 minute at 60°C. Copy number analysis used Copy caller software (Life 
Technologies). To investigate random genotyping error rate in the four SNP geno-
typing assays, the laboratory included 5% duplicate DNA samples, which showed 
100% consistency in genotype. In addition, 4% blanks were included, which were 
all negative. For the analysis of the copy number assay, we included 4 positive con-
trols, 2 for the duplication and deletion each. 
2.3 Data analysis  
Spearman correlation analysis was used to investigate whether prolactin levels 
were associated with the risperidone levels, 9-hydroxy risperidone levels, with the 
total active molecule (risperidone levels and 9-hydroxyrisperidone levels together) 
[35], oral dose of risperidone in milligram per kilogram, the ratio risperidone/9-
hydroxy risperidone and with age.  
Multiple logistic regression analysis was conducted to investigate whether the 
Taq1A A1 allele of the DRD2 gene was associated with prolactin level. We grouped 
the individuals with either one or two Taq1A A1 alleles into one group (there was 
only one boy carrying two Taq1A A1 alleles) and compared them to those individu-
als not carrying any Taq1A A1 alleles. We adjusted for age in the analysis for two 
reasons: firstly, the dopamine D2 receptor density falls with age, and secondly, the 
prolactin levels are age dependent [36, 37]. We also adjusted for the 9-hydroxy 
P H A R M A C O G E N E T I C S  
 109 
risperidone level to correct for the dose of the treatment used [38] and we adjusted 
for concomitant methylphenidate medication that theoretically could have de-
creased prolactin levels given the dopaminergic activity of methylphenidate [39]. 
To investigate the risk on hyperprolactinemia as a dichotomous outcome when 
carrying at least one Taq1A A1 allele (A1A1+A1A2) of DRD2 we calculated the odds 
ratio (OR). Hyperprolactinemia was defined as a prolactin level above the 97.5th 
percentile based on normative data for age and gender [40]. Because our data 
(prolactin level and 9-OH risperidone level) was skewed we used a log transforma-
tion to make our data more normal. 
The number of functional alleles of the CYP2D6 gene determines the activity of 
the enzyme complex, therefore we grouped the activity of the different non-
functional alleles *3, *4, *5, *6 and the gene duplication into categories of activity as 
follows: poor metabolizers (two non-functional alleles), intermediate metabolizers 
(one non-functional allele), normal metabolizers (two functional alleles) and ultra 
rapid metabolizers (three or more functional alleles). The CYP2D6 data of one pa-
tient in this group was missing, reducing the number of patients from 47 to 46. We 
described the levels of prolactin, 9-hydroxy risperidone and the presence of hyper-
prolactinemia over the categories of CYP2D6 activity and we compared the prolac-
tin level means for the normal and reduced activity group with an independent 
sample t-test. 
3.1 Results 
Baseline characteristics of the included patients are presented in Table 1. The 47 
boys had a mean age of 14.7 years (standard deviation (SD) of 2.1 years), the mean 
treatment dose of risperidone was 1.6 mg per day or 0.026 mg per kg (SD 0.95 mg 
per day, and SD 0.016 mg respectively), with a mean duration of treatment of 4.4 
years (SD 2.4 years, 74% of the boys were treated for 3 years or more), the mean 
prolactin level was 19.9 ng/ml (SD 17.0 ng/ml), and 23 out of 47 (49%) boys had 
hyperprolactinemia. None of these cases were due to macroprolactinemia. Table 2 
and 3, respectively show the characteristics of the boys with the three different 
DRD2 and the four different CYP2D6 genotypes. Multiple logistic regression analy-
sis revealed that the presence of at least one Taq1A A1 allele of the DRD2 gene was 
not associated with the prolactin level (β=0.27, SE 0.17, p=0.12). The OR for having 
hyperprolactinemia when carrying at least one Taq1A A1 allele was 1.56 (95% CI 
0.46-5.26). 
Prolactin levels were positively and significantly associated with risperidone 
levels (r=0.29, p=0.05), 9-hydroxy risperidone levels (r=0.60, p=<0.0001), the total 
active molecule (r=0.6, p=<0.0001) and with oral risperidone dose in milligram per 
kilogram (r=0.51, p=<0.0001). A positive, although not significant association was 
observed for prolactin level with age (r=0.25, p=0.09) and with the ratio risperi-
done/9-hydroxy risperidone (r=0.007, p=0.96). 
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Table 3 shows that the prolactin level was higher in normal versus reduced or no 
activity of CYP2D6. Mean prolactin level was 48.6 ng/ml for no CYP2D6 activity, 
18.4 ng/ml for reduced CYP2D6 activity, 19.8 ng/ml for normal activity and 6.8 
ng/ml for ultrarapid CYP2D6 activity. When comparing the prolactin levels with an 
independent sample t-test there was no difference for the reduced activity and the 
normal activity group (p=0.8). We did not further analyse but only describe this 
data for both the poor metabolizers (N=2) and ultra rapid metabolizers (N=2) be-
cause of lack of power.  
 
Table 1. Characteristics of boys with autism spectrum disorders (ASD) or disruptive behavior disorders 
(DBD) with long-term risperidone-treatment included in the current study (N=47).  
 N (%) Mean (SD; range) 
Age, years  14.7 (2.1; 10; 19) 
Caucasian ethnicity 46 (98)  
Height (cm)  175 (11; 143; 196) 
Height z-score  0.5 (1.1; -2.4; 2.1) 
Weight (kg)  65.1 (19; 35; 138) 
Weight z-score  0.6 (1.1; -2.5; 3.2) 
BMI  21 (4.5; 16; 42) 
BMI z-score  0.3 (0.8; -1.5; 1.8) 
Primary diagnosis 
ASD* 
DBD** 
 
45 (96) 
 2 (4) 
 
Risperidone (mg/day)  1.6 (1.0; 0.3; 4) 
Duration of use (months)  53.3 (28.7; 16; 126) 
RIS*** µg/l  3.0 (5.2; 0; 28) 
9-OH RIS**** µg/l  9.2 (7.4; 3; 36) 
Concomitant medication: 
Melatonin 
Psychostimulants 
Atomoxetine 
 
 2 (4) 
 9 (19) 
 2 (4) 
 
Prolactin ng/ml  19.8 (17.2; 2.4; 92.5) 
Hyperprolactinemia $ 23 (49)  
*ASD= autism spectrum disorders; **DBD=disruptive behavior disorders; ***RIS=plasma levels of 
risperidone; ****9-OH RIS=plasma levels of 9-OH risperidone; $Hyperprolactinemia was defined as a 
prolactin level above the 97.5th percentile for normative data for age and gender (Emlinger et al. 2002); 
z-scores were calculated using normative data for age and gender (Fredriks et al. 20001,2). 
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Table 2. Characteristics of male children and adolescents with autism spectrum disorders or disruptive 
behavior disorders (N=47) with long-term risperidone treatment carrying the Taq1A A2/A2 allele 
(N=31) compared to the Taq1A A1/A1 (N=1) and the Taq1A A1/A2 allele (N=15) carriers  
 A2/A2  
(N=31) 
A1/A2  
(N=15) 
A1/A1  
(N=1) 
 N (%) Mean (SD) N (%) Mean (SD) N (%) Mean (SD) 
Age, years  14.5 (1.8)  15 (2.7)  14.1 
Caucasian ethnicity 31 (100)  14 (93)  1(100)  
Height (cm)  174 (9)  174 (12)  174 
Height z-score  0.59 (1.1)  0.28 (1.2)  0.62 
Weight (kg)  62 (14)  64 (18)  49 
Weight z-score  0.6 (1.0)  0.6 (1.2)  -0.52 
BMI  20 (3)  21 (4)  16 
BMI z-score  0.26 (0.8)  0.39 (0.9)  -1.5 
Primary diagnosis 
ASD* 
DBD** 
 
30 (97) 
 1 (3) 
 
 
 
15 (100) 
 0 (0) 
  
0 (0) 
1 (100) 
 
 
 
Risperidone (mg/day)  1.7 (1)  1.5 (0.9)  0.25 
Duration of use in months  47.6 (22.8)  64.5 (37.2)  60 
RIS*** µg/l  3.0 (5.8)  2.9 (3.9)  1 
9-OH RIS**** µg/l  9.2 (5)  9.5 (11)  3 
Concomitant medication: 
Melatonin 
Psychostimulants 
Atomoxetine 
 
1 (3) 
7 (23) 
2 (6) 
 
 
 
1 (7) 
0 (0) 
0 (0) 
 
 
 
0 (0) 
1 (100) 
0 (0) 
 
 
Prolactin level ng/ml  16.2 (8.4)  28.8 (26)  2.4 
Hyperprolactinemia$ 14 (45)  9 (60)  0  
*ASD= autism spectrum disorders; **DBD=disruptive behavior disorders; ***RIS=plasma levels of 
risperidone; ****9-OH RIS=plasma levels of 9-OH risperidone; $Hyperprolactinemia was defined as a 
prolactin level above the 97.5th percentile for normative data for age and gender (Emlinger et al. 2002); 
z-scores were calculated using normative data for age and gender (Fredriks et al. 20001,2). 
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4.1 Discussion 
This study shows that there are no correlations between prolactin level and the 
presence of at least one Taq1A A1 allele of the DRD2 gene in risperidone treated 
boys with ASD or DBD. A previous study in male and female patients with schizo-
phrenia also showed no correlation between antipsychotic-induced prolactin levels 
and dopamine-related polymorphisms [19].  
There is one other study investigating the effect of the presence of at least one 
Taq1A A1 allele on prolactin levels in 90 non-Hispanic Caucasian children (mean 
age 12 years, primarily boys, primarily pre-pubertal, with any psychiatric diagno-
Table 3. Characteristics of male children and adolescents (N=46) with autism spectrum disorders or 
disruptive behavior disorders with long-term risperidone treatment per stratum of CYP2D6 activity. 
 Poor  
Metabolizers (N=2) 
Intermediate  
Metabolizers (N=17) 
Normal  
Metabolizers (N=25) 
Ultrarapid  
Metabolizers (N=2) 
 N (%) Mean (SD) N (%) Mean (SD) N (%) Mean (SD) N (%) Mean (SD) 
Age, years  17.7 (0.1)  14.4 (2.2)  14.8 (1.9)  14.3 (0.2) 
Caucasian ethnicity 1 (50)  17 (100)  25 (100)  2 (100)  
Height (cm)  184 (15)  175 (9)  175 (9)  171 (5) 
Height z-score  0.18 (2.1)  0.74 (1.2)  0.42 (1)  -0.03 (0.9) 
Weight (kg)  94 (25)  61 (12)  63 (13)  56 (10) 
Weight z-score  1.9 (1.8)  0.61 (0.95)  0.52 (1)  -0.005 (0.7) 
BMI  27 (3)  20 (3)  21 (3)  19 (4) 
BMI z-score  1.5 (0.44)  0.19 (0.61)  0.25 (0.9)  -0.29 (1.7) 
Primary diagnosis 
ASD* 
DBD** 
 
2 (100)  
0 (0) 
 
 
 
16 (94) 
 1 (6) 
  
25 (100)
 0 (0) 
 
 
 
 
1 (50) 
1 (50) 
 
 
 
Risperidone (mg/day)  3 (1.4)  1.4 (0.9)  1.7 (0.9)  0.63 (0.5) 
Duration of use in 
months 
 90 (40)  51.8 (28)  48.5 (27)  68 (11) 
RIS*** µg/l  14.5 (19)  3.4 (4.9)  1.7 (2.2)  0.5 (0.7) 
9-OH RIS**** µg/l  22 (20)  7.1 (3.7)  10.2 (7.5)  3 (0) 
Concomitant  
medication: 
Melatonin 
Psychostimulants 
Atomoxetine 
 
 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
 
 
2 (12) 
4 (24) 
0 (0) 
 
 
 
 
0 (0) 
3 (12) 
2 (17) 
 
 
 
 
0 (0) 
1 (50) 
0 (0) 
Prolactin level ng/ml  49 (0)  18.4 (17)  19.8 (17)  6.8 (6) 
Hyperprolactinemia$ 2 (100)  8 (47)  12 (48)  0 (0)  
*ASD= autism spectrum disorders; **DBD=disruptive behavior disorders; ***RIS=plasma levels of 
risperidone; ****9-OH RIS=plasma levels of 9-OH risperidone; $Hyperprolactinemia was defined as a 
prolactin level above the 97.5th percentile for normative data for age and gender (Emlinger et al. 2002); 
z-scores were calculated using normative data for age and gender (Fredriks et al. 20001,2). 
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sis) long-term (mean treatment duration of 3 years) treated with risperidone. This 
study showed that the Taq1A A1 allele carriers had significantly higher prolactin 
levels [20]. The higher prolactin levels in response to AP treatment in these pa-
tients may be the result of having fewer unbound dopamine receptors at any given 
AP dose. Individuals with the Taq1A A1 allele have a reduced density of brain D2 
receptors [14, 15, 41]. An early brain autopsy study [41] found a significant reduc-
tion of about 30% in the number of D2 dopamine receptors in the caudate nucleus 
of Taq1A A1allele carriers compared with non-carriers. However, our study did not 
replicate these findings. One previous study investigated the influence of CYP2D6 
genetic variants on the prevalence of adverse drug reactions, including hyper-
prolactinemia, in risperidone treated adult patients (N=537) showed that the poor 
metabolizer phenotype may be associated with risperidone adverse drug reactions 
and discontinuation [28]. Another study in children showed that the CYP2D6 ultra-
rapid metabolism may be a risk factor for more pronounced prolactin elevation (25 
children with ASD, mean age 8 years) [27], however these children were short-term 
treated (eight weeks) and the group with ultrarapid metabolism consisted of 
merely 2 patients [27]. Larger studies in children and adolescents long-term 
treated with risperidone are needed to draw conclusions about the influence of 
CYP2D6 on prolactin levels and prolactin related side effects. Moreover, children 
and adolescents have different drug metabolism and tolerability than adults; e.g. 
due to age dependent alterations in body water and serum protein composition 
[37]. Furthermore, their brains and the ratio of the D1 and D2 dopamine receptors 
density in the striatum falls with age, after age 20 years, D1 receptors decrease at 
3.2% per decade and D2 receptors decrease at about 2.2% per decade [36, 42]. 
Therefore it is important to investigate whether the findings regarding variants in 
the dopamine D2 receptor and CYP2D6 genotypes in adults [17] also apply to chil-
dren and adolescents in the different age categories. 
4.2 Limitations  
This study had some limitations that should be taken into account when interpret-
ing the results and which should be addressed in future studies. First, our sample 
size was small. In addition prolactin-elevating concomitant medication was permit-
ted, such as atomoxetine and melatonin [5, 43, 44], which could have influenced the 
prolactin levels. However, the prolactin-elevating effect of this concomitant medica-
tion is considered to be minor compared with that of the antipsychotic used [44]. 
Furthermore, eight boys were on concomitant methylphenidate medication that 
theoretically could have decreased prolactin levels given the dopaminergic activity 
of methylphenidate [39], however if this would be true the prolactin levels meas-
ured in our study were an underestimate. Furthermore, the risperidone dose was 
two times higher in the reduced CYP2D6 activity group and four times higher in the 
no activity CYP2D6 group compared to the ultrarapid CYP2D6 metabolizer group, 
therefore, and because of the small number of patiens, it was not possible to prop-
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erly analyse these data and draw any conclusions about the prolactin levels and 9-
hydroxy risperidone levels in the different CYP2D6 activity groups. 
Furthermore, we employed a cross-sectional design, did not assess pre-
treatment prolactin levels, and cannot establish causality. Nonetheless a cross-
sectional design is suitable for a genetic based study because the genes are there in 
predisposition. Finally, in the genotyping of CYP2D6 only those functional alleles 
with the highest incidence (*3, *4, *5, *6 and the gene duplication) were analysed. 
Theoretically, other non-functional alleles could be present in our study population. 
However, given the low incidence of other non-functional alleles their influence is 
expected to be minimal [45]. 
4.3. Conclusion 
Our findings suggest that the TaqA1 A1 allele of the D2DR gene do not contribute to 
one’s susceptibility to AP-induced hyperprolactinemia, and as a result to develop-
ing prolactin related adverse events such as amenorrhea, galactorrhea, and sexual 
dysfunctioning. It is important to appreciate that hyperprolactinemia is present 
without these adverse events in about fifty percent of male adolescents [46, 47, 48]. 
However, irrespective of the presence of manifest prolactin related adverse events, 
patients with hyperprolactinemia may be at risk for more serious side effects such 
as lower bone mineral density [11, 29].  
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Summary and discussion 
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Aim of the thesis 
The overall aim of this thesis was to evaluate the prevalence and (genetic) risk fac-
tors of antipsychotic (AP)-induced hyperprolactinemia and prolactin-related side 
effects (e.g., gynecomastia, galactorrhea, sexual functioning disorders) in young 
males with autism spectrum disorder (ASD) and / or disruptive behavior disorder 
(DBD) treated with APs long-term (>16 months). Further, this study investigated 
whether young males with AP-induced hyperprolactinemia had hypogonadotropic 
hypogonadism, delayed puberty, and diminished BMD (bone mineral density) when 
compared to males without hyperprolactinemia with and without AP treatment and 
compared to healthy controls. 
PART 1 – Chapter 2: Prevalence of (persistent) hyperprolactinemia in 
children and adolescents: A descriptive review 
In a descriptive review 29 studies were selected after a literature search in the 
English Medline/ Embase/ Psychinfo/ EBM databases (1965—August 2008). One 
thousand, three hundred and ninety children and adolescents (weighted average 
mean age of 10 years, of which 83% boys) were primarily treated with risperidone 
(with a weighted average mean dose of 1.6 milligrams per day). After weighted 
average mean treatment duration of 35 weeks, 62% of these children and adoles-
cents were hyperprolactinemic (Roke 2009). This descriptive review documents 
that maintenance treatment with risperidone is associated with persistent eleva-
tion of prolactin levels for periods up to two years. The very limited long-term data 
for pimozide, olanzapine, and quetiapine prohibit drawing conclusions for these 
antipsychotics (Roke 2009). Based on the high prevalence of AP-induced hyper-
prolactinemia in children and adolescents, the clinical consequences of AP-induced 
hyperprolactinemia should be investigated through systematic long-term observa-
tional studies including specific questionnaires as well as physical examinations 
and age and gender-matched reference values for prolactin levels. 
PART 2a – Chapter 3-5: Antipsychotic-induced hyperprolactinemia in 
children and adolescents: A cross-sectional study 
First I will present the main conclusions of the articles described in this thesis, then 
I will discuss the clinical consequences of AP-induced hyperprolactinemia in a dif-
ferent paragraph on page 83-84. 
In our cross-sectional study all participants were recruited from the total pa-
tient population of the outpatient adolescent clinic of the GGz Central Psychiatric 
Center, the Netherlands, from October 2006 to November 2009. We included 56 
boys in the AP-treated group (treatment with any antipsychotic medication con-
tinuously for more than 16 months) and 47 boys in the medication-naïve group. All 
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participants had an IQ above 85 and were excluded if they had a history of thyroid 
disorders, syndromes, or other chronic diseases affecting puberty, endocrine disor-
ders, if they used oral corticosteroids or anticonvulsants, or if they had a known 
cause of hyperprolactinemia (Verhelst 2003, Melmed 2011). The findings were 
that:  
• Hyperprolactinemia is a common side effect (49%) in boys treated long-term 
with risperidone.  
• 43% of the AP-treated boys had gynecomastia, versus 21% of the boys in the 
AP-naïve group. There was no association between the occurrence of gyneco-
mastia and prolactin levels. 
• Boys with AP-induced hyperprolactinemia were also more likely to report di-
minished sexual functioning (erectile and/or orgasm dysfunction, and loss of 
sexual interest) than boys not treated with antipsychotics.  
• AP-induced hyperprolactinemia had no prolactin-related side effects in 46% of 
these boys. 
• AP-induced hyperprolactinemia is related to significantly lower testosterone 
levels though within the normal reference range corrected for age and gender. 
• LH, FSH and Inhibin B levels and the Tanner stages of puberty were the same for 
the boys with and without AP-induced hyperprolactinemia. 
• The mean volumetric lumbar spine BMD z-score was lower in the AP-treated 
boys with hyperprolactinemia than in the AP-treated boys without hyperprolac-
tinemia. The volumetric BMD of the lumbar spine is a good predictor of future 
fractures (especially wrist and forearm fractures), and therefore our findings 
suggest that AP-induced hyperprolactinemia may have a negative influence on 
BMD, especially of trabecular bone, such as of the lumbar vertebrae (Jones 2006, 
Boot 2010).  
• 7–11% of the AP-induced hyperprolactinemic boys had low BMD of the lumbar 
spine (a z-score < -2). In adult patients a z-score of < -2 is defined as osteoporo-
sis. The International Society for Clinical Densitometry has decided to use the 
phrase “low BMD” for pediatric patients because children and adolescents are 
still in the dynamic process of attaining their peak bone mass; however it re-
mains a potential serious side effect, and may increase the risk of fractures 
(Lewiecki 2008, Bianchi 2008). 
PART 2b– Chapter 6: Genetic risk factors 
The Taq1A A1 allele of the DRD2 gene and the activity of the CYP2D6 enzyme com-
plex were investigated in our cross-sectional study as possible risk factors for the 
development of hyperprolactinemia. Our main conclusion was that the presence of 
at least one Taq1A A1 allele of the DRD2 gene was positively associated with higher 
prolactin levels. Furthermore, the prolactin levels and 9-hydroxy risperidone levels 
increased with reduced or no activity of CYP2D6. However our study lacked power 
S U M M A R Y  A N D  D I S C U S S I O N  
 121 
to draw firm conclusions about the influence of the activity of the CYP2D6 enzyme 
complex on prolactin levels. 
Therefore, our findings suggest that variants of the D2DR gene may contribute 
to one’s susceptibility to AP-induced hyperprolactinemia, and as a result contribute 
to developing prolactin-related adverse events such as amenorrhea, galactorrhea, 
and sexual dysfunctioning. Screening for genes relevant to the effect and side ef-
fects of pharmacological treatment may improve the effectiveness of the treatment 
and reduce side effects, thereby increasing patient quality of life and reducing the 
costs of treatment (Chou 2000). However, the variants of the D2DR gene and 
CYP2D6 enzyme are not specific enough to be used in clinical practice (Kirchheiner 
2010).  
Comparison of our total study population with normative data 
Given the cross-sectional design of our study we compared the results of our total 
study population (N=113) of boys with ASD and/ or DBD with or without AP treat-
ment with normative data on height, weight, BMI z-scores, Tanner stages, levels of 
25-hydroxyvitamin D3, body composition, and BMD (Fredriks 20001,2). The find-
ings were that:  
• Our total study population took 1.6 years longer to attain the same Tanner stage 
compared to normative data with normal mean z-scores for height (0.40), 
weight (0.48), and BMI (0.44). When correcting for autism versus DBD, autism 
showed a trend towards significance for being later in attaining the same stage 
of puberty than healthy controls. 
• Thirteen of the 113 (12%) boys had deficient levels of 25-hydroxyvitamin D3 
(<30 nmol/L) and 37 (36%) had insufficient (<50 nmol/L) levels (Allgrove 
2009. These are higher proportions than reported for Dutch young adult males 
without psychiatric disorders (4% and 22% respectively) (Boot 2011). 
• Our total study population had a lower mean lean tissue mass, a higher percent-
age of total body fat than healthy controls; however the BMD of our total study 
population was not different when compared to normative data (Boot 2010).  
 
These findings suggest first that future research should investigate the relationship 
between the disorder of ASD and a possible delay in the attainment of Tanner 
stages of puberty. Second, the higher prevalence of 25-hydroxyvitamin D3 deficien-
cies and insufficiencies is an important finding, since 25-hydroxyvitamin D3 is a 
major determinant of bone mineralization at school age (Pekkinen 2012). Supple-
ments of 25-hydroxyvitamin D3 may prevent problems in the bone mineralization 
process. Third, our study population had a higher percentage of total body fat and 
lower lean tissue mass compared to normative data. This higher percentage of body 
fat may be a risk factor for future cardiovascular disease (Lavie 2012). Further, the 
lower lean tissue mass, which is mainly muscle mass, is highly related to bone mass 
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in children and is important for the attainment of peak bone mass (Boot 2010). One 
explanation for the higher percentage of body fat and lower lean tissue mass in our 
study group could be that the boys with ASD participate less in organized outdoor 
sports activities, and their preferred leisure activities often involve an indoor set-
ting. These preferred indoor activities and the consequent lack of sunlight are 
probably also the reason for the higher prevalence of 25-hydroxyvitamin D3 defi-
ciencies and insufficiencies among this group. These findings suggest that children 
and adolescents with ASD should be stimulated to take part in outdoor physical 
activities. Our study compared results from our total study group with normative 
data; this cross-sectional design cannot establish causality. Furthermore, our study 
had limited power and used self-assessment to investigate Tanner stages of pu-
berty; future studies should be longitudinal, have a larger sample size and thus 
more statistical power than our study and should also investigate the attainment of 
Tanner stages of puberty with a physical examination instead of self-assessment 
and assess testes volume with an orchidometer.  
Considerations for the prevention and treatment of 
hyperprolactinemia 
Clinical consequences 
Bone mineral density 
Our cross-sectional study (Roke 20123) and the study by Calarge et al. (2010) show 
a relationship between AP-induced hyperprolactinemia and diminished BMD in AP-
treated boys. These two studies are the first studies investigating the effect of AP-
induced hyperprolactinemia on bone mineral density in children and adolescents. 
Our study also showed that within the hyperprolactinemic group 7-11% of the boys 
had low BMD of the lumbar spine, which is a potential serious side effect and may 
lead to bone fragility (Lewiecki 2008). An earlier 2-year longitudinal study by Colao 
et al. (2000) investigated prolactinoma-induced hyperprolactinemia and the effect 
on bone mass in 20 adults and 20 adolescents and found that the adolescents had 
persistent irreversible bone loss, even after dopamine agonistic treatment, which 
restored normal prolactin levels. In the adult patient group the bone loss process 
was reversible after treatment with dopamine agonistic drugs. This study shows 
that adolescence is an important and vulnerable period for the attainment of peak 
bone mass and that disturbances during this process may be irreversible. It should 
be noted however that the prolactin elevation in prolactinomas is 2-4 fold higher 
than in AP-induced elevations, and that we do not know at which threshold value of 
prolactin elevation the negative effect on bone mineral density begins. Because of 
the possible negative effect on bone mineralization in adolescence, we recommend 
active monitoring of prolactin levels and treatment of AP-induced hyperprolacti-
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nemia until long-term follow-up studies indicate the otherwise. In the event of hy-
perprolactinemia, the dose should be reduced or another drug should be pre-
scribed. 
Bone mineral density and fractures in ASD 
There are two previous studies, which investigated the effect of ASD on bone status 
(Hediger 2008, Mouridsen 2012). One study evaluated fracture prevalence and 
found this to be lower for patients with ASD, i.e. 12% for the patients with ASD 
versus 25% for the comparison group (follow-up for 30 years, N=118) (Mouridsen 
2012). The other study investigated bone cortical thickness in children with ASD 
(mean age 7 years, N=75) measured on a hand-wrist radiograph. When compared 
with normative data, especially the boys with ASD with a dairy-free diet had re-
duced bone cortical thickness (Hediger 2008). The patients of our study had a nor-
mal calcium intake and a fracture prevalence rate of about 20% (19% for the ASD 
boys with hyperprolactinemia versus 21% for the ASD boys without hyperprolacti-
nemia), which was also low, compared to the normative data fracture rate of 37% 
measured at a mean age of 23 years (Boot 2010). As mentioned before our study 
population had higher proportions of 25-hydroxyvitamin D3 deficiency and insuffi-
ciency compared to the normative data. 25-hydroxyvitamin D3 is a determinant of 
BMD in children and adolescents. One explanation could be that boys with ASD 
have less organized outdoor sports activities, and their preferred leisure activities 
often involve an indoor setting, which would protect them from sustaining frac-
tures but also makes than susceptible for 25-hydroxyvitamin D3 deficiency or insuf-
ficiency’s (MacDonald 2011). It is reassuring from a clinical perspective that the 
psychiatric condition of ASD does not seem to lead to a higher fracture prevalence 
rate. In our study in boys with ASD or DBD bone mineral density was not signifi-
cantly different from normal. However, one should be careful when prescribing AP 
with prolactin-elevating qualities because of the potential negative influence of 
hyperprolactinemia on BMD.  
Hypogonadotropic hypogonadism 
High prolactin levels may inhibit the pulsatile secretion of gonadotropin-releasing 
hormone, which by reducing the release of gonadotrophic hormones can cause 
hypogonadism. The effect of AP-induced hyperprolactinemia on testosterone levels 
has not been investigated in adolescent boys before. The significantly lower testos-
terone levels in boys with AP-induced hyperprolactinemia compared to boys with 
ASD or DBD without AP treatment were still within age- and gender-matched refer-
ence ranges. The gonadotrophic hormones were in the normal range. We can only 
speculate that the lower testosterone levels may lead to delayed puberty and sexual 
functioning disorders. There is one retrospective study, which found no influence 
on the attainment of Tanner stages of puberty among youths treated with risperi-
done (Dunbar 2004); however follow-up was limited to one year and a delay in 
puberty may take longer to take effect (McKeever 2000, Rosen 2001). Our study 
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was cross-sectional, had limited power, and used self-assessment to investigate 
Tanner stages of puberty; future studies should be longitudinal, have a larger sam-
ple size and thus more statistical power than our study, and should also investigate 
the attainment of Tanner stages of puberty with a physical examination instead of 
self-assessment and assess testes volume with an orchidometer. Hypogonadism is 
related to small testicular volume. More power and more precise measurement 
should clarify the relationship between low(er) testosterone levels and the possible 
negative influence on the progression of puberty.  
Sexual functioning 
Hyperprolactinemia was associated with sexual side effects. Fourteen percent of 
the boys in our study with AP-induced hyperprolactinemia experienced sexual side 
effect. An earlier study that used a specific questionnaire for adverse sexual events 
showed a prevalence of 25% sexual dysfunction among adolescents treated with 
risperidone (N=21), olanzapine (N=13) and quetiapine (N=6) irrespective of pro-
lactin levels and type of AP used; however this study included 45% females and 
irregular menses, gynecomastia and galactorrhea were part of the questionnaire; 
no actual sexual dysfunction was reported (Saito 2004). In studies of adults with 
schizophrenia or mood disorders who were treated with risperidone, the rate of 
diminished sexual functioning due to hyperprolactinemia was about 40% (Bobes 
2003, Knegtering 2004 and 2006). Since the boys included in our study could have 
been sexually inexperienced or inactive, they might have not been able to self-
assess their sexual functioning as well as adult patients. Moreover boys with ASD 
have difficulties with communication skills, which could have biased our results. 
Therefore the results of studies in adults with schizophrenia cannot be directly 
compared to boys with ASD. The sexual functioning data in our study from the An-
tipsychotic Sexual Functioning Questionnaire (ASFQ) may have been biased by 
recall and time. The boys had to reflect back to the time when they did not use 
risperidone. Moreover, some of the boys may have started risperidone before pu-
berty and may have become sexually mature thereafter, so that they might have 
considered their sexual functioning as unchanged (20% for the cases and 10% for 
the comparison group) or unknown (cases, 30% and comparison group, 40%) 
whereas it was, in fact, suppressed. Moreover, boys who were sexually inexperi-
enced or inactive could not make a before and after comparison. Therefore the 
actual rate of sexual side effects may be higher than we measured in our study. 
Nevertheless a significant number of boys (1 in 8) experienced sexual dysfunction 
in relation to AP-induced hyperprolactinemia. Therefore the clinician should ac-
tively and systematically ask about the sexual functioning before the start and over 
the course of treatment. 
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Monitoring 
Systematic longitudinal follow-up studies have not been performed to investigate 
the clinical consequences for children and adolescents of long-term AP-induced 
hyperprolactinemia on hypogonadotropic hypogonadism and bone mineral density. 
However, the data in this thesis and in earlier cross-sectional studies are sufficient 
cause for concern for us to advise active monitoring of prolactin levels and change 
of treatment in case of AP-induced hyperprolactinemia if clinically feasible. Another 
argument for active monitoring is that about half of our study population had AP-
induced hyperprolactinemia without any obvious prolactin-related symptoms (e.g., 
gynecomastia, galactorrhea, sexual dysfunctioning). Therefore, we recommend 
assessment of serum prolactin levels before and during treatment with prolactin-
elevating antipsychotics (Staller 2006, Citrome 2008, Ho 2011). To establish the 
diagnosis of hyperprolactinemia, the Endocrine Society recommends (in their prac-
tical guideline, Melmed 2011) a single measurement of serum prolactin; a level 
above the upper limit of normal confirms the diagnosis of hyperprolactinemia as 
long as the serum sample is obtained without excessive venipuncture stress. Previ-
ous short-term studies show a steep increase of the prolactin level within the first 
six weeks (Aman 2002, Snyder 2002, Biederman 2005) followed by a slow decline 
after one year of AP treatment (Turgay 2002, Croonenberghs 2005, Stevens 2005, 
Anderson 2007, Migliardi 2009). Average prolactin levels remained above the ref-
erence value after two (Staller 2006, Reyes 2006) and three years of continued AP 
use (Calarge 2010, Roke 20121,2,3) although two studies reported a tendency to-
wards normalization of prolactin after respectively 12 months (Migliardi 2009) and 
22 months (Anderson 2007) of AP treatment. Our results are based on a carefully 
performed study in a sample of adolescents with long-term treatment of AP and 
indicate that after a mean of 51.5 months, half of the adolescents still had AP-
induced hyperprolactinemia. 
Since prolactin levels rise steeply during the first six weeks of AP treatment and 
decline to a plateau phase after three months (Findling 2004), we recommend 
monitoring prolactin levels after the first three months of treatment and repeating 
the test every year. Whenever the dose of AP is increased, prolactin levels also in-
crease because of the clear dose-response relationship (Knegtering 2005). Fur-
thermore prolactin-related side effects such as sexual functioning disorders should 
be addressed before and during treatment, since these sexual side effects occurred 
in 14% of the boys in our study with ASD treated with prolactin-elevating AP. Since 
self-report is a less valid method to assess these side effects, we recommend using a 
standardized questionnaire, such as the ASFQ (Knegtering 2003). We also suggest 
investigating the presence of gynecomastia and galactorrhea before and during 
treatment. We recommend using a questionnaire to check for symptoms of gyne-
comastia or galactorrhea (Saito 2004) and also a physical examination of the 
breasts (Roke 20121). The physician may also interview the patient about the fol-
lowing topics: a (family) history of fractures, calcium intake, sun exposure, and 
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exercise. This assessment of risk factors for future osteoporosis may help the phy-
sician to decide how to treat the hyperprolactinemia and to give the patient advice 
on exercise and dietary intake to minimalize the risk of future osteoporosis. Since 
25-hydroxyvitamin D3 is a major determinant of bone mineralization and bone 
strength in children and adolescents (Boot 2011, Pekkinen 2012), we recommend 
assessment of serum 25-hydroxyvitamin D3 and starting supplementation when 
necessary (figure 1). 
Treatment 
APs are very effective in reducing maladaptive behaviors such as irritability, self-
injury, stereotypies, and hyperactivity in children and adolescents with ASD, and 
reduce irritability and aggressive behavior in children and adolescents with DBD 
(Aman 2009, Wink 2010). However, these drugs may have side effects such as AP-
induced hyperprolactinemia. If hyperprolactinemia develops the AP treatment 
should be stopped if this is clinically feasible. Prolactin levels should normalize 
within days depending on the half-life (T 1/2) of the drug (Pollock 1998, Turrone 
2002). Alternatively, the dosage should be reduced as there is a dose-response 
relation with prolactin levels (Knegtering 2005) or another AP agent without pro-
lactin-elevating qualities should be tried (e.g., quetiapine, aripiprazol, clozapine) 
(Stevens 2005, Greenaway 2009). If these strategies fail, aripiprazole addition may 
lead to normalization of prolactin levels. Aripiprazol is a partial agonist of the do-
pamine D2 receptor and therefore the addition of aripiprazol leads to normaliza-
tion of prolactin levels within one week of treatment (Byerly 2009). If the hyper-
prolactinemia persists despite these steps, further examination of the patient is 
necessary (Ho 2011) (figure 1).  
Summary of recommendations 
We recommend: 
• monitoring the prolactin level before treatment, after three months of treatment 
and repeating this every year or three months after dose increase. 
• using a standardized questionnaire, such as the ASFQ, to measure sexual side 
effects (Knegtering 2003).  
• investigating the presence of gynecomastia and galactorrhea before and during 
treatment using a questionnaire (Saito 2004) and also a physical examination of 
the breasts (2Roke 2012). 
• assessing serum 25-hydroxyvitamin D3 and start supplementation if necessary.  
• assessing risk factors for future osteoporosis. 
• changing treatment in case of AP-induced hyperprolactinemia. 
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Patient with potential prolactin elevating AP
Assessment of prolactin level and prolactin related side effects: gynecomastia, galactorrhea, and 
sexual side effects. Determine risk factors of osteoporosis such as family history, lifestyle and 
dietary calcium intake and assess 25-hydroxyvitamin D3 level
AP-induced hyperprolactinemia
Step 1 stop AP
Step 2 dosage reduction
Step 3 switch to quetiapine, clozapine, aripiprazol
Step 4 addition of aripiprazol
Persistent hyperprolactinemia despite step1-4
Further investigation of the patient to exclude other
causes for hyperprolactinemia
No other reason for hyperprolactinemia and stopping/ or switching is clinically non feasible:
Investigate the risk factors of osteoporosis:
Dietary calcium intake and lifestyle advice
Family history of osteoporosis
Assess 25-hydroxyvitamin D3, if < 35 nmol/L suppletion is necessary**
Investigate bone mineral density (BMD) lumbar spine:
Dual X-ray Absorptiometry (DEXA)
Low BMD (< - 2 SD*) 
Rethink step 1 to 4: stop or switch AP
Lifestyle/ dietary changes
Normal prolactin level
No action
Normal prolactin level
No action
Normal prolactin level
No action
 
Figure 1. Flowchart: monitoring and treatment of antipsychotic (AP)-induced hyperprolactinemia 
* in case of small stature adjust for height 
** Winzenberg T, Powell S, Shwa KA, Jones G. Effects of vitamin D supplementation on bone density in 
healthy children: systematic review and meta-analysis. BMJ. 2011 Jan 25;342:c7254 
Genotyping 
Our results also provide further input to clinical considerations and discussions 
about whether a risk assessment (genotyping) for hyperprolactinemia should be 
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performed before prescribing antipsychotics such as risperidone to children and 
adolescents with psychiatric disorders. A risk assessment may reduce treatment 
expenses and may reduce adverse events (Chou 2000). However, the variants of 
D2DR gene and CYP2D6 enzyme are not specific enough yet to be used in clinical 
practice (Kirchheiner 2010). 
Challenges and future research 
Challenges 
The problem with AP-induced hyperprolactinemia is that we do not know at which 
threshold value side effects (e.g., gynecomastia, diminished sexual functioning, 
galactorrhea) and complications such as diminished BMD and hypogonadotropic 
hypogonadism may begin. Half of the patients with hyperprolactinemia experi-
enced no side effects. The question is whether these patients, those with hyper-
prolactinemia without evident side effects, are at increased risk for future compli-
cations. In our cross-sectional study (Roke 20123) the boys with AP-induced hy-
perprolactinemia and low BMD (z-score < -2) had no other prolactin-related side 
effects. Low BMD, especially in children and adolescents, is a serious side effect 
(Lewiecki 2008), which may lead to future clinical consequences such as higher 
bone fragility and osteoporosis. Hyperprolactinemia seems to be a long-term side 
effect of AP in half the children and adolescents treated, and could potentially influ-
ence processes such as the attainment of the peak bone mass. BMD continues to 
increase during adolescence, and in boys peak bone mass reaches a plateau be-
tween 18 to 23 years of age (Boot 2010). Still, it is possible that once the prolactin 
concentration normalizes, bone mineralization increases to normal. The impact of 
hyperprolactinemia on BMD is clinically relevant only if it leads to increased bone 
fragility and fractures.  
Future research:  
AP-induced hyperprolactinemia and bone mineral density 
Our study had no longitudinal follow-up design and could thus not establish causal-
ity. Follow-up studies with more power are needed to investigate over time what is 
the influence of long-term hyperprolactinemia on bone mineral density, peak bone 
mass, bone fragility, bone fractures, and the biochemical bone markers, and to ex-
amine whether the process of bone loss is reversible or not. These studies should 
also disentangle the effects of the psychiatric conditions (ASD or DBD) and the ef-
fects of AP treatment and hyperprolactinemia and the effect of the disease and life-
style itself. These future studies can provide the answer to the question on the clin-
ical relevance raised in the previous paragraph. 
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Future research:  
AP-induced hyperprolactinemia and hypogonadotropic hypogonadism 
Future studies should be longitudinal, have more power than our study, and should 
evaluate Tanner stages and testicular volume. With more power and more precise 
measurement over time (including a physical examination rather than self-assess-
ment of puberty), the relationship between low(er) testosterone levels and the 
influence on the progression of puberty should become clear. One future study has 
already started: the EU 7th framework program (PERS – Pediatric European 
Risperidone Studies) will study the short and long-term efficacy and safety of 
risperidone in children with CD and other serious psychiatric disorders. As part of 
this program a 2-year observational long-term study will be conducted with about 
400 children and adolescents treated with risperidone to assess the drug’s effects 
on endocrinological, cognitive, bone mineral density, and other clinical measures. 
Future research:  
AP-induced hyperprolactinemia and hypogonadism and cardiovascular 
hazards 
Hypogonadotropic hypogonadism due to hyperprolactinemia may affect lipid and 
glucose metabolism (Sonmez 2011, Miner 2011) and should be investigated in fu-
ture research. Hyperprolactinemia diminishes testosterone levels and low testos-
terone levels may have a negative effect on lipid and glucose metabolism. A retro-
spective analysis among 332 male patients with hypogonadism (mean age 22 
years) showed higher fasting glucose, insulin and triglyceride levels as well as a 
higher arterial blood pressure and waist circumference when compared to 395 age- 
and body mass index (BMI)-matched healthy young men (Sonmez 2011). Another 
12 month prospective observational cohort study (N=849, mean age 52, males) 
showed that middle-aged men with hypogonadism exhibited a high prevalence of 
cardiometabolic risk factors that were correlated with testosterone levels. This 
suggests that low testosterone levels are associated with adverse medical condi-
tions that pose serious health risks, especially in younger men (Miner 2011). Future 
research should investigate at which low threshold testosterone values may cause 
cardiovascular health risks and if AP-induced hyperprolactinemia could be the 
cause of such a hypogonadic state. Theoretically high prolactin levels may be an 
indicator of future cardiovascular problems. Another considaration is that the boys 
with ASD and DBD participating in our study already had a higher total percentage 
of body fat when compared to normative data. This higher percentage of body fat is 
a risk factor for future cardiovascular disease (Lavie 2012); boys with ASD partici-
pate less in organized outdoor sports activities, and their preferred leisure activi-
ties often involve an indoor setting, which could be part of the explanation for their 
higher percentage of body fat. This could be another argument in the proactive 
monitoring of prolactin levels. In conclusion, this research confirms that Aps repre-
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sent an effective means of treating the negative effects of ASDs and DBDs in chil-
dren and adolescents but they are not without dangers for children and adoles-
cents. Clinicians should take these these dangers into consideration, and research-
ers should further investigate them. 
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In de laatste jaren is de belangstelling voor, en de toepassing van farmacologische 
interventies in de kinder- en jeugdpsychiatrie aanzienlijk toegenomen, vooral bij 
psychotische en externaliserende stoornissen. De veiligheid en de effectiviteit van 
farmacologische interventies op de kinderleeftijd zijn slechts voor een beperkt 
aantal psychiatrische stoornissen onderzocht. Off-label voorschrijven (onder de 
leeftijdsgrenzen en buiten de indicatiegebieden) is in de kinderpsychiatrie eerder 
regel dan uitzondering. Door het meer voorschrijven van psychofarmaca, zoals 
antipsychotica (AP) in de kinder- en jeugdpsychiatrie (16.000 kinderen en jongeren 
kregen een AP voorgeschreven in Nederland in 2012; bron Stichting Farmaceuti-
sche Kerngetallen), treden vaker ongewenste effecten op. Voorbeelden zijn metabo-
le bijwerkingen zoals obesitas, hyperglykemie en dyslipidemie, neurologische bij-
werkingen zoals bewegingsstoornissen en endocriene bijwerkingen zoals hyper-
prolactinemie. Dit proefschrift richt zich op één van die bijwerkingen, namelijk de 
AP-geïnduceerde hyperprolactinemie. 
De meeste AP blokkeren in mindere of meerdere mate de dopamine 2 (D2)-
receptorblokker. Hierdoor wordt de dopamineconcentratie verlaagd. Dopamine 
wordt ook wel prolactin inhibiting factor genoemd; door verlaging van de dopami-
neconcentratie valt de rem weg op prolactine in de hypofysevoorkwab, waardoor 
deze verhoogd wordt. Dit kan leiden tot hyperprolactinemie. Hoe sterker de D2-
blokkerende werking van het AP, hoe meer kans er is op hyperprolactinemie. Ris-
peridon is geen sterke D2-blokker, maar doordat risperidon en de metaboliet 9-
hydroxyrisperidon hydrofiele stoffen zijn, gaan ze niet door de bloed-hersen-
barrière en blijft de concentratie risperidon en 9-hydroxyrisperidon hoog rondom 
de hypofyse die net buiten de bloed-hersenbarrière ligt. Daarbij speelt ook nog mee 
dat 9-hydroxyrisperidon een lange halfwaardetijd heeft (t1/2 = 24 uur) en daar-
door langdurig de hypofyse beïnvloedt en de prolactinespiegel derhalve verhoogt. 
De definitie van hyperprolactinemie volgens de Clinical Practice Guidelines van the 
Endocrine Society (2011), is een in het serum gemeten te hoge waarde voor de 
leeftijd en het geslacht van het hormoon prolactine. Voor mannen is sprake van 
hyperprolactinemie boven de 18 ng/ml en voor vrouwen boven de 30 ng/ml. Bij 
kinderen en jongeren hangt de concentratie af van de leeftijd, het geslacht en de 
etniciteit. In de prolactinestudie, waar dit proefschrift over gaat, is een waarde bo-
ven het 97,5e percentiel voor leeftijd en geslacht van blanke jongeren gehanteerd. 
Het doel van dit proefschrift is het vaststellen van de incidentie van AP-
geïnduceerde hyperprolactinemie en het in kaart brengen van het voorkomen van 
mogelijk door hyperprolactinemie veroorzaakte bijwerkingen op korte en lange 
termijn, zoals gynaecomastie, galactorroe, seksuele functiestoornissen, vertraagde 
puberteitsontwikkeling, hypogonadotroop hypogonadisme en verminderde bot-
dichtheid. 
Een ander doel is om op basis van deze resultaten meer inzicht te kunnen geven 
in de mogelijke klinische consequenties van AP-geïnduceerde hyperprolactinemie 
en mede daardoor tot een monitoring- en behandeladvies te kunnen komen. 
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Hoofdstuk 1 beschrijft de eventuele gevolgen van AP-geïnduceerde hyperprolacti-
nemie voor de korte (gynaecomastie, galactorroe, amenorroe, seksuele functie-
stoornissen) en de lange termijn (hypogonadotroop hypogonadisme, puberteitsver-
traging, verminderde botdichtheid en verhoogd risico op maligniteiten). Risperidon 
is het meest gebruikte AP in de kinder- en jeugdpsychiatrie en vormt het enige AP 
waarmee langetermijnstudies met voldoende aantallen kinderen en jongeren zijn 
gedaan naar het voorkomen van hyperprolactinemie. Volgens een meta-analyse in 
2009 is de prolactinespiegel blijvend verhoogd bij 62% van de kinderen en jonge-
ren. Het merendeel van de studiepopulatie betrof jongens (83%) met een gemid-
delde dosering risperidon van 1,6 mg per dag bij een gemiddelde duur van 35 we-
ken behandeling. Recentere studies over langere termijn laten een prevalentie van 
hyperprolactinemie zien van 50% na gemiddeld 3 jaar risperidongebruik. Ongun-
stige effecten ontstaan pas wanneer de hyperprolactinemie een kritische grens 
overschrijdt, die per individu verschilt. Effecten die kunnen optreden bij hyperpro-
lactinemie zijn: oligomenorroe/amenorroe, gynaecomastie, galactorroe, libidover-
laging, orgasmestoornissen, erectie- en ejaculatiestoornissen en fertiliteitsproble-
men. Amenorroe treedt op bij een prolactinespiegel rond de 60 ng/ml; voor de 
overige klachten is geen drempelwaarde bekend. De adolescentie is de belangrijk-
ste periode voor de aanleg van de piekbotmassa (= de maximale hoeveelheid bot 
die tot het 25e levensjaar wordt verkregen). Verstoringen tijdens de aanleg van de 
piekbotmassa kunnen later meer kans geven op osteoporose. Hyperprolactinemie 
kan direct en indirect een negatieve rol bij de botstofwisseling spelen. 
Hyperprolactinemie heeft een direct remmend effect op de botombouw, door 
de botafbraak meer te stimuleren dan de botaanmaak. Daarnaast zorgt hyperpro-
lactinemie door het veroorzaken van hypogonadotroop hypogonadisme indirect 
voor een remmend effect op de botaanmaak. Bij hypogonadotroop hypogonadisme 
is er sprake van lagere spiegels van geslachtshormonen, hetgeen een negatief effect 
heeft op de botdichtheid. Het verminderen van de geslachtshormonen kan mogelijk 
ook een remmende werking hebben op de puberteitsontwikkeling en op de ont-
wikkeling van de seksualiteit. Er is geen prospectief onderzoek bekend waarin het 
effect van hyperprolactinemie op de botdichtheid en/of de puberteit en seksuele 
ontwikkeling is onderzocht. 
 
Hoofdstuk 2 is een beschrijvend overzicht van de studies die tot en met 2008 ge-
daan zijn naar de incidentie van AP-geïnduceerde hyperprolactinemie bij kinderen 
en jongeren en de incidentie van bijkomende prolactinegerelateerde klachten. In de 
databases van Medline, Embase en PsycINFO en EBM-databases (1965-augustus 
2008) is gezocht met de volgende zoektermen: “risperidone”, “olanzapine”, “pi-
mozide”, “clozapine”, “quetiapine”, “haloperidol”, “aripiprazole”, “amisulpiride”, 
“ziprasidone”, “(a)typical antipsychotics”, “adverse effects”, “side effects”, “hyper-
prolactinaemia”, “bone mineral density”, “children”, “adolescents”, “prolactinoma”, 
“osteoporosis”, “prolactin”, “hypogonadism”, “bone density”, “sex hormone”, “an-
drogen”, “estrogen”, “metabolic”, “endocrine”, “puberty disorders”, “delayed pu-
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berty”, “polymorphism”, “genetic” and “puberty”. Gegevens over prolactinespiegels 
zijn niet beschikbaar voor haloperidol, pimozide, risperidon, olanzapine, clozapine, 
ziprasidon en quetiapine. 
De gebruikte dosering van de verschillende AP is omgerekend naar een chloor-
promazine-equivalente dosering. Er zijn 29 studies met een studieduur van 3 we-
ken of meer gevonden: respectievelijk met risperidon (N = 20, gewogen gemiddelde 
dosering 1,6 mg per dag), olanzapine (N = 7, gewogen gemiddelde dosering 12,7 mg 
per dag), quetiapine (N = 5, gewogen gemiddelde dosering 378,5 mg per dag), halo-
peridol (N = 4, gewogen gemiddelde dosering 7,2 mg per dag), pimozide (N = 3, 
gewogen gemiddelde dosering 3,7 mg per dag), clozapine (N = 2, gewogen gemid-
delde dosering 269,9 mg per dag) en met ziprasidon (N = 1, gemiddelde dosering 
98,3 mg per dag). De onderzoeksduur is wisselend en varieert van 3 tot 106 weken. 
Van de 29 publicaties zijn er 6 gebaseerd op dezelfde populatie. De onderzochte 
populatie is heterogeen in diagnose, van kinderen en jongeren met autismespec-
trumstoornis (ASS) of bipolaire stoornis tot kinderen en jongeren met schizofrenie. 
Ook de intelligentie varieerde van normaal tot matig verstandelijk beperkt. 
De onderzoeksmethode verschilt per studie: 17 studies hebben een open-
labelopzet, 4 studies een observationele opzet en 8 studies zijn dubbelblind uitge-
voerd. In 7 risperidonstudies wordt de prolactinespiegel tussen de 48 en 106 we-
ken bepaald. Van de 29 studies hebben er 10 een prospectieve opzet, met prolacti-
nespiegel als primaire uitkomstmaat. Voor olanzapine, quetiapine en pimozide zijn 
slechts data van 1 langetermijnstudie bekend. Voor clozapine en ziprasidon zijn 
alleen prolactinedata over een periode van 6 weken bekend. 
Het totale aantal bestudeerde patiënten is 1382, 170, 72, 56, 46, 30 en 12 voor 
respectievelijk risperidon, olanzapine, quetiapine, haloperidol, pimozide, clozapine 
en ziprasidon. 
Het totale aantal jongens in deze studies ligt tussen de 63-83%. De kinderen en 
jongeren die behandeling krijgen met risperidon, pimozide of haloperidol hebben 
een gewogen gemiddelde leeftijd van rond de 10 jaar. Voor quetiapine, clozapine, 
olanzapine en ziprasidon ligt de gewogen gemiddelde leeftijd tussen de 13 en 15 
jaar. 
 Alle AP behalve clozapine, ziprasidon en quetiapine verhoogden de prolactine-
spiegel van uitgangswaarden van 8,0 ng/ml naar 25-28 ng/ml na 4-8 weken be-
handeling. De incidentie van hyperprolactinemie (zoals beschreven in hoofdstuk 2) 
gedurende behandeling met haloperidol, pimozide, risperidon, olanzapine en queti-
apine is respectievelijk 90%, 80%, 62%, 31% en 12%. Alleen voor risperidon zijn 
voldoende langetermijndata bekend om te kunnen concluderen dat een behande-
ling van 2 jaar kan leiden tot een blijvende AP-geïnduceerde hyperprolactinemie. 
Van de prolactinegerelateerde bijwerkingen zijn alleen gynaecomastie, galac-
torroe, amenorroe en seksuele functiestoornissen onderzocht. Kinderen en jonge-
ren die behandeld worden met olanzapine, haloperidol, quetiapine en risperidon 
rapporteren respectievelijk 14%, 14%, 6% en 5% klachten gerelateerd aan hyper-
prolactinemie. De frequentst gemelde prolactinegerelateerde bijwerkingen zijn 
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gynaecomastie (risperidon 3%, olanzapine 6% en haloperidol 7%) en onregelmati-
ge menstruatie (risperidon 6%, haloperidol 15% en quetiapine 12%). Nadeel is dat 
de incidentie gemeten is door middel van spontane zelfrapportage, wat een niet 
heel betrouwbare meting geeft en kan leiden tot te weinig rapporteren. 
Met betrekking tot de geslachtshormonen en de botdichtheid zijn er geen gege-
vens bekend. 
Twee studies hebben naar de invloed van AP-geïnduceerde hyperprolactinemie 
op de puberteit gekeken. Deze studies vinden geen vertragende invloed van de AP-
geïnduceerde hyperprolactinemie op de puberteitsontwikkeling. Echter, aangezien 
deze studies een follow-upduur hebben van 1 jaar, is er geen goede conclusie te 
trekken over puberteitsvertraging. 
 
Hoofdstuk 3 richt zich op het onderzoeken van de incidentie van AP-geïnduceerde 
hyperprolactinemie en het voorkomen van aan prolactine gerelateerde bijwerkin-
gen zoals gynaecomastie, galactorroe en seksuele functiestoornissen. Dit onderzoek 
is uitgevoerd binnen de kinder- en jeugdpsychiatrische afdeling van GGZ Centraal 
Fornhese, bij jongens met een autismespectrumstoornis (ASS) en of een disruptive 
behavior disorder (DBD) tussen de 10-20 jaar (gemiddelde leeftijd 15 jaar). Er zijn 
98 jongens met ASS en 10 jongens met DBD geïncludeerd. De AP-groep bestaat uit 
jongens die langer dan 16 maanden met risperidon behandeld zijn (groep 1, N = 51, 
gemiddelde leeftijd 15 jaar). Groep 2 bestaat uit jongens die nooit met AP behan-
deld zijn (N = 47, gemiddelde leeftijd 15 jaar). Groep 1 en 2 zijn vergelijkbaar voor 
leeftijd, lengte- en gewicht-z-score, diagnose, puberteitsstadium en overige ge-
bruikte medicatie. De 2 groepen verschillen alleen van elkaar wat betreft de BMI-z-
score: voor groep 1 was de score 0,2 en voor groep 2 was deze -0,09. Opvallend is 
dat de jongens die al langdurig met AP behandeld zijn, gemiddeld genomen geen 
overgewicht hadden. 
De prolactinespiegel is in het serum bepaald en prolactine gerelateerde bijwer-
kingen zijn gemeten door middel van gevalideerde vragenlijsten en een lichamelijk 
onderzoek. Uit dit onderzoek is als resultaat naar voren gekomen dat 47% van de 
met AP behandelde jongens een hyperprolactinemie heeft (groep 1), tegenover 2% 
van de jongens in groep 2. De jongens uit groep 1 zijn gemiddeld 53 maanden met 
risperidon behandeld, met een gemiddelde dosis van 1,5 mg per dag. Van de jon-
gens met een AP-geïnduceerde hyperprolactinemie heeft 46% geen klachten van 
die hyperprolactinemie. 
Van de groep jongens in dit onderzoek heeft 40% van de AP-gebruikers (groep 
1) gynaecomastie ten opzichte van 20% van de controlegroep (groep 2). De “lifeti-
me”-prevalentie (proportie van mensen in een populatie die ooit gynaecomastie 
hebben gehad) van het krijgen van gynaecomastie bij gezonde jongens die geen AP 
gebruiken, ligt rond de 50%, met een hoogtepunt van voorkomen tijdens de puber-
teit. Het krijgen of hebben van gynaecomastie is significant gerelateerd aan AP-
gebruik, maar niet aan de hyperprolactinemie. Waarschijnlijk komt deze verhoging 
van het aantal jongens met gynaecomastie door een relatief teveel aan oestrogenen 
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door lagere testosteronspiegels. Geen enkele jongere met of zonder AP-gebruik 
heeft galactorroe. De gynaecomastie en galactorroe zijn gemeten met een vragen-
lijst en een lichamelijk onderzoek. 
Van de jongens met langdurig AP-gebruik heeft 14% een seksuele functiestoor-
nis: 4 (8%) van hen hebben een verminderd of geen orgasme, 5 (10%) hebben pro-
blemen met ejaculeren (minder of niet), 1 (2%) jongen kan geen erectie meer krij-
gen en 2 (4%) jongens geven aan een verminderde interesse in seks te hebben. 
Deze seksuele functiestoornissen zijn significant gerelateerd aan een te hoge pro-
lactinespiegel. In de controlegroep rapporteert geen enkele jongere een seksuele 
functiestoornis. 
Deze resultaten geven weer dat AP-geïnduceerde hyperprolactinemie persis-
teert gedurende de behandeling en dat ongeveer de helft van de jongens geen 
klachten daarvan ondervindt. De vraag is of deze groep jongens mogelijk risico 
loopt op eventuele langetermijneffecten van door de AP geïnduceerde hyperprolac-
tinemie, zoals hypogonadotroop hypogonadisme, puberteitsvertraging en een ver-
minderde botdichtheid. Van de jongens met ASS die behandeld zijn met een AP 
geeft 14% aan last te hebben van een seksuele functiestoornis. Dit aantal is waar-
schijnlijk een onderschatting. Voor jongeren met ASS is het lastig om terug te den-
ken in de tijd voor het AP-gebruik, sommige jongens zijn al voor hun puberteit be-
handeld met AP en kunnen derhalve geen verschil opmerken in de situatie voor en 
na de behandeling. Een substantieel aantal jongeren (30% uit groep 1 en 40% uit 
groep 2) kan de vraag niet beantwoorden en antwoordt “onbekend” op de vragen 
over de seksuele bijwerkingen. 
Uit deze studie komt ook naar voren dat de huidige dosis van het AP de hyper-
prolactinemie voorspelt. 
 
Hoofdstuk 4 onderzoekt de invloed van AP-geïnduceerde hyperprolactinemie op 
de puberteitsontwikkeling, testosteron, luteïniserend hormoon (LH), follikelstimu-
lerend hormoon (FSH) en inhibine B. Inhibine B wordt geproduceerd door de Ser-
toli-cellen van de testes onder invloed van FSH en is een marker voor fertiliteit bij 
jongens. De groep jongens met AP-geïnduceerde hyperprolactinemie (N = 28) is 
vergeleken met de groep jongens zonder hyperprolactinemie met AP-gebruik (N = 
29) en zonder AP-gebruik (N = 37). De groepen zijn vergelijkbaar wat betreft ge-
middelde leeftijd, gewicht-, lengte- en BMI-z-score, duur van de behandeling (ge-
middeld meer dan 4 jaar) en diagnose. De groepen verschillen in gemiddelde dose-
ring AP. De groep met AP-geïnduceerde hyperprolactinemie heeft een significant 
hogere dagdosering. 
De resultaten van dit onderzoek laten zien dat AP-geïnduceerde hyperpro-
lactinemie leidt tot significant lagere testosteronspiegels. LH-, FSH- en inhibine B-
waarden en de puberteitsstadia zijn vergelijkbaar voor de groep met en zonder AP-
geïnduceerde hyperprolactinemie. De verlaagde testosteronspiegels van de groep 
met AP-geïnduceerde hyperprolactinemie blijven wel binnen de normaalwaarden 
voor de leeftijd en het geslacht. De vraag is of deze verlaging klinisch relevant is. 
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Een andere bevinding van onze studie is dat de totale patiëntengroep (N = 104) 1,6 
jaar later is in het behalen van het puberteitsstadium ten opzichte van Nederlandse 
jongens van dezelfde leeftijd. Deze puberteitsvertraging is gerelateerd aan het heb-
ben van een ASS en niet aan de diagnose DBD. 
 
Het doel van hoofdstuk 5 is de relatie te onderzoeken tussen enerzijds de AP-
geïnduceerde hyperprolactinemie en anderzijds de botmarkers en de botdichtheid. 
De prolactinespiegel en factoren (botmarkers) betreffende botaanmaak (P1NP en 
BAF) en botafbraak (CTx) zijn in het bloed gemeten. Botmarkers zijn stoffen in het 
bloed die het dynamische aspect van botaanmaak weergeven (P1NP = procollageen 
type 1 amino-terminal propeptide en BAF = botalkalische fosfatase) of van botaf-
braak (CTx = cross-linked C-telopeptide van type 1-collageen). Daarnaast is er een 
“dual-energy X-ray”-absorptiometrie (DXA)-meting gedaan om de botdichtheid te 
bepalen. De jongens met AP-geïnduceerde hyperprolactinemie (N = 27) zijn verge-
leken met de jongens met AP zonder hyperprolactinemie (N = 29) en met de jon-
gens zonder AP (N = 47). 
Dit onderzoek toont aan dat de jongens met AP-geïnduceerde hyperprolac-
tinemie een lagere volumetrische botdichtheid van de lumbale wervelkolom heb-
ben dan de jongens met AP gebruik zonder hyperprolactinemie (N = 29). Van die 
jongeren met AP-geïnduceerde hyperprolactinemie heeft 7-11% een botdichtheid 
die sterk verlaagd is (meer dan twee standaarddeviaties onder het gemiddelde). De 
jongens met AP-geïnduceerde hyperprolactinemie hebben lagere botaanmaak- 
(P1NP) en botafbraakmarkers (CTx) dan de jongens zonder hyperprolactinemie. 
Dit wijst op een remmende invloed van AP-geïnduceerde hyperprolactinemie op de 
botombouw. Longitudinaal onderzoek is nodig om deze bevindingen verder te on-
derzoeken. 
Een andere bevinding is dat deze jongens met AP-geïnduceerde hyperprolacti-
nemie een hoger percentage lichaamsvet hebben dan jongeren zonder AP-
geïnduceerde hyperprolactinemie. Een hoger percentage lichaamsvet is op oudere 
leeftijd een risicofactor voor hart- en vaatziekten. 
Behandeling met AP geeft vaak hyperprolactinemie bij jongens met ASS. Uit ons 
onderzoek blijkt dat deze behandeling zeker geen verwaarloosbare gevolgen zou 
kunnen hebben voor de botombouw. In de praktijk moet hiermee volgens ons re-
kening gehouden worden, in ieder geval tot er prospectief goed uitgevoerd onder-
zoek is dat het tegendeel bewijst. 
 
In hoofdstuk 6 is onderzocht of er een genetische associatie is tussen AP-
geïnduceerde hyperprolactinemie en het voorkomen van het Taq1A A1-allel van 
het dopamine D2-receptorgen en/of CYP2D6-polymorfismen. Voor deze studie zijn 
alleen de jongens met ASS en/of DBD die gedurende lange termijn behandeld wer-
den met risperidon geïncludeerd. Prolactine-, risperidon- en 9-hydroxyrisperidon-
spiegels zijn bepaald en de deelnemers zijn gegenotypeerd voor CYP2D6-
polymorfismen en het Taq1A A1-allel van het dopamine D2-receptorgen. 
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Het Taq1A A1-allel is geassocieerd met verminderde dichtheid van dopaminerecep-
toren in de hersenen. Patiënten met dit allel kunnen gevoeliger zijn voor het krijgen 
van een AP-geïnduceerde hyperprolactinemie. Voor CYP2D6 geldt dat dit polymor-
fisme een belangrijke rol speelt bij de omzetting van verschillende AP, waaronder 
risperidon, in de lever. Op die manier kan de medicijnspiegel beïnvloed worden. 
Normale metaboliseerders hebben 1 of 2 functionele CYP2D6-allelen; slechte meta-
boliseerders hebben geen functionele allelen (7% blanken, 1% Aziaten, 3% Afrika-
nen). Snelle metaboliseerders hebben duplicaties van het CYP2D6-gen (2% blan-
ken, 25% Ethiopiërs). De langzame metaboliseerders breken de medicijnen minder 
snel af, waardoor er hogere bloedspiegels zijn in vergelijking met normale of snelle 
metaboliseerders. De hogere AP-spiegels kunnen een verhoogd risico geven op AP-
geïnduceerde hyperprolactinemie. 
In onze studie zijn de prolactinespiegels positief en significant geassocieerd 
met risperidon- en 9-hydroxyrisperidonspiegels en met de orale dosis risperidon in 
milligrammen per kilogram. De prolactine- en 9-hydroxyrisperidonspiegels worden 
hoger met een verminderde of geen activiteit van het CYP2D6-gen. In onze studie is 
geen relatie gevonden tussen AP-geïnduceerde hyperprolactinemie en het Taq1A 
A1-allel van het dopamine D2-receptorgen. 
 
Tot slot geeft hoofdstuk 7 een advies omtrent de monitoring en de behandeling van 
AP-geïnduceerde hyperprolactinemie. Het is van belang om een uitgangssituatie 
vast te leggen voordat de behandeling met het AP start. De aanwezigheid van gy-
naecomastie, galactorroe, het seksuele functioneren, de regelmaat van de menstru-
atie en het puberteitsstadium kunnen worden vastgesteld door middel van vragen-
lijsten of door middel van een lichamelijk onderzoek. Een efficiënte – met tact uit te 
voeren – methode om gynaecomastie vast te stellen is om met de vlakke hand bij 
beide tepels te voelen of er een klierschijf palpabel is en of deze pijnlijk is. Anam-
nestisch kan nagevraagd worden of de tepels gezwollen en/of pijnlijk zijn. Naast 
het vaststellen en uitvragen van deze klachten is het ook belangrijk om in kaart te 
brengen of de patiënt voldoende calciumrijk eet, voldoende aan zonlicht is blootge-
steld (vitamine D), voldoende beweegt en of er een familiaire belasting is voor os-
teoporose. 
Voor de start van de behandeling met een AP wordt de prolactinespiegel be-
paald. Standaard wordt deze bepaald in de ochtend, 2 uur na het ontwaken. Dan 
zijn de spiegels het laagst. Een eenmalige meting is voldoende voor het vaststellen 
van een AP-geïnduceerde hyperprolactinemie. Als de patiënt op de juiste dosering 
is ingesteld, wordt de spiegel 3 maanden later opnieuw bepaald. Na verhoging van 
de dosering wordt de prolactinespiegel na ongeveer 3 maanden opnieuw gecontro-
leerd. De termijn van 3 maanden is gekozen omdat in de eerste 6 weken na het 
starten of verhogen van een AP vaak een initiële sterke stijging van de prolactine-
spiegel optreedt, veelal gevolgd door een daling, blijkbaar doordat tolerantie op-
treedt. Als na 3 maanden nog een verhoogde prolactinespiegel bestaat, zal deze 
persisteren. 
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Controle van de prolactinespiegel is ook geïndiceerd bij prolactinegerelateerde 
klachten zoals gynaecomastie, galactorroe, seksuele functiestoornissen en vermin-
derde of verdwenen menstruatie als deze mogelijk samenhangen met de AP-
behandeling. Controle van de prolactinespiegel is niet alleen aan te raden bij ado-
lescenten, zoals geadviseerd door de werkgroep somatische complicaties bij anti-
psychoticagebruik, maar ook bij kinderen en volwassenen. 
Er zijn naast AP-gebruik ook andere oorzaken voor een hyperprolactinemie 
(o.a. hypothyreoïdie, prolactinoom, nierfalen, leverziekten en gebruik van andere 
prolactineverhogende medicatie). Een klinisch handvat is dat sterk verhoogde pro-
lactinespiegels (boven de 100 ng/ml) vaak een andere oorzaak hebben dan de be-
handeling met AP. 
 
De aanwezigheid van hyperprolactinemie voor de start van de AP is een reden voor 
verder onderzoek. Zolang de effecten van AP-geïnduceerde hyperprolactinemie op 
de groei en ontwikkeling niet duidelijk zijn en zolang we niet weten welke drem-
pelwaarde gevolgen heeft, is het raadzaam bij iedere verhoging van prolactine bo-
ven de normaalwaarden als volgt actie te ondernemen. 
 
Behandeling van hyperprolactinemie 
Het AP kan bij kinderen met een ASS en/of DBD een uiterst gunstig effect op de 
doelsymptomen hebben. In de onderstaande adviezen moet altijd meegewogen 
worden hoe belangrijk het AP is in de behandeling van het kind.  
 
1. Stoppen van het AP-gebruik geeft meestal binnen 96 uur, afhankelijk van de 
halfwaardetijd van het AP, een normalisering van de prolactinespiegel. 
2. Verlagen van de dosering tot de minimaal werkzame dosering geeft vaak effect 
om de prolactinespiegel te normaliseren. 
3. Als verlagen niet goed mogelijk is, kan er geswitcht worden naar een AP dat de 
prolactinespiegel niet verhoogt (quetiapine, clozapine, aripiprazol). 
4. In de literatuur wordt additie met aripiprazol ook beschreven om de hyperpro-
lactinemie te verminderen. Omdat het nog niet duidelijk is of de hypoprolacti-
nemie die bij 60% van de kinderen door aripiprazol ontstaat klinische conse-
quenties heeft, is hiermee ook enige voorzichtigheid aan te raden. 
5. Als dosisvermindering of switchen niet mogelijk is en de AP-geïnduceerde hy-
perprolactinemie persisteert, dan kan een meting van de botdichtheid middels 
een DXA-scan worden overwogen. Daarnaast zijn preventieve maatregelen be-
langrijk om de botdichtheid zo goed mogelijk te houden. Preventieve maatrege-
len zijn onder meer voldoende lichaamsbeweging, voldoende blootstelling aan 
zonlicht, voldoende inname van vitamine D en andere voedingsadviezen (calci-
um- en vitamine D-suppletie). 
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Om te beginnen wil ik alle deelnemers (en hun ouders en/of voogden) aan mijn 
onderzoek hierbij heel erg bedanken. Zonder jullie was dit proefschrift niet tot 
stand gekomen. 
Onderzoek is van groot belang om de kwaliteit van patiëntenzorg te verbeteren. 
Met dit doel is dit onderzoek gestart; mijn dank is groot dat jullie hieraan hebben 
meegewerkt. Ik vond de onderzoeksdagen (vragenlijsten, bloedafname en dan nog 
de botdichtheidsmeting), de dagen van inclusie, de leukste. Jullie waren inspirerend 
en ontwapenend. Ik herinner me vele gesprekken en situaties, sommigen van jullie 
zijn nu bij mij onder behandeling en het is een groot genoegen zo lang met jullie 
“mee te mogen lopen”. 
 
Ik weet nog goed dat ik begon met dit onderzoek, op de dag dat ik tweemaal achter-
een de vraag kreeg van een ouder of antipsychotische medicatie geen kwaad kon 
voor de groei en ontwikkeling van hun kind. Na enige verdieping in alle beschikbare 
literatuur begon het me te dagen: er is geen goed antwoord op deze vraag. Ik ging 
met enige verontwaardiging naar mijn opleider, Peter van Harten, die zei: “Waarom 
schrijf je geen studieprotocol en ga je fondsen werven om het zelf te gaan onder-
zoeken”… en ik dacht “tja, waarom eigenlijk niet”. En zo is het begonnen, zeven jaar 
geleden. 
 
Veel mensen hebben een bijdrage geleverd aan dit promotieonderzoek, waarvoor ik 
allen zeer dankbaar ben. Vanwege het grote aantal mensen loop ik het risico ie-
mand over te slaan. Dank dus ook aan degenen die ik eventueel vergeten ben. 
 
Allereerst wil ik mijn beide promotors, prof. dr. Peter van Harten en prof. dr. Jan 
Buitelaar, bedanken. 
Peter, eerst was je mijn A-opleider (9 jaar geleden), en vervolgens werd je tij-
dens de opleiding en later als psychiater, achtereenvolgens mijn copromotor en 
promotor. Jij bent een grote bron van inspiratie voor mij, jouw kennis en kunde, 
jouw discipline en inzet en eerlijkheid waren kwaliteiten die ik al als opleideling 
heel erg waardeerde. Door samen te werken aan dit onderzoek heb ik je nog beter 
leren kennen, jouw vertrouwen, steun en interesse hebben mij beïnvloed en ge-
vormd. Je hebt me gestuurd, maar ook de vrijheid gegeven om mijn eigen mening te 
vormen. In de afgelopen jaren heb ik gemerkt dat ik mede hierdoor een persoonlij-
ke ontwikkeling heb doorgemaakt. 
Jan, vanwege de afstand tussen Nijmegen en Bilthoven, hebben wij veel per e-
mail en telefoon gecommuniceerd. Dit verliep heel goed dankzij jouw gave om te 
weten wanneer jij mij de goede kant op moest sturen. Net als ik inhoudelijk vastliep 
of als logistieke zaken niet lukten (editors die niets meer van zich lieten horen), was 
één e-mailtje van jou voldoende om de boel weer vlot te trekken. Mijn dank is groot 
Jan, voor je inzet, eerlijkheid en ook voor je brede kennis en vermogen om de juiste 
dingen in de juiste context te zetten. 
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Annemieke, jij bent de ideale copromotor voor mij geweest. Ik weet nog goed de 
eerste keer dat ik je opzocht in het Erasmus: jij straalde kennis en rust uit; intuïtief 
wist ik dat het goed zat. Jij werkt nu als kinderarts-endocrinoloog in Groningen, wat 
ook niet echt in de buurt van Bilthoven ligt. Met jou was het contact altijd persoon-
lijk, we bespraken hoe het ging met onze kinderen, en het bijbehorende en allerlei 
andere leuke, maar ook frustrerende onderzoekszaken. Juist dat persoonlijke en 
warme van jou gecombineerd met je deskundigheid en pragmatische instelling 
(stuur nu maar in, verbeteren doe je wel in de volgende versie) maakte de samen-
werking met jou heel erg fijn. 
 
De leden van de leescommissie, prof. dr. I.Y.R. Myin-Germeys, prof. dr. T.A.M.J. van 
Amelsvoort, prof. dr. S.L.S. Drop, prof. dr. J.P.C.J. Selten en dr. W. Staal, wil ik harte-
lijk bedanken voor de aandacht en tijd die zij besteed hebben aan het lezen van 
mijn proefschrift. 
 
Erik de Groot en Annet Uithof. 
Erik, onderzoekscoördinator bij toen nog de Symfora groep, zonder jou was ik 
al lang en breed gestopt met onderzoek doen. Jij hebt mij geholpen met alle hobbels 
die op de route lagen: fondsen werven, contacten met fondsen onderhouden, steun 
krijgen van de raad van bestuur, het maken van een financieel overzicht. En weet je 
nog: samen naar de medisch-ethische commissie. Uitleggen waarom ik die kinderen 
allerlei naar hun idee ongepaste seksuele vragen ging stellen. Wat was ik zenuw-
achtig en wat hebben we er om kunnen lachen achteraf.  
Annet, wat een verschil heb jij ook gemaakt. Binnen een groot instituut als het 
onze maakte jij het makkelijker voor mij, je dacht mee, nam me werk uit handen. 
Geen moeite te groot en altijd vrolijk!  
 
De onderzoeksassistenten, Gerard, Martijn, Anne en Job, jullie waren een geweldige 
steun. Met jullie alle vier deel ik leuke herinneringen aan een fijne samenwerking. 
Martijn, jij zult altijd de jongen van de interne post blijven (need I say more!), 
en ik denk nog regelmatig terug aan hoe wij met de buisjes bloed (ja ja: 3 jaar werk 
in een doos op vriesijs) gespreid in 3 ritten (want stel je voor dat er iets mee ge-
beurt, al het werk voor niets) naar het Erasmus reden in de winter met de ramen 
open, want anders kon je van het vriesijs flauwvallen. Wij voelden net op de snel-
weg dan al de eerste tekenen van een flauwte opkomen, gelukkig hebben we het 
overleefd! 
Alle medewerkers van Innova, in het bijzonder Anne Willems: Anne, heel erg 
bedankt voor de zaken die jij achter de schermen regelt! Thierry, bedankt voor het 
invoegen van mijn tabellen in mijn manuscript! 
 
Dr. Diederik Tenback, ik zal nog met veel plezier terugdenken aan de statistische 
analyses die we samen deden. Jij bent een inspirator als het gaat om de combinatie 
kansen, patiëntenzorg en wetenschap. Jij bent een voortrekker bij vele innovatieve 
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ideeën die alle de patiëntenzorg ten goede komen. Bedankt voor de fijne smaen-
werking! 
 
Dr. Rob Bakker, lieve collega. Ik was je paranimf samen met Hanneke. Wat waren 
we er trots op jou en je Tom te mogen vergezellen op zo’n belangrijke dag. Wat fijn 
ook dat je me een kijkje in de nabije keuken gaf. Ik ben erg benieuwd wat jij nu gaat 
doen, iets met zebravissen? Ook nog veel dank voor je hulp met de stukken over 
genetica. 
 
Prof. dr. Barbara Franke, jij hebt me geholpen in de wereld van de allelen, erg nut-
tig. Bedankt voor je geduld om me keer op keer weer uit te leggen hoe het nu eigen-
lijk zit met al die CYP2D6-en TaqA1 A1/A2-allelen! 
 
Tessel Galesloot, wij deden samen de statistiek voor het hoofdstuk over genetica. 
Wat ben jij snel en gestructureerd! Je deed me versteld staan, bedankt voor je inzet! 
 
Dr. Yolanda de Rijke, wij hebben samen de hormoonbepalingen en botmarkers 
bekeken en bedacht. Heel erg bedankt voor de plezierige samenwerking, je feed-
back en je interesse in mij en mijn promotieonderwerp. 
 
Ik wil mijn dank uitspreken aan de medewerkers van Saltro: Vera Talen en Mieke 
van der Geest, bedankt voor de fantastische logistiek rondom de bloedafnames. 
Heel bijzonder dat het zo soepel en vlekkeloos verlopen is. 
 
Ook wil ik een aantal medewerkers van GGZ Centraal bedanken, in het bijzonder 
Angelique Salimans en Ans Zandee. Ontzettend bedankt voor jullie hulp bij de PR, 
het mij helpen voor een interview of andere spannende dingen. Dankzij jullie hulp 
bleef ik kalm en rustig en kon ik mijn boodschap overbrengen. Hildegard Brouwer, 
Toos van Polanen en Mirjam Rus, bedankt voor jullie geduld en medeleven! Be-
dankt voor het flexibele inplannen van overlegmomenten met Peter. 
 
Mijn dank gaat ook uit naar een aantal medewerkers van het Meander Medisch 
Centrum: dr. Lorentz Quekel en Martha Peters, bedankt voor jullie vertrouwen dat 
mijn onderzoek wel zou gaan lukken en dat ik meer dan 5 patiënten zou gaan inclu-
deren. Marinus en Gerrit, super hoe jullie mijn jongeren konden geruststellen en 
hen hebben gemeten met de DXA-meter. Bedankt voor de fijne samenwerking, het 
branden van de cd’tjes. Het was altijd in orde. 
 
Ik wil mijn dank ook uitspreken aan de Open Ankh, het Fonds Wetenschappelijk 
Onderzoek Seksualiteit, en de Stichting tot steun VCVGZ voor de (deel)financiering 
van mijn promotieonderzoek. In het bijzonder ben ik Nel van Son dankbaar voor 
haar interesse, feedback en aanmoedigingen. Nel, het was heel erg fijn en leerzaam 
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om ieder half jaar mijn voortgang met jou face to face te bespreken, heel hartelijk 
bedankt daarvoor. 
 
Arnold Allertz, mijn onderzoek is bij jou begonnen. Peter had het geopperd, ik had 
erover nagedacht; nu alleen nog de logistieke zaken regelen. Jij hebt dit voor mij 
mede mogelijk gemaakt. Heel erg bedankt daarvoor en heel erg bedankt dat ik mijn 
toekomstige onderzoek mag voortzetten op andere terreinen binnen het werkge-
bied van Fornhese en Emerhese. 
Bas Koevoet en Frits Liefferink, heel hartelijk bedankt voor de onderzoekstijd 
die ik binnen mijn aanstelling op de Meregaard van jullie heb gekregen! Bedankt 
ook voor jullie steun en interesse. Bas, de werkbegeleidingsgesprekken met jou heb 
ik als inspirerend heb ervaren. 
 
Erica Harteveld, bedankt voor je steun en vertrouwen, maar ook de tijd en ruimte 
die ik kreeg om binnen de jeugdpolikliniek van Fornhese Amersfoort mijn onder-
zoek te mogen uitvoeren. 
 
Guus van Voorst, bedankt voor je steun en je humor. Is er een onderwerp waar je 
niet alles over weet? MacGyver move over, here comes MacGus! Ik hoop op veel 
toekomstig onderzoek binnen Emerhese en een nog langdurige samenwerking met 
jou! 
 
Collega’s van Emerhese en Fornhese jullie allemaal heel erg bedankt voor de aan-
dacht en interesse voor mijn onderzoek. 
 
De leden van de raad van bestuur, dr. Thea Heeren, dr. Bas Schreuder en ir. Henk 
ter Avest, en Innova wil ik bedanken voor de ruimte (tijd en geld) voor mijn promo-
tieonderzoek. Ook wil ik mijn collega’s bedanken voor hun belangstelling, en in het 
bijzonder Hanneke Heemskerk, Chris Bavinck en Graziella van der Luit. Hanneke 
omdat ze mij op het spoor van hyperprolactinemie als bijwerking heeft gezet en 
Graziella en Chris om wie zij zijn. 
 
Ik wil Peter Moleman bedanken voor zijn interesse in de antipsychotica-
geïnduceerde hyperprolcatinemie. Peter, bedankt voor je feedback en voor de kans 
om mijn resultaten te delen met een grote groep collega’s via Psyfar. 
 
Ik wil dankzeggen aan alle bibliothecaressen van GGz Centraal, die altijd veel artike-
len (en snel) voor mij hebben opgezocht en opgevraagd, zonder deze literatuur was 
promoveren onmogelijk geweest. 
 
Dessa Brashear en Jane Sykes, veel dank voor het controleren en corrigeren van 
mijn Engels. 
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Tevens wil ik Len Cuppens (Universiteit Maastricht) en Ruud Leliveld en Jordan 
Custers (Datawyse) bedanken voor hun adviezen, begeleiding en logistiek rondom 
mijn promotie. 
 
Mijn paranimfen, Sylvie Roke en Christel Hessels. Sylvie, jij bent mijn zus; jij bent zo 
goed in alles wat je doet. Ik kijk met veel bewondering en plezier hoe jij de weten-
schappelijke wereld bestormt. Wat heb ik in de rats gezeten toen jij dat ongeluk 
kreeg; gelukkig ben je hersteld. Ik ben blij en trots dat jij mijn zus bent en de tante 
van Youri, Robin en Stijn. Christel, vriendin en medepromovendus. Jij was mijn 
collega bij Fornhese, mijn overbuurvrouw met alle reserveonderdelen (zelfs broe-
ken voor het geval iemand eruit scheurde) en altijd een goed humeur; jij behande-
laar van de meisjes met persoonlijkheidsstoornissen en ik van de jongens met au-
tismespectrumstoornissen, een groter contrast is niet denkbaar, toch vullen we 
elkaar heel goed aan. Ik hoop nog heel lang jouw vriendin te kunnen zijn! 
 
Lieve vrienden en vriendinnen, dankzij jullie steun en liefde is dit alles geworden 
wat het is. Ik ben dankbaar zoveel lieve mensen in mijn leven te hebben en hoop dat 
dat nog lang zo blijft. 
 
Lieve Gea en Hans, Lieve Johan bedankt voor jullie hulp en steun gedurende mijn 
promotietraject. 
 
Lieve paps en mams, van jullie heb ik geleerd wat doorzetten is en hoe leuk leren 
eigenlijk is. Ik geniet ervan hoe jullie nu die dingen ook weer aan mijn kinderen 
leren. 
 Jullie maken mede mogelijk dat ik met zoveel plezier mijn werk en onderzoek 
kan doen, dankzij jullie steun en liefde. Zoveel dank daarvoor! Ik hoop nog heel lang 
zo te mogen genieten van het naast elkaar wonen. 
 
Lieve Ralph, jij bent mijn man al zoveel jaren. 10 jaar getrouwd, maar al zeker 20 
jaar samen, nog steeds het middelpunt van mijn leven. Jij en de kinderen, om jullie 
draait het voor mij en natuurlijk maakt jouw hulp het verschil. Ralph, dit boekje is 
een eerbetoon aan jou en de kinderen. Jullie zijn mijn leven. 
 
En tot slot Youri, Robin en Stijn, mijn kinderen. Aan jullie draag ik dit boek op, jullie 
zijn samen met jullie papa mijn alles. Jullie hebben mij geholpen om te kunnen rela-
tiveren de afgelopen 7 jaar. Ik hoop dat jullie, net als ik, alles uit het leven halen wat 
er uit te halen valt. Wij zullen er alles aan doen om dat voor jullie mogelijk te ma-
ken. 
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Yvette Roke was born March 17th, 1976, in De Bilt. At the age of 18 she moved to 
Utrecht. She attended medical school at UMCU University in Utrecht prior to her 
psychiatric training at Zon en Schild in Amersfoort. She became interested in scien-
tific research during medical school were she undertook a chart review study at the 
department of neonatology, investigating different breathing technique’s on prema-
ture children and the risk of this breathing technique on intracranial haemorrhage. 
She began her Ph.D. programme during her psychiatric training under the su-
pervision of Prof. Peter van Harten (at the time also the supervisor of psychiatric 
training) and Prof. Jan Buitelaar. 
She is married to Ralph de Geest, they have three children, two sons Youri (7 
years of age) and Stijn (two years of age) and one daughter, Robin (five years of 
age). 
